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ABSTRACT 
Advances in molecular biology techniques have permitted the 
development of radical new approaches to analyse point mutations i.e. the 
substitution of one base pair for another, at the molecular level. However, 
such approaches focus on only a small, pre-defined region of the genome 
and, because methods are dependent on prior phenotypic selection of 
mutant cells, they do not actually detect mutation. The occurrence of a 
point mutation at a given locus, i.e. base pair, in the genome is a very rare 
event and this presents a formidable obstacle to the development of a 
general method to detect point mutations. 
A generic method is needed to enrich these mutations. Direct 
enrichment is not feasible due to the fact that the base pair constituting the 
mutation is perfectly normal, at least from a chemical standpoint. It is the 
precise location of this base pair within the DNA duplex that is abnormal. 
Nevertheless, the 'normal' chemical structures of mutant base pairs can be 
specifically transformed into manifestly aberrant structures by denaturing 
the mutated duplex and reannealirig with normal, i.e. non-mutated, 
complementary strands to produce a DNA base pair mismatch at the 
mutated loci. Immunoanalytical methods, based on monoclonal antibodies 
may prove effective in detecting and enriching mismatches. This has been 
investigated. 
A series of 1 5mer single stranded oligonucleotides of defined 
sequence linked chemically by means of a tetraethylene glycol linker to a 
complementary 1 Smer strand were synthesised in such a way that the 
intramolecular duplex contains a specific central mismatched base pair. 
Since the two strands were chemically linked, a highly stable duplex, 
indicated by UV melting studies, was formed which should persist in vivo. 
These synthetic duplexes were used to evoke an immune response by 
direct immunisation, or as methylated BSA complexes. In a related 
approach a series of 75mer duplexes have been constructed such that they 
contain four evenly spaced mismatched base pairs. Each sequence was 
extended by the addition of a 5mer phosphorothioate oligonucleotide at the 
3' end to protect the DNA from nuclease degradation. In a third approach, 
a Cl OOmer phosphorothioate sequence was produced. Antibodies 
recognising cytosine in Cl OOmer may cross react with mismatches 
containing this base (A:C; C:C; T:C). 
Hybridoma cell lines obtained after fusions from 1 5mer duplex 
immunised mice were screened for antibody production using the ELISAs 
initially developed. These experiments failed to produce antibodies 
recognising mismatched base pairs. There was concern that cell lines 
producing the desired antibodies may not have been identified during the 
early stages of the project while developing screening assays. More 
recently, an ELISA format in which biotin labelled oligonucleotide 
duplexes were immobilised on streptavidin coated plates was used as a 
solid phase. For immunisations with the larger duplexes the improved 
screening methods were used to monitor antibody production. Although 
anti-mismatch antibodies were detected using AC75 and GT75 no 
monoclonal cell lines were isolated. The ClOOmer produced antibodies 
that bound strongly to single stranded DNA containing cytosine, and cross 
reacted with duplexes containing AC and CC mismatches. Monoclonal 
cell lines were isolated from these experiments with retained antibody 
specificity. These are cryopreserved at Sittingbourne Research Centre. 
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CHAPTER 1: MUTATIONS IN DNA 
1.1 INTRODUCTION 
In the Western world advances in medical care, public health 
measures and living conditions have reduced disease associated with 
infection and malnutrition (Emery and Rimoin, 1983). Genetic 
disorders as a group now represents a significant fraction of chronic 
disease and mortality. Genetic disorders account for 7% of still 
births and neonatal deaths, and approximately 8.5% of childhood 
deaths (U.S. Congress, 1986). 
Approximately 3000 different genetic diseases have been 
identified. Some genetic disease will manifest themselves shortly 
after birth, others will show indirect  effects later in life, e.g. 
increased susceptibility to some forms of heart disease, diabetes, or 
cancer. In the case of cancer there is now overwhelming evidence of 
the multi-stage nature of the disease. There may be a combination of 
an inherited genetic disorder and subsequent mutations through 
external exposures to certain mutagenic agents. Much work has been 
conducted to identify the cause, the type and the location of all forms 
genetic mutation. 
There are a considerable number of types of mutation that can 
occur. Alterations in DNA function can be a consequence of the 
change to an entire gene or a single base pair. The latter can be as 
devastating to health as the former, however its detection is 
considerably more complex. Methods to detect base pair mutations 
often rely on the artificial formation of base pair mismatches. 
Identification of duplexes containing mismatched base pairs indicate 
the presence of a point mutation. This project aimed to develop 
irnmunoanalytical methods to detect mismatched base pairs, so as to 
improve the ability to detect mutations that occur at the level of the 
base pair. These methods should offer the possibility of highly 
sensitive techniques for identifying changes in the human genome 
and thereby estimating the genetic risk associated with such 
mutations. 
1.2 NUCLEIC ACIDS 
Nucleic acids are macromolecules composed of several 
monomeric units called nucleotides. The sequence of the nucleotides 
in the polymeric structure determines the function in the storage and 
transfer of genetic information. Nucleic acids can be divided into 
two main classes, the deoxyribonucleic acids (DNA) and ribonucleic 
acids (RNA). However, only the structure of DNA will be 
discussed. 
The monomeric units of DNA are deoxyribonucleotides. 
These consist of a phosphate, a sugar, and one of four nitrogenous 
bases (adenine, (A), cytosine (C), guanine (G), or thymine (T)). The 
sugar, f3-D-2'-deoxyribose, is joined via a f3-glycosyl linkage to one 
of the four bases to give a nucleoside. Successive nucleosides are 
joined via the 3'- and 5'- hydroxy groups of the sugar by 
phosphodiester bonds to give oligodeoxyribonucleotides. Thus the 
backbone consists of alternating phosphate and sugar groups, with 





FIGURE 1. MONOMERIC UNITS OF DNA 
Native DNA from most organisms consists of two 
oligonucleotide chainsin a right handed double helical arrangement, 
known as B-DNA. The double helix is stabilised by hydrogen bond 
formation between the heterocyclic bases, see figure 2. Adenine (A) 
pairs with thymirie (T), and cytosine (C) pairs with guanine (G). The 
helix is further stabilised by base stacking within the helix. 













FIGURE 2. WATSON CRICK BASE PAIRS 
The interaction of DNA with its environment, especially 
proteins are central to its function. The original description of DNA 
based on the classical Watson and Crick model (Watson and Crick, 
1953), gave the impression of rigidity. In fact DNA is structurally 
dynamic and the original B-form DNA structure proposed by Watson 
and Crick can adopt several conformations depending on 
environmental conditions such as the nature and the concentration of 
the countenons and relative humidity and, in synthetic 
polynucleotides with the nature of the sequence. DNA double 
helixes exist in a right handed form in A-DNA and B-DNA. B-DNA 
can be further subdivided into 8 forms with closely related structures. 
There also exist a left handed variety known as Z-DNA. This can be 
subdivided into four closely related groups. The various structures of 
DNA have been reviewed (Saenger, 1984). 
The nucleotide sequence in DNA codes for the regulation of 
gene function or for a protein product of transcription or translation. 
The nucleotide sequence is arranged in triplets of nucleotides known 
as codons. A series of codons that code for a protein or regulate cell 
function are called genes. Chromosomes are made up of thousands 
of genes, dispersed amongst a large amount of non-coding DNA, in a 
complex arrangement with proteins. The entire genome is made up 
of many chromosomes in eukaryotes. The human genome contains 
46 chromosomes, comprising of approximately 3 billion nucleotide 
base pairs. 
1.3 TYPES OF MUTATIONS IN DNA 
1.3.1 Definitions of Mutation 
Mutations are changes in the composition of the genetic 
material, DNA. The types of mutation are to some extent a function 
of the cell line and the gene locus in which they occur. Mutations are 
influenced by numerous chemical and physical agents. They are 
generally divided according to size into gene mutations and 
chromosome mutations. 
Depending on the nature and location of the mutation, and on 
the function of the genes in which they occur, mutations may in 
theory be beneficial, neutral or harmful to the individual. It is 
generally thought that newly arising mutations in regions of DNA 
that directly determine the structure and regulation of proteins are 
more likely to be detrimental rather than beneficial. Therefore, 
efficient detection of any mutation is essential to avoid progression 
towards disease. 
1.3.1.1 Gene Mutations 
Gene mutations occur within or across a single gene. They 
result from either the substitution of one nucleotide for another, or 
the rearrangement, deletion or insertion, of several nucleotides within 
the gene. They can also be a consequence of duplication or deletion 
of an entire gene. For example, sickle cell anaemia is caused by the 
substitution of a single base pair. This point mutation results in one 
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codon within the glob *in gene being altered such that the amino acid 
valine replaces glutamic acid (Ingram, 1957). In comparison, a-
thallassemia occurs where the gene coding for the a-globin is 
missing (Weatherall and Clegg, 1982). 
In somatic cells, dominant  oncogenes are generated by 
mutations. Oncogenes are genes whose protein products may be 
involved in processes leading to transformation of a normal cell to a 
malignant state. They are part of a normal cellular gene that has been 
activated by mutation. There are various types of oncogenes 
involved in cell transformation. Most oncogenes are similar to genes 
that act along growth control pathways. 
There are four basic groups of oncogene protein products. 
Those that code for growth factors e.g. sis oncogene; those that 
produce mutant cell surface or intracellular receptors e.g. ros, neu, 
erbA; those that code for mutant intracellular signalling proteins, 
e.g. mutant G proteins formed by ras oncogenes, protein kinases 
formed by src oncogenes; and those that effect transcription rates 
within the nucleus e.g. fun, myc and p53 oncogenes (Daniel, 1990). 
The mutation can be in the form of a point mutation e.g. for 
rcis oncogenes, or as gene rearrangements e.g. amplification of c-myc 
genes (Bishop, 1987; Varmus, 1984). The literature on the activation 
of oncogenes is vast and beyond the scope of this text. The fact that 
activation of oncogenes by mutation is implicated in the multistage 
process leading to cancer has had many reviews (Reddy et al., 1982; 
Tubinetal., 1982; Yuasaetal., 1983; Bos et al., 1985, 1987; 
Barbacid, 1987; Forrester et al., 1987; Brookes, 1989; Grand and 
Owen, 1991; Ohgaki, 1991). 
1.3.1.2 Chromosome Abnormalities 
Major structural changes affecting more than one gene are 
described as chromosomal abnormalities. These involve loss, 
addition, or displacement of all or part of a chromosome. 
Occasionally in the production of germ cells an entire extra 
chromosome may be included. In Down Syndrome the resulting 
offspring has 3 copies of chromosome 21. Chromosome 
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translocations also occur at a high frequency in some tumours, 
suggesting they play a role in the development of these tumours, e.g. 
Philidelphia chromosome translocations associated with chronic 
mylegenous leukaemia (Rowley, 1973). 
1.3.2 Mutational Causation 
There are several known causative agents for mutation. Gene 
mutations occur spontaneously, and are induced by the interaction of 
chemical and physical agents with DNA. Evidence that ionising 
radiation causes mutation was presented by Muller (1927). Methods 
to detect mammalian mutations were discussed in the 1930's (Snell, 
1935). The investigation of mutation induction by chemical agents 
was initiated by Cattanach (1966). One of the major aims of the 
investigation of chemical mediated mutations is to evaluated 
associated risk of chemicals, natural and synthetic, within the 
environment and work place (Ehling, 1991). According to Chemical 
Abstracts there were 10 million registered chemicals in 1984, most of 
these had not been tested for toxicity (U.S. Congress, 1986). 
1.3.2.1 Spontaneous Mutations 
Mistakes in the normal duplication of DNA can give rise to 
spontaneous mutations, but they are rare events (Singer and 
Kusmierek, 1982). Misincorporation may occur as a result of 
spontaneous tautomerisation leading to mispairing of iininocytosine 
with adenine,  iminoadenine with cytosine, enolguanine with thymine, 
or enoithymine with guanine. In addition guanine can mispair with 
adenine in several forms (Kennard, 1987). Mispairs produced by 
rare tautomeric forms of the bases (Topal and Fresco, 1976a,b) are 
sterically equivalent to Watson-Crick base pairs, see figure 3 and 4, 
and are thought not to significantly destabilise the double helix 
(Kennard and Hunter, 1991). 
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FIGURE 4. G: A BASE PAIRS 
1.3.2.1.1 Methylation and Spontaneous Mutation 
Cytosines in CpG dinucleotides are methylated to 5-
methylcytosme (5MedC) in many animal systems, and these are 
known to be premutagenic lesions in human DNA (Jones et at., 
1992), 5MedC was first shown to be mutagenic in bacteria 
(Coulondre et at., 1978). The mutagenic potential is attributed to the 
deamination process. Cytosine will deaminate to uracil, not normally 
found in DNA, and will therefore be corrected by repair enzymes. 
However, 5MedC deanimates to thymine, a normal component of 
DNA, and thus does not represent an unusual site for the action of 
repair enzymes, see figure 5. if DNA replication at the site of the 
resultant T:G mismatch occurs, before mismatch repair has taken 
place, a C:G to T:A transition mutation may occur for one daughter 
strand, i.e. a point mutation arises as a result of 5MedC deammation. 
FIGURE 5. DEAMINATION OF CYTOSINE 
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The rate of 5MedC deamination  has been found to be more 
rapid than for cytosine in dsDNA (Erlich et al., 1986), this rate of 
5MedC deamination further increasing in ssDNA. During DNA 
replication, regions of dsDNA are dissociated to ssDNA, therefore 
5MedC deamination during replication may represent a major 
mutational occurrence. There is 200kda specific G:T mismatch 
repair enzyme that repairs approximately 90% of G:T mispairs to the 
original G:C matched pair (Brown and Jiricny, 1987). However, this 
repair system is not completely error free. 
It has been calculated (Sved and Bird, 1990) that methylation 
at CpG increases the possibility of transitions by a factor of 12. 
Further, it has been suggested that methylation at CpG in the human 
germline may account for 30-40% of all point mutations and 
restriction fragment length polymorphisms (Cooper and Youssoufian, 
1988 Barker et al., 1984). In colon cancer 63% of point mutations 
in p53 gene occur at CpG sequences. The mutation being consistent 
with deamination of 5-methylcytosine, leading to C:G to T:A 
transitions at the CpG sites. These observation suggest that 
mutations in the p53 gene associated with tumour progression in 
colon cancer are induced predominantly by an endogenous process 
(Vogelstein, 1990). The role of DNA methylation and mutation has 
recently been reviewed (Holliday and Grigg, 1993). It should be 
noted that there is no evidence that CpG dinucleotides, independent 
of methylation, are inherently unstable. 
1.3.2.2 Non-Spontaneous Mutations 
For many mutations exogenous agents are the predominant 
causative factors. In lung cancer transversion mutations that are not 
associated with 5MedC deamination predominate (Jones et al., 1991; 
Sommer, 1990; Chika et al., 1990). These mutations are more likely 
to be associated with exogenous factors such as those found in 
tobacco smoke (Chika et al., 1990). The following have been 




1.3.2.2.1 Alkylating Agents 
Alkylating agents are either electrophilic compounds, or 
compounds that are metabolised to electrophilic species, which can 
bind to nucleophilic centres. In DNA these are predominantly the 
nitrogen and oxygen atoms within the bases. Most of the nitrogen 
and oxygen atoms in DNA present potential targets for the attack of 
alkylating agents (Singer and Kusmierek, 1982; Pegg, 1983; Horsfall 
et al., 1990). The alkylation sites thought to be predominantly 
responsible for mutation development are 0(6)-alkylguanine and 
0(4)-alkyithymine, see figure 6. These give rise to G:C to A:T, see 
figure 7, (Safihill et al., 1985) and A:T to G:C transitions 










FIGURE 6. PRE-MUTAGENIC ALKYLATEON PRODUCTS 
OF GUANINE AND THYMINE 
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FIGURE 7. G:CTOA:T POINT MUTATION 
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1.3.2.2.2 Intercalating Agents 
Acridine dyes, e.g. ethidium bromide, are flat molecules that 
are able to insert  themselves between the stacked bases in DNA 
double helixes. The binding causes some unwinding of the DNA 
duplex, which interferes with subsequent DNA transcription. The 
anthracenes and benzopyrenes are oxidised and react at the 2-amino 
group of guanine before intercalating. 
1.3.2.2.3 Radiation 
Two forms of radiation., ionising and ultra violet (UV), interact 
with DNA and can lead to mutation. Single strand breaks in the 
sugar-phosphate backbone are a major lesion induced by ionising 
radiation, double stranded breaks occur more rarely. In addition, 
breakage of the glycosidic bond may occur, leading to a 
depyrimidated or depunnated site. lonising radiation also produces 
short lived hydroxyl free radicals, after interaction with water. These 
can cause indirect damage by interaction with the bases of DNA, see 
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FIGURE 9. DEPURINATION OF DNA 
UV radiation is not sufficiently energetic to directly ionise 
DNA, but can produce a short-lived excited, and chemically reactive 
state. UV radiation can cause alteration of bases due to the addition 
of a water molecule across the 5, 6 double bond of an excited 
pyrimidine base, see figure 10. This can spontaneously dehydrate 
forming the original base, or in the case of cytosine  may deaminate 
and dehydrate forming  uracil. 
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FIGURE 10. HYDROLYSIS AND DEAMJNATION OF CYTOSINE 
An excited pyrimidine may also interact chemically with a 
neighbouring pyrimidine to form a cyclobutane linked dimer, see 
figure 11. An excited base may also interact and form a covalent link 
with a protein. 
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1.4 MUTATION RESEARCH 
1.4.1 Introduction 
Much of our knowledge about how substances interact with 
DNA, and how they may cause mutations is derived from studies 
conducted on experimental animals. The results from animal studies 
are then extrapolated to estimate the associated risk to humans and 
associated mutation rates. For many years the validity of data 
obtained in this way has been open to question. Many compounds 
undergo transformation within the host animal prior to exerting their 
effect. Metabolic pathways for chemical transfomations vary from 
species to species, thus a precise interpretation of all results is 
difficult. 
Other methods toinvestigate mutation occurrence have 
included looking for gross changes in chromosome structure or 
number, or looking for the occurrence of mutant proteins. The 
presence of a mutant protein is indicative of alteration to the gene or 
genes that codes for the synthesis of that protein. 
With increasing developments in molecular biology, and in 
particular the extensive use of the Polymerase Chain Reaction 
(PCR), the exact molecular changes associated with mutation are 
now being investigated. This is extremely important for very 
localised mutations, e.g. single base pair substitutions, and insertions 
and deletions involving only a few nucleotides. Gross mutations in 
DNA such as amplifications, gene rearrangements, and losses of 
genes, are successfully detected by Southern blot hybridisation. In 
general, detection of single nucleotide substitution require PCR 
based methods (Caskey, 1987). 
Techniques for the physical and chemical characterisation of 
DNA damage and potential premutational lesions are continually 
being developed and improved. This area of research encompasses 
detection of DNA adducts and the detection of mutation. Many point 
mutations arise as a consequence of replication occurring before 
repair processes have taken place, or where incorrect repair of 
adducted DNA has occurred. It is important to understand the 
consequences of chemical-DNA interactions and the mechanisms by 
which DNA damage are fixed as mutations. 
1.4.2 Detection of DNA-Adducts 
Formation of carcinogen-DNA adducts is recognised as a 
necessary step in the development of most chemically induced 
cancers (Yuspa and Poiner, 1988). Although it is difficult to predict 
absolutely the relationship between adduct/mutation occurrence, 
methods to detect, identify and quantify DNA adducts have arisen. 
These serve to estimate the cancer risk in humans from 
environmental or endogenous exposures. 
Physical methods for the detection of carcinogen-DNA 
adducts include gas chromatography/mass spectrometry (Shuker et 
al., 1992), fluorescence spectroscopy (Weston et al., 1990), 
electrochemical conductance (Floyd et al., 1986) and atomic 
absorbance spectrometry (Reed et al., 1988). Several of these 
methods have recently been reviewed (Weston, 1993). 
Other methods to detect carcinogen DNA adducts in humans 
include 32-P  post-labelling assay (Reddy and Randerath, 1987) and 
enzyme immunoassay (Poirier, 1990). The combination of FIPLC 
with 32-P  postlabelling of DNA adducts is an emerging technique 
(Gorelick, 1993, and references therein). Antisera against DNA 
adducts and carcinogen modified DNA (Poirier, 1981,1984; Muller 
and Rajewsky, 1981) are used to quantify and localise chemical 
induced DNA damage (Leng, 1985; Strickland and Boyle, 1984; 
Phillips, 1990; Santella, 1988) and to monitor human exposure 
(Weston et al., 1989; Poirier and Weston, 1991). 
A major obstacle has been the requirement to fmd very low 
levels of adduct, in a vast majority of non-adducted material, where 
only limited quantities of DNA are available. Enrichment techniques 
have thus been needed prior to adduct quantification. Immunoaffinity 
chromatography (JAC) columns have been developed for this 
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purpose. One such method involves immobilisation of a monoclonal 
antibody against 0(6)-methyldeoxyguanosine (Cooper et al., 1992) 
for the analysis of DNA from human sera. IACIHPLC post labelling 
has been applied to the detection of both 0-6-methyldeoxy guanosine 
and benz(a)pyrene adducts in human samples (Sheilds et al., 1993). 
The above combination of techniques provides an 
improvement upon immunoassay methods used in isolation as usually 
less DNA will be required. The method is dependent upon the 
specificity of the antibodies produced. However, the lack of 
specificity of the antibody for an antigen can be utilised for some 
applications, e.g. where a class of adducts such as methyl, ethyl, and 
propyl groups are under investigation. The application of mixed 
antibody (LAC) columns may also be utilised in some instances 
(Cooper et al., 1992). 
1.4.3 Detection of Mutation 
There are two main reasons for the identification of human 
mutations. Firstly, unknown mutations are screened for in a gene 
suspected to be the locus of a given disease. The second area is the 
application of mutation detection for genetic diagnosis. These are 
usually used in the detection of inherited diseases in which a few 
known mutations account for all cases of the disease. 
The first disease causing mutation in a human gene was 
identified in one of the globin genes (Flavell et al., 1978). Since then 
many more mutations involved in human disease have been 
discovered. As the number of known mutations increases, so 
techniques to screen and diagnose mutation improve. There are 
several chemical based methods, enzyme specific methods, and gel 
electrophoretic methods. Increasingly many of the methods involve 
DNA amplification, using PCR techniques, to either improve 
sensitivity, or as an integral part of the technique. Only techniques 
involved in the detection of point mutations will be discussed. These 
are often detected as a mismatched base pair artificially created at the 
site of a point mutation. 
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1.4.3.1 Point Mutations and Mismatches 
The detection of point mutations has to a large extent been 
dependent upon the production of heteroduplexes. These are formed 
by combining single stranded DNA from the two sources, mutant and 
wild-type DNA. The mutant DNA is usually the DNA being tested 
(target DNA). The wild-type is usually a probe of DNA or RNA that 
is complementary to the non-mutated form of the target DNA, see 
figure 12. Mutant DNA being detected by the differing properties of 
the heteroduplex containing a mismatched base pair, compared to a 
fully complementary duplex containing no mismatched base pairs. 
The irnmunochemical basis of the project will rely on the differing 
properties of heteroduplex compared to homoduplex DNA. 
FIGURE 12. ARTIFICIAL PRODUCTION OF MISMATCHES 
Issocte 
GC 	 AC 	GT 	GC 
I + 	
2.Reanneal 	+ 	+ 
	
A  POINT MUTATION NORMAL DNA 	A:C and G:T 	NORMAL DNA 
(One Duplex) 	(Excess Duplexes) 	
MISMATCHED 	(Excess Duplexes
BASE PAIRS 
(One of Each) 
In an excess of normal DNA duplexes the mutant strand can be dissociated 
into single strands. VAien allowed to reanneal the two mutant strands will 
hybridise with normal strands to form mismatch containing duplexes. 
Any locus can exist as one of 4 possible base pair 
combinations, and for any given base pair there are 3 possible point 
mutations. Therefore, there are 12 possible point mutations. 
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Mutations of base pairs from Purine:Pyriniidine to Pyrimidine:Purine 
are known as transversion mutations, e.g. A:T to C:G, those which 
convert Pun* me:Pyrimidine to Purine:pyrimidine as transitions, e.g. 
A:T to G:C. 
When producing artificial heteroduplexes, in vitro, transition 
mutations give rise to two duplexes each containing a different 
purine:pyrimidine mismatched base pair, see Table 1(1, 4, 9 and 12). 
Transversion mutations will give rise to one duplex with a 
purine:punne mismatch and one duplex with a pyrimidine:pynmidine 
mismatched base pair, see Table 1 (2, 3, 5, 6, 7, 8, 10 and 11). 
Table 1. Types of Point Mutation 
Mutation No. Mutation Mismatches Type 
1 C:GtoT:A C:A and T:G Transition 
2 C:GtoA:T C:T and A:G Transversion 
3 C:GtoG:C C:C and G:G Transversion 
4 T:A to C:G T:G and C:A Transition 
5 T:AtoA:T T:T and A:A Transversion 
6 T:AtoG:C T:C and G:A Transversion 
7 A:T toC:G A:G and C:T Transversion 
8 A:TtoT:A A:A and T:T Transversion 
9 A:T toG:C A:C and G:T Transition 
10 G:CtoC:G G:G and C:C Transversion 
11 G:CtoT:A G:A and T:C Transversion 
12 G:CtoA:T G:T and A:C Transition 
The following mispairmgs can exist. A:A, C:C, G:G, T:T, 
A:C, A:G, C:T, and G:T. Methods to detect all of these mismatches 
would allow detection of all possible mutations in any given ssDNA 
from a DNA duplex. However, if both strands of DNA from a 
duplex are used to form heteroduplexes then only four mismatch base 
pair detection systems are required. To detect all possible types of 
point mutation combinations of detection systems are required to be 
investigated. 
UEG 
Mutation types 1, 4, 9, and 12 (see table 1) would be identified 
by detecting  heteroduplexes containing A:C or G:T mismatches. It 
would not be necessary to look for both mismatches. Similarly 
mutations 2, 6, 7, and 11 would be identified by detecting 
heteroduplexes containing A:G or C:T. Mutations 3 and 10, and 
mutations 5 and 8 would be identified by detecting heteroduplexes 
containing C:C or G:G, and T:T or A:A, respectively. Therefore, to 
identify all types of mutation you would need to be able to detect one 
type of mismatch from each of the four pairs of mismatch containing 
heteroduplexes. 
For any base pair a random process of mutation would give 
rise to 1/3 transition mutations and 2/3 transversion mutations. 
However, transition mutations predominate in DNA, representing 
59% of all point mutations (Li et al., 1984). Generally, transition 
mutations occur due to modification of one base in base pair, e.g. 
5MedC deamination converts 5MedC to thymine and thus generates 
a G:T mispair. Where this mispair is not identified and corrected a 
G:C to A:T point mutation in one daughter strand during replication 
will occur. In general, errors during replication will favour 
mismatches that form wobble base pairs. These mismatches are 
more likely to be punne:pyrimidine mispairs and so produce 
transition mutations. 
The only disadvantage of this approach is that analysis of both 
strands is required. The analysis of the products of mismatch 
analysis usually uses labelled DNA probes, and thus analysis of both 
strands increases the cost and where radiolabels are used the amount 
of hazardous waste. The four mismatch detection method does 
however reduce the number of methods required to detect 
mismatches. 
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1.4.3.2 Effect of Base Sequences 
The detection of a mismatch may be further complicated by 
the nature of the duplex base sequence in which it is positioned. This 
may take two forms: 
In G:C rich regions duplex formation is a result of base pairs 
with three hydrogen bonds, compared to only two in A:T rich 
regions. G:C rich regions are therefore energetically more stable. In 
a G:C rich region recognition of given mismatch by a mismatch 
recognition process (proteins or chemicals) may not be equivalent to 
the same mismatch in an A:T rich sequence. This difference in 
mismatched base pair exposure to the environment may give rise to 
significant variation for a mismatch specific antibodies affinity for a 
mismatched base pair. 
The immediate neighbouring base pairing may greatly influence 
the recognition of agiven mismatch, independently from the general 
DNA sequence. For all mismatches there will be any one of four 
base pairs (A:T, T:A, C:G, G:C) at a position 3' and 5' immediate to 
the mismatch. Thus, there are 16 possible neighbouring 
conformations for each mismatch, giving a possible 128 
conformations. For mismatches with the same base (A:A, C:C, G:G, 
T:T) some of the configurations are equivalent. For mismatches with 
different bases all 16 configurations are different 
3'-A-A-A-5' is the same as 3'-T-A-T-5' 
5'-T-A-T-3' 	 5'-A-A-A-3' 
whereas, 
3'-A-A-A-5' is not the same as 3'-T-A-T-5' 
5'-T-C-T-3' 	 5'-A-C-A-3' 
There are 10 different sequence configurations for the four 
mismatches formed with the same base pairing. This gives a total of 
104 possible arrangements. For some of the methods to identify 
mismatches, e.g. denaturing methods, sequence configurations may 
not be an important factor. However where specific recognition is 
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important (e.g. mismatch repair enzymes) these factors may become 
increasingly important. For the current study where monoclonal 
antibody production against mismatched base pairs is being 
investigated, recognition could be affected by neighbouring base 
pairs. This could prove a significant obstacle in this approach. 
1.4.4 Current Methods of Detecting Point Mutations. 
Mutations can be found by directly sequencing the amplified 
products of the PCR (Gyllensten and Erlich, 1988; Murray, 1989). 
However, this method is fairly laborious, and also PCR is not error 
free and thus could create mutations. 
It is possible that hot spots for mutations, in vivo, may also be 
predominant sites for PCR error? DNA sequencing is commonly 
used to identify or confirm the exact nature and position of a 
mutation, previously detected by a screening method. Methods for 
the detection of mutation have recently been reviewed (Cotton, 1993, 
1992; Prosser, 1993). Only a brief description of those methods 
currently being used will be discussed. The importance of sensitivity 
of these methods will be emphasised. 
1.4.4.1 Single Strand Conformation Polymorphism (SSCP) 
Single strands of DNA will form unique tertiary structures 
depending on their nucleotide sequence. This allows single strands 
of DNA differing by one or more nucleotide to be separated by 
electrophoresis in a non-denaturing polyacrylamide gel. This method 
has been described (Orita et al., 1989a) as Single Strand 
Conformation Polymorphism (SSCP). By combining SSCP with 
PCR a simple and sensitive method for the detection of point 
mutations was obtained (Orita et al., 1989b; Hayashi, 1991). If 
mRNA is converted into cDNA by reverse transcriptase it can also 
be analysed by PCR-SSCP (Murakami et al., 1991a,b) for the 
detection of single or multiple nucleotide mutations. 
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The advantage of this method is that it can detect a single  base 
substitution at unknown positions within target DNA fragments. The 
efficiency of detection of a single base substitution, in fragments less 
than 300 base pairs, is greater than 90% (Sekiya, 1993). DNA 
fragments for analysis from cancer specimens are often obtained 
where the tumour cells are in the minority. By physically separating 
normal strands from mutant strands, this method allows subsequent 
PCR amplification of even the faintest bands. This allows full 
characterisation of minute amounts of mutant DNA by sequencing. 
PCR-SSCP has been used to detect mutations in DNA 
associated with human cancers, e.g. ras gene mutations in lung 
carcinomas (Suzuki et al., 1990); and hereditary diseases in humans, 
e.g. gene mutation leading to cystic fibrosis (Dean et al., 1990). 
1.4.4.2 Denaturing Gradient Gel Electrophoresis (DGGE) 
A modification of standard electrophoretic gel procedures, 
allows DNA to be separated not only on the basis of size, but also on 
the basis of nucleotide sequence (Fischer and Lerman, 1983). The 
dissociation of dsDNA occurs on heating, and in the presence of 
denaturing chemicals, e.g. formamide or urea. Polyacrylamide gels 
for electrophoresis can be prepared such that they contain denaturing 
chemicals. In, addition they can be produced such that a gradient of 
denaturing chemicals exists. The concentration of denaturing 
chemicals increases as the DNA migrates through the gel by 
electrophoresis. DNA is separated according to size and it also 
moves into an increasing concentration of denaturing chemicals. 
Duplex dissociation to single strands occurs as they reach their 
distinctive critical concentration of denaturing chemicals. Single 
stranded DNA has greater flexibility than duplex DNA and can 
become stuck in the pores of the gel. Thus as single stranded 
domains are formed by the denaturing conditions the DNA 
effectively cease to migrate. 
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The concentration of denaturing chemicals that will cause 
duplex dissociation is sequence dependent. When DNA 
heteroduplexes are formed between mutant and wild type sequences, 
any point mutation will produce a mismatch site. As with thermal 
melting, chemical denaturing is greatly facilitated by the presence of 
a mismatch. Thus, mismatch heteroduplexes will melt and migration 
will cease at a lower denaturant concentration than fully matched 
sequences. The method usually requires radiolabelled probes to 
provide the necessary sensitivity. 
Originally DGGE only detected about 50% of all mutations, 
and this is attributed to differing melting domains. If the mismatch 
occurs in a high melting domain, a lower melting domain may have 
already caused dissociation and arrested migration before the 
mismatch can influence melting. PCR facilitates the attachment of a 
high melting point 40-base pair GC rich sequence (GC clamp) 
(Sheffield et al., 1989, 1992; Abrams et al., 1990). Thus all 
mutations should fall into low melting domain regions, and nearly all 
point mutations should be detected. 
1.4.4.3 Allele Specific Oligonucleotides (ASO) 
This method relies on hybndising chemically synthesised 
oligonucleotides to genomic DNA pre-immobilised to a solid 
support. These ASOs hybridise to perfectly paired sequences, but 
poorly where target DNA will form a mismatched base pair (Connor 
et al., 1983). DNA hybridisation can be detected by labelling the 
oligonucleotide probe. 
1.4.4.4 Restriction Fragment Length Polymorphism (RFLP) 
Certain nucleotide sequences in DNA are specifically 
recognised and cleaved by bacterial restriction enzymes. There are a 
variety restriction enzymes all recognising different restriction sites. 
Genomic DNA is isolated from white blood cells and treated with 
restriction enzymes. The number of fragments produced is 
determined by the occurrence of a particular enzyme restriction site. 
Fragments can be processed by two methods. 
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Fragments can be cloned, or amplified by PCR, to produce 
large quantities of DNA fragments. These can then be cut into 
smaller fragments, with a further set of restriction enzymes, and 
separated by gel electrophoresis. The presence of extra or reduced 
bands is indicative of mutation. 
Fragments from an entire human genome are separated by 
gel electrophoresis. Double stranded DNA is then dissociated into 
single strands, within the gel. The DNA is then transferred to a 
plastic membrane (Southern blotting), and complementary DNA 
probes are then annealed. 
Cloning, and to a lesser extent PCR, may introduce new 
mutations, but does not rely on the availability of DNA probes. The 
method using probes is however more rapid. The major shortfall of 
the method is its reliance on mutation recognition only at restriction 
sites, and not the entire gene sequence. 
1.4.4.5 PCR Amplification of Specific Allele (PASA) 
For PCR amplification to occur Taq polymerase requires the 
primer sequence and target sequence to form perfect base pairing. If 
two alleles of a gene differ by only one nucleotide then the allele that 
is perfectly complementary with the primer sequence will amplify in 
preference to the allele forming a mismatched base pair. The closer 
the proximity of a mismatched base pair, formed between the primer 
and target sequence, to the 3' end of the primer the less likely the 
PCR can occur. This technique has been successfully applied to 
screen for hereditary disorders, e.g. screening humans for abnormal 
factor VIII gene, and mutations in phenylalanine hydroxylase gene 
(Somner et al., 1992). 
1.4.4.6 RNase A 
This method relies on the ability of the enzyme ribonuclease A 
(RNase A) to cleave double stranded RNA:DNA heteroduplexes at 
the site of a mismatched pair (Myers et al., 1985). DNA is cut into 
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fragments with restriction enzymes, then heat denatured into single 
strands. These are then reannealled with radiolabelled single strands 
of wild-type RNA to form a heteroduplex. Treatment of the 
heteroduplex with RNase A will then cause strand breakage at 
mismatched base pairs. RNase A products are then separated by gel 
electrophoresis according to size. Where cleavage occurs the loss of 
one band on the gel and the occurrence of two new bands of lower 
molecular weight are seen. 
However, RNase A is an inefficient  cutter of all mismatched 
base pairs in heteroduplexes, only cutting pyrimidine:pyrimidine 
mismatches well. There are 12 possible mismatched base pairs, only 
4 of which are pyrimi dine: pyrimidine, see Table 1. If both single 
strands from the mutant duplex are used for the analysis then 2/3rds 
of the mismatch types can be identified, see 1.4.2.1. 
1.4.4.7 Chemical Based Methods 
Chemicals have been used to study nucleic acids in a variety 
of ways. These include studies on single stranded DNA (Kochetkov 
and Budvoskii, 1972), on RNA structure (Metz and Brown, 1969a, 
1969b), and on Z-DNA (Johnson and Rich, 1985). DNA sequencing 
(Maxam and Gilbert, 1977, 1980) was the first chemical method to 
be able to identify point mutations in DNA. Maxam-Gilbert 
sequence analysis uses base selective partial chemical cleavage to 
determine the DNA sequence. 
A second method known as the Sanger dideoxy-sequence 
analysis relies upon the use of 2',3'-dideoxynucleoside 5c 
tnphosphates as base specific chain terminators of the synthesis of a 
complementary DNA copy by a DNA polymerase (Sanger, 1977, 
1981, 1988). Both of these methods rely on gel electrophoresis to 
interpret the chemical reactions. 
PCR amplification coupled to sequencing by the Sanger 
method has been carried out (Ruano and Kidd, 1991). Both methods 
require many manipulations, and are fairly time consuming. 
Although some laboratories still use sequencing methods to find 
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mutations, more often they are used as a reference method to 
determine the exact nature of a mutation, after a more rapid screening 
method has identified a gene sequence containing a mutation. 
Some chemicals that react with single stranded DNA or 
variants of normal DNA structure, such as Z-DNA, can react with 
mismatched base pairs. Mismatched base pairs can be formed 
artificially, at sites of point mutation, by annealing mutant and wild 
type DNA. Two chemical methods for the detection of point 
mutation, based on mismatch recognition, have emerged. Both rely 
on specific modification at the site of a mismatched base pair in an 
otherwise normal DNA duplex. 
These methods have been successfully used in the detection of 
previously unknown mutations. In addition they not only detect 
mutation, but also locate the mutation (to within approximately 10 
nucleotides). This is advantageous when compared to some of the 
simpler methods such as (DGGE) (Myers et al., 1985), and (SSCP) 
(Orita et al., 1989a). Both methods have the potential to detect all 
mutations in relatively long stretches (up to 2kb) of DNA. 
1.4.4.7.1 Carbodiimide (CDI) 
It was shown (Metz and Brown, 1969a) that modification of 
RNA and DNA occurs with 1-cyclohexyl-3-[2-(morpholinyl) ethyl]-
carbodiimidemetho-p-toluene suiphonate (carbodiimide or CDI). 
CDI will react with unpaired thymine and uracil (at N3) and guanine 
(at Ni), see figure 13. The difference in electrophoretic mobility 
caused by the modification is then used to separate mutant and 
wildtype strand (Novack et al., 1986). The method thus having 
similarities with DGGE and SSCP, in that mutation is detected but 
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An improvement to this method was the use of the Escherichia 
coil (E. coil) repair enzyme UvrABC exonuclease. The enzyme 
cleaves both sides of the modified region of DNA (Thomas et al., 
1986). However, this enzyme has only recently become readily 
available. Immunochemical methods for the detection of CDI 
modified DNA were investigated. Specific antisera have been 
produced (Wani et al., 1989; Ganguly et al., 1989), and the 
identification of a previously unknown mutation (Ganguly et al., 
199 1) has been carried out. The use of PCR (Ganguly and Prockop, 
1990) has been incorporated into this method. The modification to 
the heteroduplex prevents the PCR reaction from proceeding, thus 
indicating the presence of a point mutation. 
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1.4.4.7.2 Chemical Cleavage of Mismatch (CCM) 
Several chemicals have been tested for their ability to modify 
mismatched base pairs, such that subsequent treatment with 
piperidine would cause cleavage of the nucleic acid backbone. 
Those tested include hydrazine, potassium permanganate, formic 
acid, sodium hydroxide, diethylpyrocarbonate, methylene blue, 
hydroxylamine, and osmium tetroxide (Cotton et al., 1988). 
Hydroxylamine, which modifies mismatched cytosines, and 
osmium tetroxide, which modifies mismatched thymines, proved to 
be most successful. Combining the two methods provides a 
technique capable of detecting all possible mutations. However, T/G 
mismatches are often poorly recognised (Forrest et al., 1991; Cotton 
et al., 1993). This is related to the stability of the mismatch. This 
method has also been applied to mutations in RNA, where 
mismatches in RNA:DNA heteroduplexes, formed by annealing with 
a DNA probe, are recognised (Cotton and Wright, 1989; Dahl et al., 
1989). There are two main advantages of the CDI and CCM 
methods: 
They can detect all eight possible mismatches and therefore all 
point mutations. Unlike other cleavage methods, e.g. RNase A 
method that fail to recognise approximately 30%. 
They disclose the region of the DNA duplex containing the 
mutation. This is not possible using methods such as DGGE and 
SSCP, where only the presence of a mutation is identified. 
CDI and CCM thus serve as less labour intensive methods to 
provide the information obtainable by DNA sequencing.  They are 
however more labour intensive than some other methods. Both 
methods rely on PCR to amplify DNA sequences for heteroduplex 
formation. The major disadvantage of the CCM method is its 
reliance on very toxic chemicals, e.g. osmium tetroxide. The use of 
alternatives to osmium tetroxide have been investigated, e.g. 
replacement with potassium permanganate (Gogos et al., 1990). 
However, to date this replacement has not become routinely used. 
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1.4.5 Sensitivity of Mutation Detection 
The ability to detect the majority, preferably 100%, of 
mutations is not the only important development of research into 
mutation detection. In heritable genetic disorders 50 or 100% of the 
target DNA will contain the mutation. However, in the somatic 
mutations of tumour tissue, sensitivity, i.e. the ability to measure the 
proportion of mutant material to normal DNA, is important. During 
biopsy normal as well as tumour tissue will be excised, often mutated 
cells will represent a considerable minority of the total cell 
population excised. Therefore, techniques are needed to identify a 
very small percentage of the total DNA which has undergone 
mutation. 
Most of the above detection methods will detect mutations if 
mutant DNA represent 5-20% of the total DNA extracted. DGGE 
for example will detect mutations where 10-15% of the DNA being 
analysed contains the mutation (Heimdal et al., 1993), for CCM 
(osmium tetroxide) 2-5%, and CCM (hydroxylamine) 1-2% (Prosser, 
1993) of the DNA needs to contain the mutation. A few technique 
have been developed to address this problem. They are usually used 
for the detection of previously identified mutations, rather than 
discovering  previously unidentified mutations. 
1.4.5.1 Mismatch Repair Enzymes 
The method relies on the high specificity of Mut Y, an E. coli 
mismatch repair protein (Lu and Chang, 1988; Au et al., 1988; Tsai-
Wu et al., 1991), to recognise mismatches. Mut Y specifically 
recognises and nicks G:A mismatches only (there is a weak activity 
for A:C mismatches). The method is analogous to the chemical 
cleavage methods in that a mismatched base pair artificially produced 
at a site in DNA containing a point mutation will lead to cleavage of 
the heteroduplex, producing two strands of DNA. Wild-type DNA 
will not be recognised by Mut Y, and therefore will not be cleaved. 
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This method has been used to detect mutations in I% of 
starting material (Lu and Hsu, 1992). Other mismatch enzymes will 
be needed to screen for all types of mutations. If more types of 
mismatches were to be detected utilising repair enzymes, they may 
become very useful tools in mutation detection. 
1.4.5.2 Mismatch Amplification Mutation (MAM) Assay 
The MAM assay is a modification of the PCR Amplification of 
Specific Alleles (PASA) assay, previously described (1.4.3.5). The 
PASA assay relies on the inability of PCR to amplify sequences 
containing mismatches at or near the -3' end. Wild type target DNA 
and wild type primer will form perfect Watson-Crick base pairings, 
and thus will undergo the PCR reaction. Production of a mismatch 
occurs between mutant target DNA and wild type primer DNA, 
therefore amplification is greatly reduced. The technique permits 
preferential amplification of one allele relative to another. 
The technique is rapid and simple in comparison to methods 
such as RFLP and oligonucleotide hybridisation, and can be used to 
detect mutations in nanogram quantities of DNA. However, it lacks 
the sensitivity of detection of other methods. RFLP in combination 
with PCR has been reported to be able to detect a point mutation in 
genomic DNA samples occurring at a frequency of 1 in 10,000 
(Kahn et al., 1991; Kumar and Barbacid, 1988), as compared to 
about I in 40 for PASA (Sarker et al., 1990). The low sensitivity is 
due to an estimated 15-50% amplification per cycle of most 
mismatch containing sequences under a variety of PCR conditions 
(Kwok et al., 1990). 
This method has recently been modified to allow the detection 
of mutations with comparable sensitivity to the RFLP-PCR method 
(Cha et al., 1992). The modifications are based on the ability to 
design specific primers for known mutations, where the primers are 
designed to be complementary to the known mutation product, and 
has a second mutation adjacent to the mutation being detected. 
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Hybridisation between mutant target DNA and mutant primer, 
plus an additional mutation, yield a heteroduplex with one mismatch. 
Under suitably modified PCR conditions amplification of single 
mismatch heteroduplex sequences can be carried out. However, 
hybridisation between wild type target DNA and the above primer 
yield a heteroduplex with two mismatches. The presence of a double 
mismatch reduces PCR efficiency to such an extent that amplification 
will be effectively non-existent, see figure 14, (the extension of the 
assay method from PASA is shown). PCR conditions have been 
optimised and this method has been used to detect the G to A 
transition in the 12the codon in the rat c-Ha-ras gene (Cha et al., 
1992). They report the ability to detect mutations where present as 
low as one in 
105 
 to background wild type DNA. 
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FIGURE 14. BASIS OF MAM ASSAY 
A 	5—/t\'\r\N'----G—G--A---../N/\.'\J\/\/'---3 Wild Type allele 
B 	 Mutant allele 
C 	3/'\,'/C—C—T.J\J\/\/'-5' 	Wild Type probe 
D 	3''\./N'—C—T—T—'A./\t5' 	Mutant probe 
Basis ofPCR Allele Specific 
Wild Type allele hybridised with Wild Type probe: A and C 
G---G—A —'./NN'N/\/"--3' 
	
C—C--T---/'J'---5' 	No Misntch 
Good amplification 
Mutant allele hybridised with Wild Type probe: B and C 
tc A —\/.J\/'--3' 3'—'N/\/'—T—'/\J'/'5' 	One Misntch Poor an,lification 
Wild Type allele hybridised with Mutant probe: A and D 
C+A T 	/\'\/ 	 One Mis mtch 
Poor amplification 
Mutant allele hybridised with Mutant probe: B and D 
3—''"---C—T—T--/'/\/\/'--5' 	NoMisntch 
Good Airpli&ation 
Basis of MAN/I Assay 
3' C—T—A 5' 	
Mutant probe 
plus nlutation* 
Wild Type allele hybridised with Mutant probe plus mutation *: A and E 
Two Misimtches 3'—'../\/'.JN/'--C 
No Amplification 






1.5 MISMATCHED BASE FAIRS AS IMMIUNOGENS 
The exact nature of the immune response to B-DNA is 
uncertain. It forms part of the immune response in SLE, though the 
induction of antibodies by B-DNA that will bind to native B-DNA 
has not been reported (see chapter 3). It is hoped that modification 
of duplexes such that they contain a mismatched base pair will 
suitably alter the structure of B-DNA so that immune recognition at 
this site may be possible. Most of the methods to detect point 
mutations in DNA duplexes rely on the in vitro production of 
mismatched base pairs. The properties of the subsequent 
heteroduplexes formed allowing them to be distinguished from 
perfectly paired sequences. 
1.5.1 Mismatch Structure 
Protein DNA interactions are involved in many of the 
fundamental processes that occur within cells. These include 
packaging, replication, recombination, restriction and transcription. 
The requirement for sequence specific recognition of DNA binding 
protein to DNA varies greatly. Many proteins, e.g., histories and 
DNA polymerases, have little sequence specificity. Others proteins, 
e.g. repressors and restriction enzymes have very high sequence 
specificity, possibly binding to a single site of 10-20 base pairs in a 
background of 10 
6 
 to 10 
9
base pairs,. 
It is now known that many mismatches that can be formed in 
DNA do not cause gross perturbations in the double helix. Proteins 
that recognise and repair these must therefore identify the DNA at 
the level of the individual base pair (Freemont et al., 1991). The 
neighbouring base pairs may also have a role in mismatch repair 
enzyme recognition. To discover the molecular mechanisms 
underlying mismatch repair a great deal of work has focused on the 
elucidation of the structure of a variety of synthetic DNA duplexes 
containing mismatched base pairs. 
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Polyacrylamide gel electrophoresis (PAGE) has been used to 
determine the longer range effects of mismatched base pairs on DNA 
sequences. A combination of three other techniques have been used 
to study the structure of mismatches in DNA, these are 
Ultraviolet Melting Studies. 
X-Ray Crystallography. 
Nuclear Magnetic Resonance (NMR) Spectroscopy. 
The literature on this subject is vast, key references only have 
been used in this discussion. Mismatches in DNA duplexes has 
recently been reviewed (Brown et al., 1993, and references therein). 
1.5.1.1 Polyacrylamide Gel Electrophoresis (PAGE) 
Although techniques such as NIVIIR spectroscopy can give us 
very detailed information on the spatial arrangement of the atoms, 
these are not useful for looking at long range structural changes, e.g., 
duplex bending.  Gel electrophoresis can provide such information on 
gross structural alterations in the duplex, which affect duplex 
migration within the gel. It has been found (Bhattacharya and Lilley, 
1989) that all mismatches are associated with minimal or no global 
structural changes (in a 458 base pair fragment studied). 
1.5.1.2 Ultraviolet Melting Studies 
The relationship between thermal melting and mismatch repair 
efficiency has been investigated (Werntges et al., 1986). All 16 
possible base pair arrangements were investigated in an 
octadecameric oligonucleotide duplex. The melting temperatures of 
all mismatched base pairs were lower than for fully matched 
duplexes. However, the melting temperatures did not correlate to the 
repair efficiency of the mispair. There was however a correlation 
between the type of mispair formed and the repair efficiency. Those 
mispairs that can form wobble base pairs e.g., T:G, G:G, C:A are 
best repaired, those forming  weak base pairing or permanent loops 
e.g., T:T and C:C are generally poorly repaired. 
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It was shown (Kramer et al., 1984) that mismatches that are 
most often formed show the highest repair efficiency and vice versa. 
Base pair mismatches most likely to occur during DNA replication 
are those that will form the best, all be it non Watson-Crick., base 
pairing i.e. wobble base pairs. Mismatches forming loops, i.e.., 
Pyrimidine:Pyrimidine pairing are not likely to be stable enough to 
be incorporated into newly synthesised strands. Thus evolution has 
developed a system to repair the most frequently occurring errors. 
1.5.1.3 X-Ray Crystallography and NMR Spectroscopy 
Crystals have been grown for various forms of synthetic 
oligonucleotides including those forming B-DNA, A-DNA and Z-
DNA, RNA-DNA hybrids, and RNA (reviewed by Kennard and 
Hunter, 1989). The first mismatched base pair to be characterised by 
X-ray crystallography was the purine:pynmidine G:T mismatch 
(Hunter et al., 1987). This base pair adopts a wobble configuration, 
viable non Watson-Crick hydrogen bonds between the base pairs. 
The thymine base projects into the major groove and the guanine 
base in the minor groove. The mismatched base is accommodated 
into the normal double helix by small adjustments in the 
configuration of the sugar phosphate backbone. 
The geometry of the G:T mismatch is essentially identical in 
all structures so far studied (B-, A-, and Z- form DNA). The A:C 
mismatch in DNA has a similar structure to the G:T mismatch. It can 
theoretically exist in two forms (Hunter et al., 1986). The adenine 
base may be either protonated or exist in a rare tautomeric form. 
X-ray crystallography cannot provide molecular details at the 
level of individual hydrogen atoms. However, ultraviolet melting 
studies and NMR spectroscopy indicate that DNA duplexes 
containing A:C base pairs are unusually stable at low pH, i.e.., under 
conditions favouring protonation at N-i of adenine (Brown et al., 
1990). It is possible to postulate base pairs with rare tautomers 
(Topal and Fresco, 1976a,b) previously discussed in section 1.2.3.1. 
However, it is not thought that these are likely to occur, and no direct 
evidence has been provided. 
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The G:A mismatch is unusual in that it can adopt many 
different forms and is repaired less efficiently than G:T and A:C 
mismatches. Four possible configurations have been proposed after 
characterisation studies using X-ray crystallography and NMR (Prive 
et al., 1987; Gao and Patel, 1988; Brown etal., 1986; Leonard etal., 
1990; Ebel etal., 1992; Lane etal., 1992). 
1.5.1.4 Conclusions 
The small degree of distortion associated with mismatches 
implies that recognition of gross structural perturbations will be 
difficult, and therefore direct recognition of the mismatched bases 
must occur by repair enzymes. X-ray crystallography indicates that 
duplexes with mismatches are not distorted. However, not all 
mismatches will allow crystal formation. 
It should be noted that the methods for analysing the structure 
of base pair mismatches may influence the results obtained. It has 
been argued that this may be particularly true when the method of 
analysis is X-ray crystallography. It has been suggested that the 
duplex conformation in solution, by interpretation of NMIR 
spectroscopy data, may not be identical with the static picture 
provided by X-ray diffraction in the crystal state (Roongta et al., 
1990). Structural variations observed in the X-ray crystallographic 
studies maybe a result of crystal packing forces. X-ray 
crystallographers argue that the crystals formed by DNA homo- and 
heteroduplexes are very different from those obtained by small 
molecules, they are in fact highly hydrated (up to 50%), and can to 
some extent be regarded as in solution. As many duplexes, some 
containing mismatches do not form crystals they argue against the 
forced nature of DNA crystal formation. 
The combined evidence of X-ray crystallography, NIMR 
spectroscopy, ultraviolet melting and gel electrophoresis suggest that 
mispairs can be incorporated into the double helix with only slight 
distortion of base stacking within the helix. Although the 
thermodynamic stability varies with the bases involved, the 
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stereochemical nature of the mispair is likely to determine the 
recognition of mismatched bases by repair enzymes. 
Those forming wobble base pairs (T:G, C:A, G:G) will 
produce more rigid, if slightly distorted, structures, and are therefore 
more likely to provide recognition sites for the repair enzymes. They 
are consequently more likely to form recognition sites for the immune 
system when synthetic duplexes containing these mismatch sites are 
used as immunogens. Mispairs where no hydrogen bonding (C:C, 
T:T, C:T) occur present no real recognition site to repair enzymes as 
they are not bulky and can easily be accommodated within the helix. 
However, they are thought to rotate in and out of the helix reasonably 
freely. Therefore antibodies to cytosine or thymme in the single 
stranded state may also recognise these bases in mispairs. 
Inimunisations with single  stranded DNA of either cytosine or 
thymine may produce antibodies that recognise mismatched base 
pairs containing their respective bases, i.e.. C:C, C:T, and T:T 
mispairs. 
1.5.2 Mismatches in DNA and Mismatch Repair 
1.5.2.1 Introduction 
The recognition of errors or mutations in DNA is essential to 
maintain the normal biological processes of all organisms. For 
example a system exists to remove DNA damage by 0(6)-alkylation 
of guanine (0(6)-dG). An enzyme 0(6)-alkyl guanine DNA 
transferase removes the alkyl group of 0(6)-dG, by means of an 
internal cysteine residue (Pegg et al., 1983) thus preventing this pre-
mutagenic lesion developing. 
Another enzyme system of great interest is the nucleotide 
excision repair in E. coli, known as the UvrABC complex, recently 
reviewed (Houten, 1990). This enzyme system recognises and 
repairs a large variety of different modifications to the Watson-Crick 
double helix, based on the overall structural perturbation caused by 
modification, rather than the specific agent causing the disruption. It 
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was thought that such an enzyme system may recognise the structural 
disruption due to the presence of mismatched base pairs. However, 
UvrABC does not recognise mismatches unless they contained  G or 
T residues that were first chemically modified with 1 -cyclohexyl-3-
(2-morpholinoethyl) carbodiimide, a reagent specific for unpaired G 
and T residues (Thomas et al., 1988). Thus UvrABC cannot be 
described as part of mismatch recognition systems. 
DNA replication is not error free, and a proofreading 
mechanism exists (Brutlag and Kornberg, 1972) which dramatically 
increases the fidelity of the base-pairing mechanism. However, this 
mechanism on occasions may fail and a normal, but incorrect 
nucleotide is introduced. This incorrect base forms a mismatched 
base pair site, and will lead to a point mutation on subsequent DNA 
replication. Mismatch repair systems exists that recognise and 
correct base pairing errors within the Watson-Crick helix. 
The efficient correction of mismatches that arise in DNA 
during replication is dependant on two main factors:- 
Mismatch recognition - guides the repair enzymes to the error; 
Strand discrimination - recognises the incorrect base. 
1.5.2.2 Mismatch Repair Systems 
A mismatch repair system was proposed in the 1960s 
(Holliday, 1964) in eukaryotic cells, as a mechanism for gene 
conversion in fungi. However, most of our knowledge is based on 
repair processes first suggested in the bacteria E. co/i (Nevers and 
Spatz, 1975). Bacteria possess multiple mismatch repair systems in 
two classes (Claverys and Lacks, 1986; Modrich., 1987; Radman, 
1988; Radman and Wagner, 1986): 
(A) A long patch repair system that processes a variety of mispairs 
in a strand specific manner involving excision-repair tracts of a 
kilobase or more. 
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(B) A short patch repair system that corrects a particular type of 
mismatch e.g. G:A in a strand specific reaction that involves a few 
nucleotides in the excision-repair tracts. 
In F. coli the long patch repair system (Wagner and Meselson, 
1976) and one short patch pathway (Au et al., 1988; Radicella et al., 
1988) function to eliminate DNA biosynthetic errors. A different 
short patch system is involved in the correction of G:T mispairs 
resulting from the spontaneous deamination of 5-methylcytosine in 
m5C:G base pairs (Lieb, 1985; Lieb et al., 1986; Jones et al., 1987; 
Zell and Fritz, 1987). 
1.5.2.2.1 Methyl-directed (long excision tract) Mismatch 
Correction 
This pathway in E. coli functions in the correction of base pair 
mismatches and small insertions and deletions generated through 
errors in DNA replication (Wagner and Meselson, 1976). The DNA 
strand to be repaired is identified by virtue of the methylation state of 
adenine, a post replicative process that occurs at d(GATC) 
sequences (Pukkila et al., 1983; Lu et al., 1983; Wagner et al., 1984; 
Kramer et al., 1984; Dohet et al., 1986; Raposa and Fox, 1987). 
There are five components involved in mismatch repair, Mut 
S. Mut L, Mut H, Mut U (also known as uvrD) and a single strand 
DNA binding protein. Mut S recognises all eight mismatches 
although not equally (Modnch, 1989; Radman and Wagner, 1988). 
After recognising and binding large regions of DNA, up to several 
kilobases, are excised and resynthesised during the course of repair 
(Wagner and Meselson, 1976; Su et al., 1988). The system corrects 
a variety of mismatched base pairs, but not all with equal efficiency 
(Kramer et al., 1984; Dohet et al., 1985; Jones et al., 1987c; Su et 
al., 1988; Lahue et al., 1989). 
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1.5.2.2.2 Mismatch Specific (short excision tract) Repair Systems 
Two systems exist that are independent of d(GATC) 
methylation. They have restricted mismatch correction specificity. 
(A) Very Short Patch (VSP) Mismatch Repair 
The VSP repair system was first identified by Lieb (1983, 
1985). This repair system recognises and corrects G:T mismatches 
that arise in resting DNA through spontaneous deamination of 5-
methylcytosine in m5C:G base pairs (Zell and Fritz, 1987). The 
recognition process is sequence specific. The repair usually involves 
the excision of less than 10 base pairs, and uses Mut L and Mut S 
gene products (Jones et al., 1987b; Lieb, 1987; Fritz and Zell, 1987) 
(B) Mut V Dependant G:A to G:C Correction 
The Mut Y repair system functions independently of Mut H, 
Mut L, Mut S, and Mut U gene products. The Mut Y protein is 
involved in a repair pathway that corrects G:A mismatches to G:C 
Watson-Crick base pairs (Radicella et al., 1988). The nicking 
activity of Mut Y is specific for G:A containing (weakly for A:C 
containing) DNA fragments, and has no activity on DNA containing 
other mispairs or homoduplex DNA. Mut Y removes the mispaired 
adenines of G:A (or A:C) mismatches, its endonuclease activity then 
cleaves at the first phosphodiester bond 3' to the apurinic/apyrimidic 
sites. 
The high specificity of Mut Y has recently allowed it to be 
used in a highly specific manner to detect mismatches in DNA 
artificially produced (Lu and Hsu, 1992). Thus, one of the biological 
methods to ensure DNA fidelity can be used in vitro to detect sites of 
point mutations. 
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1.5.2.3 Mismatch Correction in Eukaryotes 
Mismatch repair systems in eukaryotes have received 
considerable attention in the last decade. Base pair mismatches and 
small insertions and deletions have been shown to be repaired by a 
mismatch repair system in the fungi Saccharoinvces cerevisiae 
(Bishop and Kolodner, 1986). The efficiency of correction is 
dependent upon the nature of the mismatch pair (Bishop et at., 1987, 
1989). The order of mismatch repair efficiency was found to be: 
G:G > A:C, G:A, G:T> T:C > T:T, C:C, A-A. 
These results were confirmed (Kramer et at., 1989) except that 
C:C mispairs were not found to repair. 
1.5.2.3.1 Human Mismatch Repair Systems 
Transfection experiments in mammalian cells (Brown and 
Jiricny, 1987, 1988) have demonstrated that all mispair types are 
repaired. However they are repaired with different efficiencies and 
specificity's. Mismatches are divided into two classes, 
heterogeneous (involve different bases) and homogeneous (involve 
the same bases), and the type of repair reflects the class. 
For heterogeneous repair, repair to G:C predominates in all 
cases, with G:T showing both highest efficiency of repair and that 
repair preferring G:C correction. The picture is more complicated for 
homogeneous repair. The type of repair is highly dependent upon 
flanking sequences. The mismatch repair efficiencies for 
homogeneous base pairs was found to be: 
G:G>> C:C >A:A>T:T. 
The overall efficiencies for both classes was 
G:T, G:G>A:C>C:T> C:C >A:A>>A:G,T:T. 
42 
This general eukaryotic mismatch repair pathway (Holmes et 
al., 1990; Thomas et al., 199 1) is believed to be analogous to the 
Mut H, Mut L, Mut S pathway (Lu et al., 1983). 
A specific pathway may exist that recognises G:T and corrects 
to G:C in the absence of strand discrimination. G:T mismatches 
arising from deamination of 5-methylcytosine in resting i.e.. non-
replicating and non-recombining, DNA. They are repaired by a 
system that specifically removes the thymine and replaces cytosine 
(Wiebauer and Jiricny, 1989). This pathway not only prevents 
mutation it also maintains methylation patterns in DNA by restoring 
CpG sites. 
A 200kd protein extracted from HeLa cells, first thought to be 
a specific G:T binding protein (Jiricny et al., 1988), has been 
recently purified and further characterised (Hughes and Jiricny, 
1992). The protein binds independently of flanking sequences and 
has a high affinity for G:T mismatches. It has also been found to 
bind,  albeit with lower affinity, to A:C, G:U, G:G, and G:A 
mismatches. This protein is now regarded as a more general 
mismatch recognition protein, similar in function to Mut S in F. co/i. 
Eukaryotes posses another mismatch binding  protein. A 
1 00kda polypeptide has been found in extracts of a Burkitts 
lymphoma cell line (Stephenson and Karran., 1989). This binds 




Mismatched base pairs in DNA are a result of errors in DNA 
replication, spontaneous deamination of 5 -methyl cytosine to thymine, 
and occur during recombination processes. To avoid mismatch 
occurrence leading to point mutation, highly specialised repair 
systems exist. These function to maintain DNA fidelity by the 
recognition of mismatch sites and the ability to strand discriminate. 
Although most of the work has been carried out in F. coli there 
appears to be some correlation between their mismatch systems and 
those in mammalian systems. However, there is still a large amount 
to be discovered about mismatch repair. 
Mismatch repair processes are of great interest for their 
potential in screening for point mutations. Of particular note is the 
recent work in the development of a screening method for point 
mutation by using purified Mut Y to detect artificially produced 
mismatches (Lu and Hsu, 1992). By using several specific, or one 
general mismatch recognition protein(s) (with relatively high affinity) 
these proteins could be used to screen for all point mutation. 
Additionally, mismatch repair processes provide information 
on the types of mispairs that are best recognised. Where 
immunochemical methods to detect mismatches in DNA are to be 
investigated, the ability of mispairs to be recognised by the repair 
system may reflect the type of mispairs to be used as antigens in the 
production of anti-mismatched base pair antibodies. 
The proposed experimental work aimed to produce antibodies 
that are capable of specific recognition and binding to a variety of 
mismatched base pairs in DNA. This necessitates mismatched base 
pairs being structurally distinct from Watson-Crick base pairs. The 
physical evidence, provided by PAGE, UV melting, X-ray 
crystallography, and NIvIR, in addition to the methods of detecting 
point mutations supply considerable indication that duplexes 
containing a mismatched base pair are significantly dissimilar from 
fully complementary strands. This evidence is strongly supported by 
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the discoveries of both prokaryotic and eukaryotic systems capable 
of recognising  inismatched base pairs. This evidence provides 
considerable confidence at the outset of the project. The production 
of specific antibodies to mismatched base pairs would provide a 
substantial tool in mutation research. 
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CHAPTER 2: SYNTHESIS OF 
IMMUNOGENIC DNA SEQUENCES 
2.1 INTRODUCTION 
The object of the study was to produce antibodies that 
recognise mismatched base pairs in DNA duplexes. Synthetic 
oligonucleotides were used throughout the study. Production of 
synthetic oligonucleotides is now routinely carried out using 
automated DNA synthesisers and is briefly described below. There 
were several major concerns with the use of duplex oligonucleotides 
for immunisations. 
Firstly, the duplexes produced must remain thermally stable 
throughout the immunisation regime. Therefore, duplexes must only 
dissociate into single strands at temperatures above physiological 
temperature. The thermal stability of short DNA duplexes of less 
than 30 base pairs is greatly reduced by the inclusion of a 
mismatched base pair. The thermal stability of a duplex formed by 
the association of single  strands is also dependent upon the 
concentration of the strands. This is a crucial factor during 
immunisation as relatively small amount of duplex are used, diffusion 
and therefore dilution of DNA will occur during the immunisation 
regime. 
The thermal stability of an intramolecular duplex, formed by 
the folding of a self complementary single strand, is independent of 
the concentration of single strand present. It was hoped that the 
production of a suitable linker would allow the production of 
oligonucleotide duplexes containing a mismatched base pair that 
would not dissociate at physiological temperatures. A central non-
complementary region within an otherwise self complementary single 
strand could be used. However, during immunisation this would be 
likely to induce an immune response to single stranded DNA. The 
presence of anti-single stranded DNA antibodies, in addition to the 
desired anti-mismatched base pair antibodies, may interfere with the 
screening processes. 
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Secondly, DNA is unstable in serum due to the presence of 
nucleases (DNase enzymes). The oxidation step in the production of 
synthetic oligodeoxyribonucleotides can be altered such that a 
phosphorothioate (a sulphur analogue of phosphate), instead of 
phosphate group is produced. Phosphorothioate 
oligodeoxyribonucleotides are resistant to the effects of DNase 
enzyme degradation. They can be used parallel studies with standard 
oligonucleotides where DNA degradation is a concern. 
Thirdly, molecules with molecular weights <10,000 are 
generally considered to be too small to be immunogenic. They are 
usually covalently attached to larger carrier protein (e.g., Bovine 
Serum Albumin (BSA), Chicken Gamma Globulin (CyG), Keyhole 
Limpet Haemocyanin (KLH) prior to immunisations. A short double 
stranded oligonucleotide containing 20 or 30 bases is still relatively 
small to be used as an immunogen. It may therefore be necessary to 
covalently attach the oligonucleotide to a protein carrier. Due to the 
recent increase in non-radioactive DNA probe technology, there are 
several specific methods available to bind DNA and oligonucleotides 
to proteins. 
Where synthetic oligonucleotides are being produced this can 
be achieved by the use of modified nucleotide phosphoramidites, 
containing a specific linker function for conjugation (lJrdea et al., 
1988; Jablonski et al., 1986; Zuckermann et al., 1987). These can 
be incorporated as part of automated DNA synthesis such that the 
conjugation to the protein will occur at a defined site in the 
oligonucleotide. Secondly there are methods where the synthetic 
oligonucleotide is produced normally and then modified to allow 
conjugation to proteins (Renz and Kurz, 1984; Borel et al., 1984; 
Murakami et al., 1989; Chu and Orgel, 1988; Pollard-Knight et al., 
1990). However, the earliest methods to enhance immunogenicity of 
DNA relied on simple complex formation between positively charged 
methylated BSA (MeBSA) and negatively charged DNA (Sueko and 
Cheng, 1962). 
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2.2 OLIGODEOXYRIBONUCLEIC ACID SYNTHESIS 
Production of synthetic oligonucleotides is now routinely 
carried out using the solid phase phosphoramidite technique. Over 
the past 10 years this process has been automated, allowing the rapid 
production of synthetic oligodeoxyribonucleotides sequences of up to 
about 100 bases. Modern machine-aided oligonucleotide synthesis 
has recently been reviewed (Brown and Brown, 1991) so only an 
overview will be presented here. 
The process uses the addition of successive, protected, 
cyanoethyl phosphoramidites to a nucleoside attached at the 3'-
terminus to a solid phase. The incoming phosphoramidite binds to 
the deprotected 5'-terminus of the solid phase nucleoside. An excess 
of reagent is used to drive the reaction to completion, any unreacted 
5' solid phase is then capped, rendering it inert  to further monomer 
additions. The phosphite group is then oxidised to produce a 
phosphatetriester group. The dimer is then ready for subsequent 
phosphoramidite additions. 
On the completion of monomer additions, to produce the 
desired oligonucleotide sequence, the protecting groups can be 
removed and the sequence cleaved from the solid support, see figure 
15. The major advantage of this process is that a large number of 
reactions can be carried out without the need for elaborate 
purification procedures between each reaction. Excess reagents are 
simply removed by repeated solvent wash steps, and the process is 
rapid. 
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FIGURE 15 OVERVIEW OF AUTOMATED DNA SYNTHESIS 
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2.3 RESULTS AND DISCUSSION 
2.3.1 Production of an Oligonucleotide Linker Molecule 
2.3.1.1 Synthesis of Linker Molecule, Compound [3] 
Two molecules (tetraethylene glycol and 1,1 2-dodecanediol) 
were investigated as candidate molecules to be used as the DNA 
interstrand linker. The interstrand linker was to be incorporated at a 
specific site into an oligonucleotide during automated DNA 
synthesis. Automated DNA synthesis occurs via successive addition 
of phosphoramidites, therefore the candidate linker molecules need to 
be converted into phosphoramidites. Both tetraethylene glycol and 
1,1 2-dodecanediol can be readily converted by reaction with 
dimethoxytrityl chloride followed by 2-cyanoethyl N,N-
disopropyichiorophosphoramidite (see experimental) to produce 
phosphoramidites. 
The purification of the products for the conversion 1,2-
dodecanediol to a phosphoramidite proved more difficult when 
compared to that for tetraethylene glycol. Therefore, tetraethylene 
glycol was chosen as the linker molecule. Fig 16 shows the synthesis 
of the tetraethylene glycol monomer, for solid phase oligonucleotide 
synthesis, compound [3]. 
2.3.1.2 Coupling Efficiency during Oligonucleotide Synthesis 
The coupling efficiency of the tetraethylene glycol 
phosphoramidite during solid phase synthesis, as measured by the 
amount of trityl cation release (measured at 494nm), was 80%. This 
coupling efficiency was low when compared to that observed for the 
normal (A, C, G and T) DNA phosphoramidite synthesis monomers 
(coupling efficiency >98%). 
The time allowed for phosphoramidite coupling to the 5' end of 
the oligonucleotide chain is known as the wait step. For normal 
DNA phosphoramidite synthesis monomers this wait step was 30 
seconds. The coupling efficiency for the tetraethylene glycol 
50 
FIGURE 16. SYNTHESIS OF TETRAETHYLENE GLYCO 
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monomer was improved to greater than 94% when an extended wait 
step of 3 minutes was carried out for its addition. The chemistry for 
solid phase synthesis has been optimised for the use of normal 
phosphoramidite bases. The use of extended wait procedures is not 
uncommon practise where unusual phosphoramidite additions are 
being carried out. 
During automated DNA synthesis it was essential that each 
incoming monomer couples to the immobilised oligonucleotide with 
high efficiency. If this does not occur the overall yield will be very 
low. Ideally 100% coupling is desirable, in practise >98% was 
acceptable. For one addition of an unusual monomer a reduced 
coupling efficiency can be tolerated. All of the normal bases added 
prior to or after compound [3] coupled at >98%. Compound [3] was 
stored at -200C under nitrogen prior to use, and was stable for at 
least 3 months. 
Three other non-nucleotide monomer phosphoramidites were 
used in this project. The coupling efficiency of the three monomers 
in solid phase synthesis was high. Amino Link 2 monomer (see 
figure 17) coupled at >98%, the Biotin monomer (see figure 18) 
coupled at >97%, and the Dinitrophenyl monomer (see figure 19) 
coupled at >95%. The use of these three monomers will be 
discussed later. 
F3C -NH °  
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FIGURE 19. DINITROPHENYL MONOMER 
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2.3.2 Purification of DNA Sequences 
All of the phosphoramidite monomers used contain a 5-4,4-
dimethoxytrityl group. After addition of each nucleotide this group 
remains attached to the oligonucleotide. The group was removed, 
under acidic conditions, to allow the next nucleotide to react. This 
group is very hydrophobic and thus DNA sequences with this group 
attached are retained by reverse phase HPLC columns relative to 
DNA sequences without this group. Oligonucleotide purification by 
reverse phase HIPLC was thus facilitated by synthesising sequences 
and leaving the 5' terminal trityl group attached. All failure 
sequences will have had this group removed prior to the terminal 
nucleotide addition. Therefore, only the full length oligonucleotide, 
the desired product, will contain a tern-unal 5' 4,4-dimethoxytrityl 
group. 
Apart from the cytosine lOOmer phosphorothioate (C lOOPS) 
all sequences were purified by both reverse phase HIPLC and gel 
filtration. Cl OOPS is to be used as an immunogen to raise anti-
cytosine antibodies that may also interact with mismatches containing 
cytosine. All C lOOPS failure sequences will contain only cytosine 
bases and thus I-IIPLC purification was unnecessary. Figure 20 shows 
a typical HIPLC purification of an oligonucleotide. 
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FIGURE 20. HFLC PURIFICATION AND ANALTICAL 
I-TPLC OF COLLECTED PEAK FOR Al2XT12 
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2.3.3 OlionucLeotide Sequences Produced. 
Oligonucleotides were synthesised for three main purposes 
To establish the thermal stability of covalently linked duplexes. 
The production of sequences for immunisation. 
The production of sequences to establish screening procedures. 
2.3.3.1 12mer Duplexes for Thermal Stability Studies 
A series of short oligonucleotides were synthesised to 
investigate the effect on thermal stability of duplexes linked via the 
tetraethylene glycol monomer, compared to duplexes formed by the 
association of independent complementary strands. Sequences were 
produced such that they were fully complementary, or contained a 
central base pair mismatch, see Table 2. An additional sequence was 
produced incorporating  two consecutive additions of the 
tetraethylene glycol monomer. This was to confirm that the linker 
was of an optimum length for duplex formation. 








Where X is the tetraethylene glycol linker, -(CH7CH70)40- 
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2.3.3.2 15mer DNA Duplexes 
1 5mer DNA duplexes were synthesised to carry out 
immunisation experiments with, see table 3. The first five DNA 
sequences AT15-CC15 are 15mer duplexes, stabilised with an inter 
strand linker, and the duplexes contain a central matched base pair 
AT or mismatched base pair AA, AC, GG or CC, see figure 21. 
DNA sequences AA 1 5P-CC 1 5P were similar except the sequences 
were "complete phosphorothioate oligonucleotides". 
Table 3, 15mer Duplexes for Immunisation 
NAME SEQUENCE 
AT 15 A7AA7-X-T71:T7 
AA 15 A7AA7-X-T7AT7 
AC15 A7AA7-X-T7CT7 
GG1 5 A7GA7-X-T7GT7 
CC 15 A7CA7-X-T7CT7 
AA15P A7AA7-X-T7AT7 
AC 1 5P A7AA7-X-T7CT7 
GG iSP A7GA7-X-T7GT7 
CC1 5P A7CA7-X-T7CT7 
FIGURE 21. 15nr DUPLEX FOR IMMUNIZATIONS 





2.3.3.3 75mer DNA Duplexes 
Two 80mer single stranded DNA sequences were synthesised 
such that on hybridisation a 75mer duplex containing normal 
nucleotides would form. The nucleotides in the duplex formed were 
predominantly A and T, but contained 4 evenly spaced AC 
mismatched base pairs. The 3-termini of each oligonucleotide 
overhangs the duplex by five nucleotides and all of these were 
thymine phosphorothioates, see figure 22. 
Two 80mer single strands were synthesised as above 
incorporating 4 evenly spaced GT mismatched base pairs. For this 
duplex the five overhanging 3-thymine phosphorothioate nucleotides 
were replaced with adenme phosphorothioates. The duplexes, 
named AC75 and GT75 respectively, were used to carry out 
immunisation experiments. 
FIGURE 22. 75mer DUPLEXES FOR IMMUNIZATIONS 
MISMATCHES 	 PHOSPHOROTHIOATES 
NORMAL PAIRINGS 
PHOSPHOROTHIOATES 
Additionally SOmer single strands were synthesised as above, 
except that on hybridisation the sites for the mismatched base pairs 
were replaced with GC paired nucleotides. This was to be used as 
control DNA during screening experiments for anti-mismatched base 
pair antibodies. It was thought that the presence of single stranded 
regions, that contained one of the bases present in the mismatch of 
interest should be avoided. When screening for specific mismatch 
antibodies they may give rise to false positives. Therefore, two types 
of duplex containing GC matched pairs were produced. To screen 
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against antibodies for AC mismatched base pairs the 3-terminal 
phosphorothioate nucleotides were Ts, and for GT mismatched base 
pairs they were Ass, named GC75T and GC75A respectively. 
2.3.3.4 C100PS Single Stranded Oligonucleotide 
A complete phosphorothioate oligonucleotide containing 100 
cytosines (C lOOPS) was synthesised to carry out immunisation 
experiments. This single  stranded sequence will not directly be able 
to elicit an immune response such that mismatched base pairs are 
recognised. However, it may produce antibodies to single strands 
containing cytosine. It was hoped that mismatched base pairs 
containing cytosine may be sufficiently displaced from the duplex 
that some recognition by anti-polycytosine antibodies may occur. 
2.3.4 Additional Oligonucleotide Sequences Produced 
A series of additional oligonucleotides were synthesised as the 
project developed. These were generally produced in response to the 
development of screening techniques. These modified 
oligonucleotides will be briefly described here. Their role in assay 
development will be elaborated upon in the relevant sections of 
chapter three. 
2.3.4.1 Single Strands and Biotin Labelled Oligonucleotides 
A variety of single stranded oligonucleotide sequences were 
synthesised, see Table 4, to develop one of the immunoassays to 
screen for antibodies specific for mismatched base pairs. The assay 
was based on the binding of a biotin end labelled single stranded 
oligonucleotide to streptavidm pre-immobilised on a solid support. A 
fully complementary oligonucleotide strand (second strand), or one 
that would form a single central mismatched base pair, would then be 
allowed to hybridise to the immobilised strand to form a duplex. 
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TTT-DNP T1 pIT i p-Dinitrophenyl 
TCT-DNP T1 0CT 1  p-Dinitrophenyl 
TAT-DNP T1 OAT i  p-Dinitrophenyl 
AC 1 5B Biotin-A7AA7-X-T7CT7 
C20B 	I C')O-Biotm 
To ensure equivalent duplex formation occurred, for fully 
matched and mismatched duplexes, and was maintained through the 
time course and conditions of the immunoassay,  a method to 
quantitate duplex formation was required. It was decided that 
labelling the second strand with 2,4-dinitrophenyl (DNP) would 
allow us to compare duplex formation for fully matched and 
mismatched sequences. The amount of DNP labelled solid phase 
duplex formed could be measured using an anti-DNP antibody. 
A series of DNP end labelled second strands were synthesised 
such that duplexes would either be fully matched or contain a single 
base pair mismatch, The DNP monomer is a non-nucleoside 
phosphoramidite produced by a colleague in Edinburgh (Grzybowski 
et at'., 1993). The DNP labelled oligonucleotide was synthesised 
such that on hybridisation to the immobilised biotin labelled 
oligonucleotide the biotin and DNP groups will be at opposite ends 
of the duplex. Therefore, the detection of the DNP group will not be 
sterically hindered by its proximity to the solid phase. Additionally, 
the hybridisation of the second strand to the support may also be 
hindered, by the presence of the DNP group, if the DNP group was 
positioned at the site adjacent to the solid phase. 
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As an alternative method to immobilise  duplex 
oligonucleotides to a solid phase a sequence was produced as a 
1 Smer copy of AC 15 (used for immunisation experiments) with the 
addition of a 5'-terminal biotin group, see figure 23. A cytosine 
20mer was also synthesised end labelled with biotin.  This was 
attached to solid phases as above to screen C lOOP immunisations. 
FIGURE 23. BIOTIN LABFIJ.FD 15mer DUPLEX 
Mismatch Base Pair 
Linker 
AAAAAAAAii 
2.3.4.2 Extended Biotin-Linker Labelled Oligonucleotides 
A series of single  stranded and duplex (via tetraethylene glycol 
linker) oligonucleotides were synthesised, see Table 5. They were 
end labelled to biotin directly (as previously described), or linked via 
an additional tetraethylene glycol monomer. The additional linker 
serves to extend the distance between the biotin group and 
oligonucleotide. An additional series of oligonucleotides were 
synthesised, incorporating a dinitrophenyl group as well as the biotin 
group. This provides a readily detectable label to establish 
oligonucleotide duplex binding to immobilised streptavidin as 
previously described. The DNP group was incorporated into the 
oligonucleotide such that it forms an integral part of the interstrand 
linker, thus the DNP group and the biotin group are at opposite ends 
of the duplex. 
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Table 5, Biotin-Linker Oligonucleotides 
NAME SEQUENCE 
AT 1 OB A1 p-DNP-X-T 1  p-Biotm 
AT 1 OBL A 10-DNP-X-T1 p-X-Biotin 
Cl OB DNP-C 1  p-Biotin 
CI OBL DNP-C 1  p-X-Biotin 
CuB DNP-C1i-Biotin 
AC30BL A1 pM 1 oMi p-X-T  ioTi  0CT  1  p-X-Biotin 
GT30BL A10GA10GA10-X-T10TT10TT1p-X-Biotin 
C20BL C20-X-Biotin 
Where DNP is Dinitrophenyl. 
2.3.5 UV Melting Curve Determinations 
The thermal dissociation of the strands in a double helix is 
called melting  because it occurs abruptly at a specific temperature. 
The melting  temperature (Tm) is defined as the temperature at which 
half of the helical structure is lost. The melting  of DNA was 
monitored by measuring the increased absorbance, hyperchromism, 
caused by the unstacking of the base pairs as the duplex dissociates. 
The absorbance was monitored using a UV light source at 264nm. 
The Tin values presented are the mean value, of triplicates, obtained 
by UV melting experiments. Tin values in all cases are +1- 0.5°C or 
less. 
2.3.5.1 12mer Duplexes 
Concentration dependent UV melting curve determinations 
were carried out to compare the thermal stability of 12mer duplexes. 
The duplexes were formed by hybridisation of separate single 
stranded oligonucleotides and a self complementary sequence 
covalently linked, via a central tetraethylene glycol, at one end. The 
thermal stability of fully matched duplexes and those containing a 
central base pair mismatch were studied. 
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Graph 1 shows the results of typical UV melting curve, and 
derivative of the curve for a I2mer duplex produced by combining 
Al2 and T12. The characteristic DNA melting curves were obtained 
for all DNA concentrations tested. The temperature at the maximum 
point of the first derivative of the melting curve was the melting 
temperature (Tm). 
GRAPH 1 UV MELTING CURVE OF Al2 + T 12 
31?Mfi 	327,ii 
The Tin's of fully matched, graph 2, and mismatch containing, 
graph 3, duplexes (formed by separate single stranded 
oligonucleotides and a self complementary sequence (described 
above) were measured at several DNA concentrations. 
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For all of the DNA concentrations tested the Tin of sequences 
was increased if the strands were covalently linked with tetraethylene 
glycol, see Graph 2 and 3. In the absence of the linker the Tm of the 
sequences (fully matched or containing a central mismatched base 
pair) decreases by about 2°C as the concentration of the DNA is 
halved. The tetraethylene glycol linker greatly increased the melting 
64 
temperature of the duplex with and without the mismatch. It would 
be possible to envisage the tetraethylene glycol linked single strands 
forming a larger duplex via hybridisation of two separate self 
complementary strands. However, for both matched and single 
mismatched base pair containing sequences the melting temperature 
was found to be independent of DNA concentration. Thermal 
melting of duplexes formed by independent self complementary DNA 
strands is concentration dependent. Therefore, as expected the linker 
was creating a duplex formed by a single strand forming a hairpin 
loop. 
It was essential that the duplex produced was not only formed 
via a hairpin loop, but also that the hairpin loop allowed all base 
pairing to occur. if the linker was of insufficient length then some of 
the nucleotides would be involved in forming the hairpin loop and 
thus exist as short single strand regions, either side of the linker 
molecule. This would slightly reduce the thermal stability, but more 
importantly would provide an extra, unwanted, form of DNA. These 
short single stranded regions could significantly influence the 
immune response during immunisation experiments. This situation 
would be unacceptable for our purposes. 
Concentration dependant UV melting studies on the 12mer 
duplex AT2X (incorporating two tetraethylene glycol linkers) were 
undertaken to investigate the length of the linker. The Tin of AT2X 
was equivalent to that of AT 12 (the same duplex with only one 
linker) at all concentrations tested (8, 17, 33, 65, 130 p.g/ml). if the 
Tm for AT2X was higher than AT 12 this would indicate that AT2X 
was forming a more stable duplex. Therefore, this study clearly 
indicates that the linker molecule was of optimum length for the 
stabilisation of oligonucleotide duplexes. 
Duplexes produced by the hybridisation of short independent 
oligonucleotides, such that the duplex contained a mismatched base 
pair, will be unsuitable for immunisation.  Synthetic DNA duplexes 
will be used for immunisation  experiments at a concentration < 
1000 j.xg/ml. Diffusion of the duplexes during the immunisation 
regime will further decrease the concentration of the duplexes. The 
Tm of 1 000 j.ig/ml of a 1 2mer, containing a central base pair 
mismatch, could very roughly be estimated by extrapolation (based 
on the observation on page 64) of the results presented in graph 3. 
The Tm at 1000tgIml would be about 28.7°C by this process. The 
DNA will thus remain fully dissociated during the immunisation  as its 
Tm will be well below physiological temperature. The concentration 
of this duplex with a Tm at physiological temperature would be about 
20mg/mi. 
The incorporation of the linker has not only increased the Tm 
to above physiological temperature it also means that the sequence 
will remain as a duplex even at high dilution. Although the Tm of 
stabilised duplexes for perfectly matched 12 mer duplexes is very 
high, the Tm of mismatch containing sequences is only about 10°C 
above physiological temperature. The Tm is the temperature at 
which the half of the duplexes will be dissociated. It is important 
that majority of the DNA is in the form of a duplex. Melting of 
sequences occurs over a 15-20°C range, about 10°C either side of 
the Tm. The use of slightly longer sequences should increase the 
duplex stability, such that a Tin > 500C will be obtained. 
It was decided to synthesise a series of 1 5mer duplexes of a 
similar nature to the tetraethylene glycol stabilised 1 2mer duplexes, 
described above, to be used in immunisations experiments. 
2.3.5.2 15mer Duplexes 
UV melting studies were carried out on 1 Smer duplexes 
containing a variety of mismatched base pairs, stabilised by the 
tetraethylene glycol linker, see Table 6. Concentration dependent 
studies were not carried out on the 1 Smer duplexes as the thermal 
stability of hairpin loop duplexes has been previously demonstrated 
to be independent of the DNA concentration. 
Table 6, UV Melting of 15mer Duplexes. 











All the normal oligonucleotide duplexes containing a 
mismatched base pair have a melting temperature well above 
physiological temperature. These sequences should remain as 
duplexes during immunisation  experiments. 
The Tm's for complete phosphorothioate 1 5mer duplexes, are 
all below physiological temperature. This will cause the sequences 
to dissociate into single stranded oligonucleotides after 
immunisations. These sequences will not present a mismatched base 
pair within a duplex to the immune system and so were unsuitable for 
immunisation experiments. Phosphorothioates contain a sulphur atom 
in the phosphate backbone of DNA instead of one of the oxygen 
atoms. Sulphur atoms are bulkier than oxygen atoms. The decrease 
in Tin may reflect constriction of duplex formation caused by all the 
phosphate linkages being replaced with bulkier phosphorothioates. 
Further studies could investigate the use of phosphorothioate linkages 
dispersed amongst normal phosphate linkages within a duplex, such 
that thermal and enzymic stability are combined. 
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2.3.5.3 75mer DNA Duplexes 
The melting temperatures for the 75mer duplexes was high, 
see Table 7. These longer sequences were not chemically stabilised 
by an inter strand linker. Although AC75 and GC75 contained four 
instead of one mismatched base pair, the greater number (71) of 
Watson-Crick base pairs affords reasonable duplex stability to these 
sequences. The thermal stability of DNA duplexes of this length 
were independent of concentration and they will therefore remain 
hybridised even at high dilution. The five phosphorothioate bases 
should reduce nuclease degradation of these DNA duplexes during 
immunisation experiments. The Tm of the two fully complementary 
strands, GC75T and GC75A are equivalent and slightly higher than 
mismatched sequences, as expected.. 







2.3.5.4 Biotin Labelled Duplexes 
AT 1 O and AT1OLB are tetraethylene glycol stabilised lOmer 
duplexes. They were synthesised such that biotin was directly 
attached or attached via a 13 atom spacer arm at the free 5'-terminal 
of the duplex. They were produced to investigate possible steric 
hindrance, for biotirilstreptavidin interaction caused by the close 
proximity of the bulky duplex DNA to the biotin molecule. 
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The tetraethylene glycol linker for these duplexes was 
extended by the additional adjacent incorporation of the DNP 
monomer. The incorporation of this monomer simply creates a larger 
hairpin loop, and the thermal stability of the duplex is still high, see 
Table 8, as seen for AT2X. These duplexes should remain fully 
associated over the time course of the assay. 




A 3 65.1 
GT3O 68.4 
The Tm's of the two 30mer duplexes was higher than 
physiological temperature, thus, during the immunoassay for 
screening anti-DNA antibody production the duplex will remain 
associated. They also each provide two mismatched base pair 
binding sites for antibody recognition, compared to AC15B which 
contained only one. 
2.4 OLIGONUCLEOT1DE PROTEIN COMPLEXES 
The 1 5mer duplexes containing mismatched base pairs were to 
be used for immunisation experiments. These duplexes have a 
relatively low molecular weight, <10,000, compared to the type of 
proteins that are commonly used as immunogens, molecular weight 
usually >50,000. Because of this, and the inherently low 
immunogenicity it was decided to investigate the conjugation of the 
duplexes to large proteins. Compounds of low molecular weight to 
be used to evoke an immune response (haptens) are routinely bound 
to large "carrier proteins" to aid their immunogenicity. 
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DNA sequences are degraded by serum nucleases if injected 
into animals. The tetraethylene glycol linked terminus may afford 
some protection as it presents an unusual structure to the nuclease 
enzymes. If the non-linked terminus of the duplex is attached to a 
carrier protein then it will be shielded from direct attack of serum 
nucleases. The proximity of the protein to the whole oligonucleotide 
duplex should also afford some nuclease protection to the sequence 
by sterically hindering the approach of serum nuclease enzyme. Thus 
conjugation may aid immunisation by increasing the size of the 
immunogen and the serum half life of the oligonucleotides. 
Antibody production from immunisation / fusion experiments 
is generally detected by means of an enzyme linked immunosorbent 
assay (ELISA). This requires adsorption of antigenic material to 
plastic microtitre plates. In general, proteins bind well to these solid 
phases, whereas binding of duplex DNA is limited. Therefore, the 
production of oligonucleotide/protein conjugates could also be used 
to enhance the binding of the duplexes to the microtitre plates for 
screening of antibody production. 
Heterobifunctional linkers were used to conjugate 
oligonucleotides to proteins. These methods involved the synthesis 
5'- amino linked oligonucleotides, Fig. 17. The reactions included 
the use of disuccinimidyl suberate (DSS) and 3-maleimidobenzoyl-N-
hydroxy succininiide ester (MBS). DSS links amino modified 
oligonucleotides to primary amine sites, e.g. lysine  residues, in 
proteins. NMS links through a primary amine  at one end and thiol at 
the other. To obtain a stable thiol modified oligonucleotide, amino 
modified oligonucleotides were reacted with N-succinimidyl-3 -(2 
pyridyldithio) propionate. The proteins free primary amines are 
functionalised using MBS. The stable thiol modified oligonucleotide 
can then be reduced, with dithiothreitol, to give a suiphydryl group 
just prior to reaction with an MBS modified protein. 
A variety of purification methods were investigated to try to 
separate the products of the conjugation reactions. HPLC methods 
were unsuccessful, and gel filtration was attempted. Using sephacryl 
S-400 no separation of protein and oligonucleotides was observed. 
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Sephadex G50 separated the oligonucleotide from protein, however, 
we were never confident that the proteinloligonucleotide peak 
obtained was specific conjugation products or simply a non-covalent 
protein/oligonucleotide complex. To dissociate possible 
proteinloligonucleotide complexes, increased salt concentration in 
the gel filtration elution buffers were used. However, the increase in 
salt concentration affected the separation of the reaction products. 
Thus we were unable to confirm specific conjugation had occurred. 
Nucleic acid immunisations are often carried out as complexes 
formed by mixing with MeBSA. It was decided to abandon the 
specific conjugation procedures and use nucleic acidfMeBSA 
complexes. These complexes should also provide protection from 
serum nuclease enzymes during immunisation experiments. For 
larger oligonucleotides, 75mer duplexes and C lOOPS single strand, 
the greater molecular weight should obviate the need for a carrier 
protein. The addition of phosphorothioate nucleotides for all of the 




All solvents were of analytical grade. All reagents, specified 
laboratory grade, were supplied by FSA Laboratories Supplies unless 
otherwise stated. Tetraethylene glycol and dimethoxytrityl chloride 
were supplied by Aldrich Chemicals Co. Ltd., 2-cyanoethyl N,N-
diisopropylchloro phosphoramidite was supplied by Fluka. Methyl 
ester of Bovine  Serum Albumin (MeBSA), Tris (Tris 
[hydroxymethyl) aminomethane) base and Tris HCl were supplied by 
Sigma Chemicals Company. Acetonitrile (HPLC grade) was 
supplied by ABI, ethylenediaminetetraacetic Acid (EDTA) disodium 
salt, BDH Ltd., toluene p-sulphonic acid (AR) by May and Baker 
Ltd., and chloroform-d by Goss Scientific Instruments Ltd. 
Anhydrous Reagents 
Anhydrous pyridine was obtained by distillation from potassium 
hydroxide. Anhydrous tetrahydrofuran was obtained by distillation 
from sodium-benzophenone. Anhydrous dichioromethane was 
obtained by distillation from calcium hydride. Anhydrous 
triethylamine was obtained by distillation from calcium hydride. 
'H-NMR spectra were obtained using a Brucker WP-200 
spectrometer (200.13 M1I-iz). 13C-NMR spectra were obtained using a 
Brucker WP-200 spectrometer (50.32 Mil-Iz). 31P-NMR spectra were 
obtained using an FX-90Q spectrometer (81 MHz). 
Mass Spectra 
Mass spectra were obtained using a Kratos MS50TC spectrometer. 
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Chromatography 
Flash column chromatography was carried out using silica gel 
60 (220-440 mesh ASTM), (Fluka). Thin layer chromatography 
(TLC) was carried out on aluminium sheets, silica 60 F256,  0.2mm 
(Merck). Six solvent systems were used for TLC (each contained 
1% triethylamine). 
Solvent Systems for TLC 
SOLVENT MOBILE PHASE Ratio (vlv) 
A Dichioromethane : Ethyl acetate 1:1 
B Dichloromethane : Ethyl acetate 9:1 
C Dichioromethane : Methanol 95:1 
D Ethyl acetate  
B Ethyl acetate : Diethyl ether 1:1 
F Ethyl acetate : Toluene 7:3 
Synthesis of Compound 121. 11 -(4,4' -Dimethoxytrityloxy)-3,6,9-
tnoxa-undecan-1 -ol. 
Dimethoxytrityl chloride (1 .Oeq., 9.72g, 28.7mmol), dissolved 
in anhydrous pyridine (40 mIs), was added dropwise to tetraethylene 
glycol (5.Oeq., 27.90g, 144mmol) which had previously been dried 
by co-evaporation with anhydrous pyridine (2x5Omls). The solution 
was allowed to stir at room temperature for two hours. 
Dichioromethane (175 mIs) was added to quench the reaction and the 
organic phase extracted with 5% aqueous sodium bicarbonate (2x100 
mis). The organic phase was dried over sodium sulphate, filtered, 
then evaporated in vacuo. The residue was then dissolved in 
minimum solvent B and purified, by flash column chromatography on 
a silica gel column, to give an oil (8.713g, 17.5mmol, 61%). RF: 
0.18 (solvent A); 0.15 (solvent B); 0.31 (solvent Q. FAB ms 
(M+H) mlz 496. NMR data 8H  (CDCI3) 2.82-2.95 (1H, brs, OH), 
3.21-3.26 (2H, t, CH2CH20C(Ar)3, J=5.2Hz), 3.55-3.71 (14H, in, 
[(CH2CH20)3 and (OCH2CH20(Ar)3)]), 3.71 (6H, s, OCH3), 6.79-
6.85 (5H, m, aryl), 7.18-7.49 (8H, m, Ar-0-); c(CDCL3) 54.94, 
61.46, 62.90, 70.15, 70.50, 72.30, 76.25, 76.89, 77.52, 85.70, 
112.80, 126.42, 127.51, 127.96, 129.83, 136.07, 144.85, 158.13. 
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Synthesis of Compound (31  (Tetraethylene glycol monomer). 
2-Cyanoethyl- [11 -(4,4'-di methoxytrityloxy)-36,9-tri oxa-undecan-
1-vu N,N-diisopropvlphosphoramidite. 
To a stirring solution of [2] (1 .Oeq., 1.592g, 3.2mmol, which 
had previously been dried by coevaporation with anhydrous 
tetrahydrofuran (10 mIs)) in 20 mIs of anhydrous tetrahydrofuran was 
added diisopropyiethylamine (4.Oeq., 1. 18g, 1.59 mIs, 9.1mmol) and 
2-cyanoethyl N,N-diisopropylchlorophosphoramidite (1 .Seq.,1 .14g, 
1.07 mis, 4.8mrnol). The reaction was quenched after 30 minutes 
with ethyl acetate (50 mis). The organic phase was extracted with 
10% aqueous sodium bicarbonate (2x80 mis) followed by saturated 
aqueous sodium chloride (50 mis). The organic phase was dried over 
sodium sulphate, filtered and evaporated in vacuo. The residue was 
then dissolved in solvent D and purified by flash column 
chromatography. The appropriate fractions were then precipitated 
from excess hexane at 780C. The product was obtained as an oil 
(1.20g, 1 .72mmol, 54%). RF: 0.68 (solvent D); 0.64 (solvent E); 
0.53 (solvent F). 31P-NIvIR data (CDC13): 148.75 lppm. FAB ms 
(M+H) mlz 697. NIMIR data: 8H  (CDC13) 1.14-1.19 (m, 14, 
N[CH(CH3)212), 2.56-2.63 (2H, t, OCH2CH2CN, J=6.5Hz), 3.18-
3.24 (2H, t, OCH2CH2CN, J=5.2 Hz), 3.62-3.70 (16H, in, 
(CH2CH20)4), 3.77 (6H, s, OCH3), 6.79-7.84 (13H, in, aryl); 6c  
(CDC13) 20.07, 20.20, 24.41, 24.49, 42.76, 43.01, 55.04, 58.17, 
58.54, 62.24, 62.97, 70.57, 70.99, 71.13, 76.29, 76.93, 77.56, 85.76, 
112.87, 117.62, 126.49, 127.59, 128.04, 129.90, 136.16, 144.93, 
158.21. 
Oligonucleotide Synthesis 
Synthesis of oligonucleotide sequences was carried out by the 
solid phase phosphoramidite method, using Applied Biosystems ABI 
380B DNA synthesisers. Cyanoethyl phosphoramidite monomers 
(Adenine (A), Cytosine (C), Guanine(G), Thymine (T)) for DNA 
synthesis were supplied by ABI, and were used as 0. 1M solutions in 
DNA synthesis grade acetonitrile (Applied Biosystems). The 
tetraethylene glycol monomer, compound [3], was a non-nucleoside 
cyanoethyl phosphoramidite, and was used as a 0.2M solution in 
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anhydrous dichioromethane. The biotin monomer was a non-
nucleoside cyanoethyl phosphoramidite (Cambridge Research 
Biochemicals), the Aminolink-2 phosphoramidite was supplied by 
ABI, both were used as normal phosphoramidite monomers. The 
dinitrophenyl (DNP) monomer (Grzybowski et al., 1993) a non-
nucleoside cyanoethyl phosphoramidite (2-cyanoethyl [ 1 -(4,4'-
dimethoxytrityloxy)-4-oxa-6-(2,4-dinitrophenylamino) hept-2-ylJ 
N,N-diisopropylamino phosphoramidite). It was used as normal 
DNA synthesis monomers, and was kindly donated by Mr. John 
Grzybowski. 
Normal cyanoethyl phosphoramidite monomers for DNA 
synthesis are coupled for 30 seconds during which they react with the 
terminal end of the oligonucleotide. The tetraethylene glycol and 
DNP monomers required an extended wait step of 3 minutes during 
its addition to the oligonucleotide. All sequences were deprotected 
in 33% ammonia at 550C for Shours), they then underwent gel 
filtration on NAP- 10 columns pre-equilibrated with distilled water. 
All sequences (except aminolink-2) were synthesised leaving the 5'-
dimethoxytrityl group attached to aid purification by reverse phase 
I-IIPLC (see below). All aqueous solutions and buffers were prepared 
using distilled water and filtered through 0.45itm Sartolon (nylon 66) 
filters (Sartorius GmbH). 
Reversed Phase HPLC 
Column - Brownlee Aquapore Reverse-Phase Octyl (C8) 
Dimensions 	: 25cm x 10mm 
Loop volume : imi 
Buffer A 	: 0.1M ammonium acetate pH 7.0 
Buffer B : 0.1M ammonium acetate pH 7.0 + 50% 
acetonitnie 
Flow rate 	: 3mllmin. 
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Gradient: 
Time/minutes % Buffer A % Buffer B 
0:00 100 0 
2:00 100 0 
3:00 80 20 
23:00 20 80 
24:00 0 100 
27:00 0 100 
28:00 100 0 
30:00 100 0 
Detection: UV 264nm 1 .0jM scale synthesis analytical 
UV 290nm 1 .0.iM scale synthesis preparative. 
Gel Filtration using NAP-10 Columns 
NAP- 10 columns (Pharmacia) are prepacked disposable 
columns containing Sephadex G25 Medium of DNA Grade. They 
are used for the removal of low molecular weight (<1000) 
compounds from nucleic acids and oligonucleotides (>10 
nucleotides) in aqueous solution. Removal of low molecular weight 
compounds was carried out by equilibrating the column with 3x5m1 
of distilled water (or the desired buffer), under gravity. The nucleic 
acid/oligonucleotide sample was then loaded in imi of aqueous 
solution. 1.5m1 of eluting solution (distilled water or buffer) was 
added and the eluant collected, if the column is pre-equilibrated 
with, and the loaded sample eluted with, a buffer solution other than 
the buffer solution originally containing the oligonucleotide then an 
effective buffer exchange occurs. Thus nucleic acids can be purified 
from low molecular weight contaminants, and transferred to an 
alternative buffer solution if required, rapidly. 
Detritylation of Trityl-On Purified Sequences 
After HPLC purification, solutions containing 'Trityl-On' 
oligonucleotide sequences were evaporated to dryness, and 
detntylated with 3% acetic acid (lOmis). After 30 minutes  they were 
evaporated to dryness and dissolved in appropriate buffer. Low 
molecular weight contaminations were removed by gel filtration 
using NAP- 10 columns, as described above. 
Oligonucleotide Sequences Produced. 
Sequences for 12 mer DNA duplexes 
Name 	Sequence 
AAA  5'- AAA AAA AAA AAA -3' 
TTT1 5'-TTT TTT TTT TTT-3' 
TAT1 5'- TTT TTA TTT TTT -3' 
AT12 5'- TTT TTT TTT TTT XAA AAA AAA AAA A -3' 
AA12 5'- TTT TTA TTT TTT XAA AAA AAA AAA A -3' 
AT2X 5'- TTT TTT TTT TTT XXA AAA AAA AAA AA-3' 
15 mer DNA duplexes 
Name 	Sequence 
• AT 15 5'- TTT TTT TTT TTT TTT XAA AAA AAA 
AAA AAA A-3' 
• AA 15 5'- TTT TTT TAT TTT TTT XAA AAA AAA 
AAA AAA A-3' 
AC15U 5'- TTT TTT TCT TTT TTT XAA AAA AAA 
AAA AAA A-3' 
GG 15 5'- TTT TTT TGT TTT TTT XAA AAA AAG 
AAA AAA A-3' 
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CC 15 5'- TTT TTT TCT TTT TTT XAA AAA AAC 
AAA AAA A-3' 
AA15P 5'- TsTsTs TsTsTs TsAsTs TsTsTs TsTsTs XAA 
AsAsAs AsAsAs AAsAs AAA A -3' 
AC15P 5'- TsTsTs TsTsTs TsCsTs TsTsTs TTT X8AA 
AsAsAs AsAsAs AsAsAs AAA A -3' 
GGISP 5'- TsTsTg TsTsTs TsGsTs TsTsTs TsTsTs XAA 
AsAsAs AsAsGs AsAsAs AAA A -3' 
CC  5P 5'- TsTsTs TsTsTs TsCsTs TsTsTs TsTsTs XsAsAs 
AsAsAs AsAsCs AAAs AsAsA A 3' 
AC15B 5'- BTT TTT TTC TTT TTT TXA AAA AAA 
AAA AAA AA -3' 
X = (CH7CH20)40; 
N=A,C, G,T,orX, 
Ns = Phosphorothioate link. 
75 mer Duplexes 
Two 80mer single stranded DNA sequences were synthesised, 
shown below, such that on hybridisation a 75mer duplex, containing 
normal DNA bases, would form containing 4 evenly spaced AC 
mismatched base pairs. The 3'-termini of each end overhung the 
duplex by 5 bases, all of these were phosphorothioate bases. Two 
80mers were synthesised as above incorporating 4 evenly spaced GT 
or CC mismatched base pairs. Sequences forming GC matched base 
pairs at the sites of the above mismatches were also synthesised. 
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Oligonucleotide 1 
5'- TTA TTT ATT ATA TTT X1AA TAT AAA TTA 
TTA X2AT TAA TAA ATT ATA X3TA TAA ATT TAA 
TAA X4AT AAT TAA TAA TTT PsPsPs PsPs -3'. 
Oligonucleotide 1 
5'- AAA TTA TTA ATT ATX1 TTA TTA AAT TTA 
TAX, TAT AAT TTA TTA ATX3 TAA TAA TTT ATA 
TTX4 AAA TAT AAT AAA TAA PsPsPs PsPs -3'. 
For duplex forming: 
AC75 mismatch X1 = A, X2 = C, X3  = A, X4  = C and Ps = T 
GT75mismatch X1 =G,X,=T,X3 =G,X4 =Tand P5=A 
CC75 mismatch X1  = C, X2 = C, X3 = C, X4  = C and Ps = T 
GC75Amatch X1 =G,X2 =C,X3 =G,X4 =C and P=A 
GC75T match X1 = G, X2 = C, X3 = G, X4  = C and Ps =T 
Single Strands to form Immobilised Duplex 
TTT 	5'- TTT TTT TTT TTT TTT TTT TTT -3' 
TCT 	5'- TTT TTT TTT TCT TTT TTT TTT -3' 
. TAT 	5'- TTT TTT TTT TAT TTT TTT TTT -3' 
Is 	1111 1111 	111, 	111 1 	111 111 	11 	11 1 	1111 	1111, 
TTTDNP 	5'- DTT TTT TTT TTT TTT TTT TTT T -3' 
TCTDNP 	5'- DTT TTT TTT TTC TTT TTT TTT T -3' 
TATDNP 	5'- DTT TTT TTT TTA TTT TTT TTT T -3' 
DNP = 2,4-Dinitrophenyl 
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Cl OOPS was synthesised with all bases having 
phosphorothioate linkages, the sequence was only purified by gel 
filtration. 
Biotinylated Sequences 
C20B 5'- BCC CCC CCC CCC CCC CCC CCC -3' 
AT lOB 5'- BTT TTT TTT TTX DAA AAA AAA AA -3' 
AT1OBL 5'- BLT TTT TTT TTT XDA AAA AAA AAA -3' 
C1OB 5'- BCC CCC CCC CCD -3' 
CIOBL 5'- BLC CCC CCC CCC D-3' 
Cl lB 5'- BCC CCC CCC CCC D -3' 
AC30BL 5'- BLT TTT TTT TTT CTT TTT TTT TTC TTT 
TTT TTT TXA AAA AAA AAA AAA AAA 
AAA AAA AAA AAA AAA A-3' 
GT30BL 5'- BLT TTT TTT TTT TTT TTT TTT TTT TTT 
TTT TTT TXA AAA AAA AAA GAA AAA 
AAA AAG AAA AAA AAA A -3' 
C20BL 5'- BXC CCC CCC CCC CCC CCC CCC C -3' 
B = Biotin; X and L = (CH7CH20)40; D = 2,4-Dinitrophenyl. 
DNA Monomer Coupling Efficiency 
Coupling efficiencies of phosphoramidites were measured by 
comparison of the absorbance, at 494nm, of the dimethoxytrityl 
cations produced in the detritylation steps of successive synthesis 
cycles. The coupling efficiency was calculated as follows: 
Coupling efficiency = [A494(cycle n)/ A494(cycle n- 1)] x 100. 
The absorbance values were measured as dilutions of the 
detritylation product fractions in I 25m1 of p-Toluene 4-suiphonic 
acid (0.1M) in acetonitrile. Triplicate values for each tntyl colour 
were measured. 
UV Melting Curve Determination 
DNA UV melting curves were obtained using the Lambda 15 
UV/VIS Spectrophotometer (Perkin-Elmer), the Digital Temperature 
Controller for UV Spectrophotometer (Perkin-Elmer) and 
PECSS/peccs2 and PECSS/tconv3 programmes for UV 
spectroscopy (Perkin-Elmer), all programmes run on an IBM 
Personal Systems/2, Model 50 computer. 
Fully complementary or partially complementary strands, 
containing one or more base pair mismatches, were monitored for 
their melting curves between 50C - 750C. Where single stranded 
sequences were combined equimolar concentrations of each were 
used. Each sequence under investigation was measured in triplicate. 
All sequences were dissolved in sodium dihydrogen phosphate buffer 
(iOmM), EDTA (1.0mM) and sodium chloride (0.20M), pH 7.2 prior 
to melting curve determinations. 
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CHAPTER 3 PRODUCTION OF ANTI- 
MISMATCHED BASE PAIR ANTIBODIES 
3.1 ANTIBODIES TO NUCLEIC ACIDS 
3.1.1 Introduction 
The immunogenicity of nucleic acids has received 
considerable attention. In general, mammalian DNA, most notably 
dsDNA in the B-conformation, is poorly immunogenic, even when 
complexed to a carrier protein and administered in adjuvant (Plescia 
and Braun, 1967). However, other forms of nucleic acids, from a 
variety of sources, have been found to be immunogenic. These 
include ssDNA, Z-DNA, DNA-RNA duplexes, ssRNA, dsRNA, 
triple helix DNA, and mono, di and tri-nucleotides. 
Production of antibodies by immunisation with nucleic acids 
has not produced an immune response directed to dsDNA. However, 
a major area of research has focused on the autoimmune disease 
systemic lupus erythematosus (SLE). The hallmark of this disease 
are the presence of autoantibodies to the B-form of dsDNA (Tan et 
al., 1966; Schwartz and Stollar, 1985; Stollar, 1986; Braun et al., 
1986). The production of these types of antibodies provided 
evidence of a possible immunogenic role for nucleic acids. The 
development of methods to monitor anti-DNA antibodies occurring 
in autoimmune diseases aids the development of methods to detect 
the production of anti-nucleic acid antibodies after immunisations. 
Autoantibodies for nucleic acids have also served as a source of 
information on protein-nucleic acid interactions (Anderson et al., 
1988). 
Antibodies that recognise nucleic acids are also of interest as 
probes of different nucleic acid structures. Antibodies have been 
produced that recognise and study Z-form DNA duplexes (Nordheim 
et al., 1981; Lee et al., 1984a), triple helical structures (Lee et al., 
1987), and various ribopolynucleotides (Rudkin and Stollar, 1977). 
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3.1.2 Historical 
The earliest reported production of antibodies to nucleic 
acids, by direct immunisation, came in the 1940's. A globulin was 
detected in equine sera, pre-inoculated with pneumococci, possessing 
an activity for nucleic acids (Lackman et al., 1941). Similar 
globulins were not found in normal sera. The reaction was inhibited 
by purine nucleotides, nucleosides and bases. Pyrimidines showed 
weak inhibition, and pentoses and phosphates showed no inhibition. 
Related methyl purines such as caffeine and theophyllin also gave 
rise to inhibition. In addition the reaction was sensitive to ionic 
strength and dependant upon the type of ions present. 
There have been other reports on antibodies raised by nucleic 
acid immunisations (Blix et al., 1954; Phillips et al., 1958). At about 
the same time antibodies were detected in the sera of patients with 
SLE, that reacted with DNA (Deicher et al., 1959). 
Another source of anti-DNA antibodies was discovered using 
ruptured T4 bacteriophage (Levine et al., 1958). Antibody 
production appeared to be directed towards the DNA. Further work 
on a polyclonal antisera obtained from immunisation with ruptured 
T4 bacteriophage was undertaken. Antisera was found to react with 
thermally denatured DNA from T4 bacteriophage, but showed no 
reactivity with native T4 DNA or non T4 DNA (Levine et al., 1960). 
The T4 bacteriophage DNA is known to contain modified bases. 
These are repeating units of glucosylated 5-hydroxymethylcyto sine. 
The reactivity of the antisera was suspected to be directed towards 
these modified bases. Murakami et al., (196 1) showed that 
antibodies raised by ruptured T4 bacteriophage DNA was directed 
towards glucosylated 5 -hydroxymethylcyto sine, rather than DNA 
that was unmodified. 
During  the early 1960 evidence was presented that RNA may 
be immunogenic. Barbu and Panigel (1960) produced antibodies that 
reacted with RNA. The reactivity was directed to the modified bases 
which are present in RNA. 
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The validity of the results of all of the assay systems used to 
detect anti-DNA antibodies described above are open to criticism. 
The purity of the nucleic acid preparations and characterisation of the 
DNA in the antigen-antibody reactions are inconclusive. Murakami 
et al., (1961) suggested that DNA contaminated with 0.5% w/w 
amino acids obtained from DNA hydrolysates was sufficiently pure, 
and assumed that the antibodies were specifically recognising the 
DNA. Any contaminating material present may interfere with correct 
characterisation of antibody specificity. The antibody may recognise 
DNA, contaminant, or DNA-contaminant as a non covalent complex. 
Additionally, non-covalent interactions of any contaminant (small 
molecules or proteins) may alter the conformation adopted by the 
complex (Pohl et al., 1973; Thammen et al., 1981; Sinha and 
Patterson, 1983). 
Chemically pure DNA was found not to induce antibody 
formation (Plescia et al., 1964). Antibody production was possible 
where DNA-protein complexes were used, however, the antibodies 
produced were directed against thermally denatured DNA. 
Characterisation of such antibodies is difficult because denatured 
DNA will contain single stranded regions, but may also fold into 
secondary structures where self complimentary regions allow some 
internal base pair formation. The induction of anti-dsDNA 
antibodies has proved more difficult. 
Over the last 20 years many laboratories have been 
investigating the ability of the immune system to produce antibodies 
to modified bases, nucleosides, nucleotides, oligonucleotides and 
DNA. The aim of the research is the quantitation and localisation of 
DNA adducts using antisera elicited against DNA adducts and 
carcinogen modified DNA. Highly specific polyclonal and 
monoclonal antibodies have been raised to a large number of 
adducted species including various alkylation products, and 
metabolites of benzo(a)pyrene (Poirier etal., 1980; Santella etal., 
1984) and aflatoxin-Bi (Hsieh etal., 1988). 
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Antibodies have been generated with two different types of 
immunogens. Modified DNA can be electrostatically complexed to 
methylated bovine serum albumin, or monoadduct derivatives can be 
covalently coupled to carrier proteins. However, a detailed review of 
immunodetection of adducted or modified bases in DNA is beyond 
the scope of this text. There have been several recent reviews on the 
subject (Poirier, 1981; Poirier, 1984; Strickland and Boyle, 1984; 
Santella, 1988; Poirier 1991) and references there in. 
3.1.3 Antibodies to Nucleosides and Nucleotides. 
Immunisations using immunogenic forms of DNA, e.g. T4-
bacteriophage DNA (Levine et al., 1960) did not produce DNA 
specific antibodies. In the production of anti-nucleic acid specific 
antibodies, nucleosides and nucleotides (nucleic acid building blocks) 
have been used as immunogens. BSA-purine (adenine and guanine) 
conjugates have been used to immunise  rabbits (Butler et al., 1962). 
Antibodies released into the serum of these immunised animals were 
found to react with denatured but not native DNA. BSA 
ribonucleoside and ribonucleotide conjugates have been shown to be 
immunogenic (Erlanger and Beiser, 1964). Antibodies binding to 
adenine, guanine and cytosine recognised bases in RNA and 
denatured DNA. Antibodies binding to uridine recognised RNA but 
not DNA. BSA-deoxyadenylate conjugate produced antibodies to 
deoxyadenylate (Humayun and Jacob, 1973). They found that the 
sugar and phosphate backbone were important immunogenic 
components as well as the heterocyclic bases. 
Antibodies have been raised to dinucleoside phosphates 
(Wallace et al., 197 1) and trinucleoside phosphates (Bonavida et al., 
1972) conjugated to BSA. These antibodies recognised the 
immunogen and also the individual nucleosides. The nucleoside 
coupled to the protein carrier and not the terminal nucleoside was 
found to form the immunodominant portion of the antigenic 
determinant. 
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In the autoinimune disease SLE antibodies have been found 
in the serum that recognise dsDNA (Tan et al., 1966). This has 
raised the question of whether dsDNA antibodies are inducible or 
only formed after some kind of somatic mutation. The specificity of 
inducible antibody formation for a variety of nucleic acid structures 
has thus received considerable attention. 
3.1.4 Antibodies to DNA from SLE patients. 
Systemic lupus erythematosus (SLE) is characterised by an 
exuberant immune response. This is manifested by the presence of 
autoantibodies with a wide spectrum of specificity's, and by their 
presence in high concentration. There are at least 11 separately 
distinct antigens in SLE ranging from DNA to various nucleic acid 
binding proteins (Tan, 1989). As previously stated the hallmark of 
SLE are antibodies to dsDNA, although there is a greater frequency 
of autoantibodies to ssDNA (Stollar et al., 1962). 
Antibodies to DNA were the focus of research in the 1960s 
and 1970s. The subject has been reviewed (Tan, 1982), and more 
recently (Stollar, 1986). In general antibodies defined as reactive 
with ssDNA recognise polymers of purine and pyrimidine bases 
which are available for reaction with antibody in the single stranded 
form but not accessible in the dsDNA form. Antibodies reactive with 
dsDNA recognise mainly the deoxyribose phosphate backbone and, 
therefore, are reactive with both dsDNA and ssDNA. In certain 
cases antibodies recognise helical structures on dsDNA and only 
react with ssDNA where secondary structures were possible. 
Secondary structure can occur as a consequence of folding caused by 
base pairing of self complementary nucleotide sequences. 
The use of antisera from SLE patients to evaluate anti-DNA 
responses was limited by the multitude of the immunogenic response. 
However, antibodies to DNA arise spontaneously in different strains 
of murine lupus (Theofilopolous and Dixon, 1985). This is an 
autoimmune disease of inbred mice, that develops in a similar manner 
to human SLE. New Zealand Black (NZB) and the F-i hybrids 
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produced by the mating  of NZB and New Zealand White were the 
first described models of spontaneous lupus-like autoimmune disease 
(Heylen and Howie, 1963). Two other strains were subsequently 
described in the literature (Andrews et al., 1978). A lupus like form 
of human SLE in a non-human primate (rhesus macaque) has recently 
been proposed (Anderson and Klein, 1992). 
Hybridoma technology allowing the production of specific 
monoclonal antibodies has provided information on the precise 
characterisation of autoantibodies to DNA. Hybridomas have been 
produced by fusing the spleens of autoimmune diseased mice to 
create a variety of cell lines secreting anti-DNA monoclonal 
antibodies (Pollard, et al., 1986; Pisetsky and Caster, 1982; 
Andrezejewski et al., 1981). Monoclonal autoantibodies to DNA are 
being used both as probes for nucleic acid structure and also to try 
and elucidate the nature of the immune  response in the production of 
anti-dsDNA antibodies that cannot be mimicked by immunisation 
regimes. 
Surprisingly, murine lupus models respond poorly to 
exogenous immunisations with mammalian dsDNA (Stollar, 1981; 
Madaio, 1984). The ability of lupus individuals to generate high 
affinity responses to self endogenous antigen, despite poor responses 
to immunisations with self antigens or foreign antigen thus remains 
an enigma. To elucidate possible mechanisms of SLE antibody 
production, comparisons with two anti-DNA producing systems have 
been investigated. Firstly,  the production of antibodies to DNA by 
bacterial immunisations,  and secondly the drug induced lupus like 
symptoms seen in several mammalian systems. 
3.1.5 Immunisation with Bacterial DNA 
Bacterial DNA has been shown to be immunogenic in mice 
(Gilkeson et al., 1989a,b; Messina et al., 1992). A sex difference for 
E. coli DNA induced antibodies in Balb/c immunised mice has been 
reported (Palmer et al., 1992), with the greater response to all test 
antigens occurring in sera of female mice. The induction of anti- 
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DNA antibodies in normal mice with E. co/i DNA is attributed to the 
presence of unusual nucleotide sequences that are rare in mammalian 
DNA (Gilkeson et al., 1989a,b; Pisetsky et al., 1990). Monoclonal 
antibodies produced from Balb\c mice immunised  with E. co/i DNA 
bind  predominantly to denatured DNA containing AATGTG 
sequences (Messina et al., 1992), rather than denatured DNA in 
general. Antibody production has also been shown to occur after 
immunisation with viral DNA (Schattner and Ragar-Zisman, 1990,   
Flaegstad, 1988), and from parasites (Jones, 1977; Fischer et al., 
1981, Ternynck et al., 1990). 
The sera of non-SLE patients infected with E. co/i have been 
found to contain anti-DNA antibodies (Robertson and Pisetsky, 
1992). They reacted to both ssDNA from E. co/i and denatured 
DNA from a variety of eukaryotic sources. They also reacted to 
synthetic oligonucleotides poly dC and poly dT. Although E. co/i 
induced antibodies to DNA showed high cross reactivity to DNA, as 
seen in SLE, no anti-mammalian dsDNA reactivity has been found 
for F. co/i induced antibodies. 
Monoclonal antibodies produced after Balb/c mice were 
immunised with F. co/i DNA were found to bind ssDNA, and to non-
nucleic acid antigens, e.g., 3-galactosidase, cardiolipin, and various 
nuclear antigens (Pyun et al., 1993). This resembles lupus anti-DNA 
antibodies in the pattern of cross reactivity. However, no binding of 
these induced anti-DNA antibodies was observed with mammalian 
dsDNA, the hallmark of SLE. 
Genetic analysis of variable regions of anti-DNA antibodies 
from E. co/i immunised  and auto immune mice have been carried out 
(Foster et al., 1992; Gilkeson et al., 1993). Similarities in the amino 
acid sequences in the complementarity determining regions (CDRs), 
(part of the variable (V) region which forms the antigen binding site), 
have been observed. Many spontaneous anti-DNA antibodies have 
multiple arginine residues in the V region, particularly in part of the 
CDR, not seen for antibodies from bacterial DNA inimunised animal 
(Gilkeson et a/., 1993). These differences may account for the 
inability of induced anti-DNA antibodies to bind mammalian dsDNA. 
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This may point to important mechanisms underlying the production 
of antibodies to DNA in SLE patients. They suggest that as well as 
DNA presentation, to initiate the immune system to respond, 
inimunoregulatory abnormalities may exist in SLE development. 
Normally immunoregulation removes autoantibody producing cell 
precursors from the immune system. In SLE immunoregulation 
abnormalities prevent the elimination of autoimmune cell precursors 
thus an autoimmune response occurs. 
3.1.6 Z-DNA and Drug Induced Lupus 
The right handed B-form of DNA is the usual double helical 
structure as proposed by Watson and Crick. The Z-form is a left 
handed helix which occurs in nucleic acid with alternating G-C 
purine-pyrimidine sequences under certain conditions of solvent 
composition or helical stress. Z-DNA was first discovered using 
atomic resolution X-ray crystallographic analysis of the 
hexanucleoside pentaphosphate (CpGpCpGpCpG), (Wang et al., 
1979). In this conformation the DNA forms a double helix with 
Watson-Crick base pairs and anti-parallel sugar phosphate chains, 
the sugar phosphate back-bone following a zig-zag course, hence Z-
DNA. 
Z-DNA can be induced from solutions of B-DNA by altering 
the ionic strength (Pohl et al., 1973; Thammen et al., 198 1) provided 
that the DNA has alternating punne-pynmidine sequences. 
Brominated dC (5BrdC) in poly (dG-dC) : poly (dG-dC) sequences 
remains in the Z-form independent of ionic strength (Lafer et al., 
1981). The methylated polymer, poly (dG-5MedC): (dG-5MedC), 
(methylation at position 5 of cytosine) was converted to Z-DNA at 
relatively low concentrations of MgCl2 (Behe and Felsenfield, 1981). 
While it is the base sequence or primary structure of nucleic 
acids that contains the genetic information, the helix conformation is 
also important for site specific interactions. Protein-nucleic acid 
interactions are critical for regulation of gene expression, replication 
and packaging of genetic material. It is also possible that a small 
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region of Z-DNA within a DNA molecule that is mostly in the B-
DNA form could act as a signal for protein binding. There is 
evidence to suggest a role for Z-DNA in recombination (Kmiec and 
Hollomen, 1986). Unusual structures such as cruciforms (Lilley, 
1980; Panayotatos and Wells, 1981), and bent helixes (Marini et al., 
1982; Zahn and Blattner, 1987) might constitute protein recognition 
sites. Therefore, there is great interest in the factors influencing 
nucleic acid conformation and recognition of such by proteins. 
The structural features of Z-DNA as compared to B-DNA 
were detected by the use of immunochemical methods, Z-DNA was 
found to be highly immunogenic in experimental animals (Lafer, et 
al., 198 la,b; Zarling et al., 1984, Gunnia et al., 1991). Antibodies 
have been produced from immunisations with Z-DNA that are highly 
specific for Z-DNA, showing no cross reactivity with B-DNA, RNA, 
DNA-RNA hybrids and several synthetic polynucleotides (Lafer et 
al., 1981b). 
It has been reported that drugs such as hydralazine bind to 
DNA duplexes (Sinha and Patterson, 1983), and can facilitate the 
transition of poly (dGm5dC) from the B-form DNA to Z-form DNA 
(Thomas and Messner, 1986). The Z-DNA helix differs from B-
DNA in several structural features that render it highly immunogenic. 
The purine bases of Z-DNA are rotated into a syn rather than the 
anti-conformation found in B-DNA. (Stollar, 1986). To allow the 
pyndine bases to hydrogen bond their deoxynbose groups are 
rotated. With this alternating different geometry of adjacent bases, 
there are associated changes in the backbone geometry, the base 
stacking, and the orientation of the base pair axis to the fibre axis. 
With the alternating pyrimidine-purine sequence, the repeating unit of 
Z-DNA is a dinucleotide, rather than a mononucleotide seen for B-
DNA. 
From an immunological point of view the deoxyribose-
phosphate backbone in Z-DNA follows a zig-zag left handed course 
compared to the smoother helix of right handed B-DNA. The 
interphosphate distances differ from those of B-DNA, and the helix is 
slimmer with more base pairs per helical turn. In addition, the major 
groove in B-DNA is replaced by a convex surface on which the 
purine N7 and C8 and the pyrimidine CS positions are exposed and 
are accessible to recognition by proteins (Stollar, 1986). Therefore, 
the structure of Z-DNA is quite immunological distinct from B-DNA. 
It is believed that the production of autoantibodies to dsDNA 
in drug related lupus might involve the induction and stabilisation of 
Z-DNA (immunologically distinct from B-DNA) by drugs such as 
hydralazine (Thomas and Messner, 1986 Thomas et at., 1993). 
3.1.7 Conclusions 
There is great interest in the study of antibodies that bind to 
nucleic acids. Antibodies which bind DNA occur spontaneously in 
the autoimmune disease Systemic Lupus Erythematosus and have 
been implicated in the pathogenesis of the disease (Schwartz and 
Stollar, 1985). These antibodies have a large range of specificity's. 
There is also great interest in studying general DNA binding protein 
interactions. Hybridoma technology allows the production of large 
amounts of anti-DNA antibody (a DNA binding protein) to be 
produced. Many of the types of interactions between antibodies and 
DNA are likely to be similar to those between DNA binding proteins 
and DNA. 
The production of antibodies by classical hybridoma 
technology relies on the immunogenicity of DNA to evoke a 
response in immunised animals. Although the B-conformation of 
DNA is generally considered to be non-immunogenic, other forms of 
DNA have proved useful in the production of anti-DNA antibodies. 
In addition, several strains of mice have developed a form of SLE 
and spontaneously produce anti-DNA duplex antibodies. The fusion 
of splenocytes, from lupus mice, with a myeloma cell line has 
allowed monoclonal antibodies to duplex DNA to be produced 
(Stollar, 1986). Also the synthetic duplex poly d(TC). poly d(GA) 
has been found to be weakly immunogenic, and monoclonals have 
been produced (Lee et at., 1985). 
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3.2 PRODUCTION OF ANTIBODIES: GENERAL 
3.2.1 The Immune System 
The vertebrate immune system is a network of molecules and 
cells capable of distinguishing self from non-self. It functions to 
protect against the invasion of foreign micro-organisms and their 
toxins. Part of the vertebrates immune system is an adaptive 
response (1-lilderman and Reddy, 1973; Marchalonis, 1976). This 
works by continually scanning its environment and initiating the 
destruction of any foreign material found. This adaptive system 
learns from experience and remembers its encounters. It is thus 
specific, adaptive and possesses memory. 
There are two types of leukocytes involved in the adaptive 
immune response, the B-lymphocyte and T-lymphocyte. Soluble 
proteins known as antibodies are products of antigenically activated 
B-lymphocytes (plasma cells). The antibodies are highly specific 
recognition elements of the "humoral" immune response. Each 
antibody has a specific affinity for the foreign material that stimulated 
its production. T-lymphocytes also aid the humoral response by 
helping stimulate the changes that transform resting B-lymphocytes 
to antibody producing plasma cells. 
Immunisation of an animal causes the production of a wide 
range of antibodies capable of binding to the immunogen, the 
antibodies are released into the serum of the immunised animal. On 
antigenic challenge the majority of the B-lymphocytes remain 
unstimulated. Only a small number possessing the specific receptors 
are stimulated, the receptors being cell surface immunoglobulins on 
the B-lymphocytes (Ada, 1970; Raff, 1971). Antigenic stimulation 
initiates B-lymphocyte activation to antibody producing cell. Thus 
several related but not identical highly specific immunoglobulins all 
recognising the same antigen are released into the animals 
circulation. 
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3.2.2 Monoclonal Antibodies 
For many purposes the use of polyclonal antisera is perfectly 
acceptable, and good accuracy and precision of assays utilising these 
sera will be obtained. For certain applications polyclonal antisera 
may be unsuitable, e.g. they may not be able to distinguish very 
closely related molecules. In these instances affinity purification of a 
polyclonal antisera may be used to increase the specificity of the 
remaining antibody content of the antisera. However, it is often more 
desirable to use a monoclonal antibody. 
A monoclonal antibody is defined as the antigen specific 
homogeneous immunoglobulin product of an immortalised plasma 
cell clone. Monoclonal antibodies are therefore the selected product 
secreted from a hybrid cell line produced by the fusion of a myeloma 
cell line with an antibody producing plasma cell (Kohler and 
Milstein, 1975, 1976). Cell fusion technology now allows the 
immortalization of specific antibody producing cells, followed by 
their growth in tissue culture systems to generate potentially 
unlimited quantities of monoclonal antibody. Monoclonal antibody 
secreting hybridomas will probably be needed where specific 
recognition of a mismatched base pair in a DNA duplex, compared to 
fully matched DNA, is required. 
Each fusion experiment combines spleen cells with a 
plasmacytoma cell line. For the first two weeks post fusion the 
supernatants from cell culture wells are frequently changed. This 
serves two purposes. Firstly, it ensures a constantly high 
concentration of nutrients around the cells. This is particularly 
important in terms of hypoxanthine (H) and thymine (T) 
concentration. These are essential for hybrid cell growth in the 
presence of aminopterin (A) put in the medium to kill unfused 
plasmacytoma cells and hybrid cell formed by fusions between two 
plasmacytoma cell lines. The selective medium is normal growth 
medium containing H, T and A, usually called 'HAT' 
Secondly, it ensures the removal of dead material from the 
wells. Fusion wells will contain other cellular products in addition to 
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the desired splenocyte-plasmacytoma hybrid cell line. Each fusion 
will also give rise to plasmacytoma-plasmacytoma hybrids, 
splenocyte-splenocyte hybrids, and unfused plasmacytomas and 
unfused splenocytes. All of the cell types apart from splenocyte-
plasmacytoma hybrids (the desired cell type) will die in the selective 
'HAT' culture conditions used. The dead cells do not remain strongly 
attached to the plastic culture wells and are removed over successive 
changes of medium. 
Production of hybndorna cell lines by cell fusion is essentially 
a random process and occurs at low frequency (about 1 in 105). 
Immunisation greatly increases the percentage of active spleen cells 
producing the desired antibody. Thus, immunisation greatly 
increases the probability that the relatively rare cell fusion events 
occur between myelomas and the desired antibody producing spleen 
cells. Additionally, fusions are carried out with large numbers of 
spleen cells (about 1-2x108). The stimulatory effect of immunisation 
will vary with immunogenicity of the test antigen. As previously 
stated dsDNA is generally regarded as poorly immunogenic. There 
are two main disadvantages when trying to produce monoclonal 
antibodies to potentially poorly immunogenic material. 
Low affinity antibodies may be produced, these will be harder to 
detect at low concentration immediately post fusion. 
Immunisation with poorly immunogenic material will not be as 
effective in stimulating the immune system, compared 
immunisation with highly immunogenic material. The ratio of the 
desired antibody producing splenocytes compared to irrelevant 
splenocytes will be reduced. If this occurs than a smaller 
proportion of the splenocytes that undergo fusion will produce the 
desired hybridoma cell line. 
These problems may be increased for antibody production 
where the antigenic site only represents a small proportion of the 
injected immunogen. Thus, where the production of hybndomas 
secreting antibodies against the antigen of interest occurs at very low 
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frequency, extremely effective and rapid screening will be required to 
avoid missing the few positives that occur. 
3.2.3 Detecting Monoclonal Antibody Production 
As previously stated (section 3.2.2) cell fusions yield a mixture 
of cellular products. The growth medium used allows only the 
growth of myeloma cell lines. However, after every 
immunisation/fusion experiment irrelevant hybridomas will be 
produced. Fusion products are grown in multiwell containers 
(usually hundreds of wells for each fusion). Each well may contain 
cells produced by separate fusion events. Each separate fusion event 
may produce colonies of cells producing the desired antibody 
product, an irrelevant antibody product, or no antibody at all. 
The first few weeks post-fusion are a critical period, during 
which identification of hybridomas secreting the desired antibody 
must occur. The desired cell lines must then be isolated from other 
cell lines, producing monoclonal cell lines. If the identification and 
cloning  procedures are not rapidly undertaken then a cell line 
producing the desired antibody may become overgrown by an 
irrelevant cell line. Hybridoma cell lines that do not produce 
antibody usually grow more rapidly than antibody producing 
hybndomas. Therefore, it is vital to have a rapid and reliable 
screening assay. The essential features of a screening assay for 
monitoring hybridoma production of antibody are: 
It must be sensitive and capable of detecting very small amounts 
of antibody. 
It must be accurate, false positives as well as false negatives 
must not occur. 
It must be rapid to perform and capable of handling large 
numbers (hundreds) of samples. 
(D) It must be reproducible and reliable. 
Antibody secreting hybridomas are usually detected by 
methods that measure the antibody content of the spent media. There 
are several methods of detecting antibody. the two most commonly 
used methods are radioimmunoassay (RIA) and enzyme linked 
immunosorbent assay (ELISA). 
RIA uses radiolabelled antibody or antigen as the means of 
detecting specific antibody antigen interactions. It many formats it is 
desirable as it is often regarded as a positive screen for antigen. This 
point will be discussed later in this chapter. Although RIM are 
generally very sensitive assays there are some disadvantages in their 
use. There are hazards associated with the handling of radioisotopes. 
When screening for antibody production the antigen must be 
radiolabelled. For DNA radioactivity is most easily incorporated as 
32p labelled ATP and polynucleotide kinase. This incorporates 32 P 
phosphate at the 3-OH of deoxynbose. 
Large numbers of screening experiments are required for each 
fusion carried out. Separation steps are major contributors to 
reproducibility problems in immunoassay.  RIAs are generally 
solution phase assays, and require specific separation methods e.g. 
antibody precipitation, immobilised secondary antibodies (often on 
insoluble beads) or exclusion using dextran coated charcoal (charcoal 
cannot be used to separate antibody from macromolecules). Efficient 
separation steps using radiolabelled materials becomes less amenable 
to rapid throughput when large numbers of samples are being 
assayed. 
The use of microtitre format solid phase immunoassay 
provides easy and highly reproducible separation of bound and non-
bound antibody. Alternative labels such as enzymes have been 
developed to detect antibody antigen interactions on solid phases. 
Due to the high reproducibility, sensitivity and ability to handle the 
large numbers of samples ELISA is the most commonly used method 
to monitor antibody production from fusion experiments. 
3.2.4 ELISA Techniques 
There are two types of ELISA for measuring antibody 
production of hybridoma cell lines. They are the non-competitive 
ELISA and competitive ELISA. 
In non-competitive ELISA the presence of antibody that binds 
to some component of the test compound is detected. A solid phase, 
usually a 96 well microtitre plate, is coated with a fixed level of test 
compound (immunogen or hapten-carrier protein conjugate) by 
passive adsorption. Antibody secreted into the growth medium by 
hybndoma cells is added to the microtitre wells, antigen specific 
antibody will bind to the coating material. The growth medium is 
removed by washing, leaving antigen specific antibody bound to 
immobilised coating material. An enzyme labelled species specific 
secondary antibody is added. This will bind to imniobilised primary 
antibody in the well. Excess second antibody is then washed away 
and the amount of enzyme remaining bound is measured. This is 
usually carried out by adding a colourless enzyme substrate that 
produces a coloured product that can be measured 
spectrophotometrically. The amount of colour produced is directly 
proportional to the amount of antigen specific antibody that binds to 
the solid phase coating material. This reflects the amount and/or the 
affinity of the antigen specific antibody in the growth medium tested. 
In competitive ELISA information may be obtained about the 
specificity of antibody binding. This is particularly important where 
antibodies against small molecules are being produced. These will 
either be compounds that needed to be coupled to a carrier protein, 
or where antibodies are required that only recognise a specific part of 
a large molecule, i.e. a mismatched base pair in a DNA duplex. In 
competitive ELISA, a limiting amount of antibody is incubated with 
antigen. The antibody/antigen solution is added to antigen pre-
coated wells. Antibody will compete for binding to antigen in 
solution and antigen immobilised to the solid phase. Maximum 
antibody binding to the solid phase will occur for test samples where 
no antigen is added. As the amount of antigen in solution increases 
the availability of antibody that binds to the solid phase will 
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decrease, described as inhibition. The amount of immobilised 
antibody is detected as for non-competitive ELISAs. Inhibition of 
binding to the solid phase is thus a measure of specific antigen 
binding,  and for specific antigens their concentration. 
The results from competitive ELISA provide greater certainty 
regarding the specificity of the antibodies. In the development of 
antibodies to small molecules binding of antibody to the carrier 
protein or to the link between the hapten and the carrier protein may 
occur giving rise to false positive results. Additionally, for all 
antigens non-specific binding of antibodies to uncoated portions of 
the solid phase may occur. Detergents and irrelevant proteins are 
often added to reduce non-specific binding. 
3.3 ANTI-DNA ANTIBODY ASSAYS 
3.3.1 Introduction 
A variety of mimunoanalytical methods exist for the 
measurement of anti-nucleic acid antibodies. These include 
precipitation from solution, precipitation in gels, complement 
fixation, immunofluoresence, passive haemaglutination, and 
radioimmunoassay, and are reviewed by Stollar (1973). Although 
successful, most of these methods have been developed for the 
screening of either serum from patients with SLE or bleeds from 
immunised animals. 
These methods are useful when analysing relatively few 
samples (tens of samples), however, this is not the case when 
screening hybridomas where up to 1000 samples may be screened. 
The advances in hybridoma technology coupled with a desire to 
produce monoclonal antibodies to nucleic acids (from autoimmune 
and nucleic acid immunised animals) has led to the development of 
anti-DNA antibody screening using ELISA techniques (Klotz, 1982; 
Silvestris et al., 1987) 
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3.3.2 ELISA Techniques 
A variety of anti-nucleic acid ELISAs have been described, 
though to date there is not a generally accepted method. There are 
two main areas of variability in ELISA techniques in the literature: 
Methods of immobilisation of nucleic acid to the solid phase. 
Buffer requirements, especially the inclusion of EDTA, during 
the assays. 
Several ELISA methods have been established to test for anti-
nucleic acid antibodies in serum from SLE patients, others are used 
with purified monoclonal antibodies from studies on munne lupus. 
Differing assay requirements to some extent reflect the differing 
requirements of the test systems. 
3.3.2.1 Immobilisation Techniques 
Methods for the direct attachment of DNA to polystyrene have 
not been standardised. Interactions with polystyrene are 
predominantly hydrophobic (Kochwa et al., 1965) so that dsDNA 
molecules present a particular problem because the most 
hydrophobic portions of the macromolecule are held within the 
duplex. Dissociation of duplexes to produce ssDNA increases the 
possibility of interaction with the polystyrene, and has been used for 
direct fixation (Pesce, 1974). 
The nature of the diluent used for immobilisation of single 
stranded DNA has also been investigated. The addition of M902 
(0. 1M) to phosphate buffered saline was found to dramatically 
enhance the adsorption of DNA onto the wells (Negata, et al., 1985), 
a similar effect was seen with Ca2+  ions but not with Na+  ions. 
The ionic strength of the diluent also affects the adsorption of 
ssDNA to polystyrene. It was found that 1.5M NaCl or 0.5M 
ammonium sulphate gave maximum adsorption of a 642 base pair 
sequence (Inouye and Hondo, 1990). Other studies have combined 
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highly alkaline buffers (pH 11-12) with high ionic strength (1 .2-1.3M 
NaCl) to increase adsorption (Lacy et al., 1989 Loon et al., 1992). 
The influence of buffer conditions on adsorption is also believed to 
be dependant upon the size of the DNA fragments and on the type of 
microtitre plates used, the latter occurs commonly in all ELISA 
techniques. In addition there appears to be an optimal concentration 
for DNA adsorption, and above this optimal concentration less 
immobilisation of DNA occurs (Guesdon, 1992). 
For dsDNA, indirect  methods have been used that involve 
electrostatic interactions of the negatively charged phosphate 
backbone in DNA and positively charged proteins, such as protamine 
sulphate (Klotz et al., 1979), poly-L-lysine (Fish and Ziff, 198 1) and 
methylated BSA (Rubin et al., 1983). A major concern with these 
methods is the possibility of increased non-specific binding of 
antibody to these charged proteins.  For protamine sulphate 
precoated wells it has been recently suggested (Rupin et al., 1993) 
that complete saturation of the precoat with dsDNA removed false 
positives, that had previously been reported using this method. 
There is also concern that specific structural features of the 
duplex may be altered by interaction with positively charged 
proteins. Immunisations with nucleic acids are generally carried out 
as complexes with MeBSA. Thus MeBSA enhanced coating of 
dsDNA would present obvious cross reactivity problems during 
antibody screening assays. It has also been suggested that binding of 
B-DNA to MeBSA coated plates could induce certain regions of it to 
form Z-DNA (Lafer et al., 1981). Therefore, in experiments  to 
produce anti-B-DNA antibodies by immunisations with B-
DNA/MeBSA complexes, antibodies to Z-DNA may be produced. 
These may be incorrectly described as anti-B-DNA antibodies if 
MeBSA enhanced B-DNA coating methods were used. It has also 
been suggested that anti-Z-DNA antibodies may be able to induce 
susceptible B-DNA sequences to the Z-DNA conformation (Lafer et 
al., 1981), this may be thought as analogous to the ionic strength 
induction of Z-DNA previously reported (Pohl et al., 1973; 
Thammen et al., 1981). 
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More recently pre-treatment of polystyrene microplate wells 
with UV light has been shown to enhance the binding of both 
ssDNA, dsDNA and synthetic oligonucleotides (Zouali and Stollar, 
1986). The mechanism whereby UV irradiation increases the 
binding capacity of polystyrene wells is unknown. Hydrocarbon 
polymers with saturated backbone chains are susceptible to oxidation 
involving singlet oxygen (Rabek et al., 1985). 
UV treatment of polystyrene in the presence of air has been 
associated with ring opening oxidation and formation of chemically 
reactive muconic dialdehyde structures (Rabek et al., 1985). This 
may occur through formation of a dioxetane intermediate. During 
photoxidation of polystyrene, polyene structures in the main chain 
can also be generated. In this case 02  oxidation may generate 
reactive peroxides on the polymer. 
Over the last few years more specific methods of 
immobilisation of nucleic acid have been introduced. The 
modification of ssDNA with biotin has allowed attachment to 
microtitre plates that have been precoated with either anti-biotin 
antibodies (Coutlee et al., 1989a,b), or streptavidin (Emlen et al., 
1990). Immobilisation of ssDNA has also been reported by direct 
covalent linkage to modified microtitre plates (Rasmussen et al., 
1991). Covalink NT-I plates (Nunc) have a secondary amine on a 
spacer arm, this allows reaction via carbodiimide to the 5'-terminal 
phosphate group of DNA. 
3.3.2.2 Assay Conditions 
In addition to inimobilisation techniques the type of 
antibody/DNA interactions are reported to be dependant upon the 
buffer system used in the ELISA. The most commonly used buffers 
used are phosphate buffered saline (PBS) and Tris buffered saline 
(TBS). Two anti-DNA monoclonal antibodies, from autoimmune 
mice, showed higher titres when assayed in TBS compared to PBS 
(Pisetsky and Semper, 1984). Similar results were obtained for sera 
from some human SLE patients. Other sera showed higher titres 
with PBS compared to TBS. They suggest that antigenic sites on 
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DNA may be variably affected by the conditions of the assay, 
altering quantitative and qualitative assessment. 
To validate the production of antibodies by immunisation with 
Z-DNA high ionic strength buffers were used to induce the transition 
from B-DNA to Z-DNA. Phosphate buffer containing up to 4M 
NaCl was used to induce the Z-DNA transformation in susceptible 
duplexes, during the assay (Moller et al., 1982). It should be noted 
that the use of such high ionic strength buffers during an assay is 
unusual. Immunoassays are usually carried out in physiological 
buffer using 0.13 - 0.14M NaCl. The harsh salt conditions to 
transform B-DNA to Z-DNA (Moller et al., 1982) would normally 
reduce antibody antigen interaction. 
Nucleic acids are degraded in serum by the action of nuclease 
enzymes. These enzymes can also be found in actively growing cells 
in vitro. This can be due to the addition of animal serum proteins to 
supplement the growth medium, or possibly the release of nuclease 
enzymes from dying cells within the cell culture. Clearly, when 
screening for anti-DNA activity in such medium the elimination or 
inactivation of such enzymes is highly desirable. 
There are conflicting  suggestion as to the use of nuclease 
inhibitors during anti-DNA ELISAs. To a certain extent the nature of 
the assay system may influence the requirement for nuclease 
inhibitors. Where immobilisation involves the interaction of random 
multiple sites of the nucleic acid to a solid phase, and where binding 
of antibody to the bound DNA only will be measured, the use of 
nuclease inhibitors may not be essential. In these case the proximity 
of the DNA to the solid phase will reduce the accessibility of the 
DNA to nuclease enzymes. Where purified monoclonal anti-DNA 
antibodies are being used the use of nuclease inhibitors may also be 
unnecessary. 
However, the immobilisation of DNA to microtitre plates can 
be specifically carried out at one terminus of the DNA molecule, e.g. 
covalent linkage through the terminal phosphate group. This allows 
the DNA sequence greater freedom of movement and interaction 
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with components within the solution around it. Additionally, 
competitive ELISA use DNA (as inhibitor) free in solution. In both of 
these situations the DNA will be more susceptible to nuclease 
degradation, and thus attempts to reduce DNA degradation may need 
to beinvestigated. 
The most commonly used nuclease inhibitor is EDTA. EDTA 
binds divalent cations which are essential for nuclease enzyme 
activity. Although EDTA has been used by several workers (Lacy 
and Voss Jr., 1989; Moller et al., 1982), it may interfere with anti-
DNA antibody binding to DNA. Attempts have been made to 
develop standard incubation conditions, while inhibiting serum 
enzymes that break down nucleic acids (Brosalina et al., 1988). The 
addition of nuclease inhibitors, EDTA, urea, and 
diethylpyrocarbonate to the serum not only inhibited the action of the 
nucleases, but also led to a sharp decrease in the binding of anti-
DNA antibodies to oligonucleotides. They suggested the addition of 
an excess of an irrelevant oligonucleotide as an inhibitor. More 
recently the effect of EDTA on anti-DNA binding has been 
confirmed. The presence of 10mM EDTA has been reported (Pyun 
et al., 1993) to lead to a 50% decrease in binding of monoclonal 
antibodies to bacterial DNA. 
During the production of anti-DNA antibody secreting 
hybndomas it was reported that DNA may be introduced into the 
growth medium due to the loss from cells in culture (Ehrenstein et 
al., 1993). Anti-DNA antibodies secreted into the cell growth 
medium may then not be available for interaction with DNA when 
screening is carried out. Cell lines producing antibody may then be 
incorrectly discarded after screening for anti-DNA activity. This is 
particularly important  where low quantities of high affinity anti-DNA 
antibodies have been released into the growth medium, i.e. at early 
screening stages post fusion or post cloning. They suggest that 
supernatants harvested from cell culture should be always be pre-
treated with DNase 1 (a nuclease enzyme) in the presence of IniM 
MgC12 and 0.02mM CaC12, for lhr at 370C. The reaction should 
then be stopped by the addition of 15mM EDTA. This process may 
of course affect subsequent DNA binding for some anti-DNA 
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antibodies. In the production of anti-DNA antibodies the presence of 
nucleic acids in the growth medium has not been reported in other 
studies. However, this report adds to the uncertainty when 
developing screening methods. 
3.3.3 Conclusions 
Development of screening methods to detect the release of 
antibodies, into the growth medium, that specifically recognise and 
bind  to mismatched base pairs is not a trivial task. This is in sharp 
contrast to screening methods for classical haptens. If classical 
haptens are immunogenic screening is relatively straightforward and 
useful monoclonal antibodies will usually be obtained within 6-12 
months. For anti-mismatch base pair antibodies the diversity of 
immobilisation methods and assay buffer requirements generates 
considerable confusion as to the choice for assay conditions. For our 
purposes we are using B-form oligonucleotide duplexes (generally 
considered to be poorly immunogenic or non-immunogenic) 
containing a mismatched base (of unknown immunogenicity). We 
are therefore attempting to devise suitable screening methods for 
antibody production (based on the varied methods in the literature) to 
detect the possible production of antibodies from material of 
unknown, but probably weak, inimunogenicity. 
The choice of immunogen as well as screening strategy is 
clearly of great importance  in the outcome of this work. For these 
reasons a variety of potentially immunogenic materials were 
produced. There are clearly many variables involved in developing 
an effective screening method for detecting any anti-DNA antibody 
production. A considerable amount of time was therefore spent in 
devising, developing and testing of ELISA screening methods. 
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3.4 SCREENThG ASSAYS FOR ANTI-MISMATCHED BASE 
PAIR ANTIBODIES 
Apart from the unknown immunogenicity, and the 
immobilisation and buffer conditions for assaying, detection of 
antibodies to mismatched duplexes presents particular problems in 
the initial screening. In terms of immunisation, a mismatched base 
pair to some extent can be regarded as a hapten attached to a larger 
carrier molecule, analogous to a small molecule (hapten) attached to 
a carrier protein, if the mismatch is immunogenic, antibodies will be 
produced which can be detected by screening using an ELISA. 
A variety of different antibodies will be produced that will 
recognise different components of the immunogenic material. Some 
of the antibodies will recognise the hapten (of interest) and some will 
recognise the carrier protein. When the antisera are screened in an 
ELISA they will bind both the hapten and the carrier protein if the 
same protein is used for the immunisation and the coating material. 
To avoid detection of antibodies to the carrier protein, the hapten is 
attached to a different protein, where possible, using a different 
means of attachment. Therefore detection of any antibodies should 
indicate specific recognition of the hapten. 
However, for a mismatched base pair the 'hapten' is an integral 
component of the duplex. Therefore, this cannot be isolated and 
placed in another non-B-DNA duplex for screening. In this case, a 
positive screen using a mismatch containing duplex only implies anti-
duplex antibodies are present. The mismatch could be screened for 
in a different duplex, i.e. immunise  with poly d(AT) and screen with 
poly d(GC) containing the same mismatch. This may be sufficiently 
different to aid specific mismatch recognition. However, the 
antibody recognition of the mismatch structure may be affected by 
local base sequence. Thus recognition of an AC mismatch by an 
antibody may be different in different sequences. 
If every mismatched base pair were to present a different site 
for recognition in every different sequence there would be limited use 
of anti-mismatched antibodies. It is more likely that certain 
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sequences will present the same mismatches slightly differently. 
Thus anti-mismatch base pair antibodies may have a range of 
affinities for the same mismatched base pair if different DNA 
sequences. 
This may still create problems during screening. Antibody 
screening for classical haptens usually avoids non-specific binding 
associated with the carrier protein. Antibody recognition should only 
occur for haptenlantigen specific antibodies. For DNA duplexes 
containing a mismatched base pair, overall sequence differences that 
do not effect recognition of the mismatch may mean the sequences 
are very similar. Antibodies produced that recognise irrelevant (fully 
matched) regions of the DNA duplex would probably cross react 
with the irrelevant regions of the alternative, but similar, duplex used 
for screening. This may be compared to immunising  with an antigen 
bound to rat albumin and screening for antibody using human 
albumin. Although they are different there will also be considerable 
identity/similarity between the protein carriers. Binding of antibody 
to irrelevant (non-antigen) sites is extremely likely. 
The successful production of monoclonal antibodies usually 
relies on the ability to carry out cloning  experiments as early as 
possible. Therefore, the results from the first screen are crucial to 
avoid loss of desired hybridomas by overgrowth of non-secretors or 
irrelevant secretors. For classical haptens detection of antibody 
binding in a non-competitive assay suggests antigen specific antibody 
is present. Competitive ELISA then confirms the specificity. As 
previously discussed, a mismatched base pair cannot be isolated and 
thus inhibition studies need to be carried out with matched and 
mismatch containing duplexes. Clearly with anti-mismatch antibody 
detection, the amount of information obtained by the initial, non-
competitive, screen will be less than those involving classical haptens 
and carrier proteins. 
In addition, for a classical hapten, high bindingin the first 
screen (assuming no non-specific binding) may imply good 
recognition of the hapten, and these cell supernatants will be chosen 
for competitive studies. The difference in immunogenicity of 
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matched compared to mismatched base pairs in a B-DNA duplex is 
unknown, but matched base pairs are more abundant in the duplex 
for screening. Therefore, there will be uncertainty  selecting cell 
supernatants for competitive ELISA prior to cloning  experiments. 
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3.5 RESULTS AND DISCUSSION 
3.5.1 Immunisations and Serum Analysis 
Mice were immunised with 1 5mer duplexes either as a free 
oligonucleotide or complexed with MeBSA. 75mer duplexes and 
C lOOPS were immunised as free DNA. All immunisations were 
carried out with the oligonucleotide (or complex with MeBSA) in 
adjuvant. This not only helps evoke an immune response, it also acts 
as a depot for the prolonged release of the test immunogens. Three 
mice were immunised per immunogen, individual mice are referred to 
by number e.g. AC 15-1, AC15-2 etc. Sera from mice bleeds were 
obtained to assess anti-DNA antibody production, prior to fusion 
experiments. 
3.5.2 15mer Oli2onucleotide Duplexes 
One of the main challenges in the immunochemical aspects of 
the work has been the establishment of reliable screening 
methodology. It was decided that ELISA was the most appropriate 
assay format, for reasons discussed previously. The first concern 
was to physically attach an oligonucleotide duplex to a 96 well 
microtitre plate and still present a mismatched base pair to any anti-
DNA antibodies. Initially pre-coating methods using poly-L-lysine 
and MeBSA were investigated to enhance oligonucleotide binding to 
the solid phase. Poor end point colour development was observed 
using poly-L-lysine precoat and non-specific binding was occurring 
for plates precoated with MeBSA. The MeBSA method was also 
unsuitable for all serum taken from mice immunised with 
oligonucleotide/MeBSA complexes, for obvious reasons. 
Results from plates coated by simple incubation with 
oligonucleotide, with no precoat, indicated limited or no binding of 
antibody occurred, this probably reflects the weak binding of duplex 
DNA to microtitre plates. Although single stranded DNA binds well 
to the polystyrene plates used, duplex DNA will bind much less 
efficiently. The reduced binding for duplex DNA was probably a 
consequence of the purme and pynmidine groups being unavailable 
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for interaction with the polystyrene as they are hidden by base pair 
formation. Duplex oligonucleotide binding  was enhanced by UV 
irradiation of microtitre plates prior to oligonucleotide incubation. 
Increased binding of antibody to DNA coated plates that were pre-
treated by UV-irradiation was seen. Antibody was not found to non-
specifically bind to UV-irradiated  plates. 
3.5.2.1 Non-competitive Assay of Serum 
All of the serum collected from mice after immunisations with 
15mer duplexes (AC 15, AA 15, CC 15, GG15) gave some binding to 
DNA coated plates in non-competitive ELISA, using non specific 
coating methods 1A-D (see experimental). Antibodies were 
produced from immunisations using both free DNA and DNA 
complexed to MeBSA. 
Only results for microtitre plates coated with oligonucleotide 
by means of UV-irradiation are reported here, see Graph 4 and 5. 
All values plotted were means of triplicates (standard deviation <5% 
for these and subsequent graphs). Each mouse yields only a small 
amount of blood for serum analysis, typically 5-40p1. A large 
number of assays were carried out using several of the coating 
methods before binding of antibody to DNA was observed in non-
competitive ELISAs. For a number of the mice all of the serum 
obtained was used in non-competitive assays and thus competitive 
assays could not be carried out. Competitive assay were carried out 
to test sera from three mice. 
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3.5.2.2 Competitive Assay of Serum 
A limiting dilution of serum obtained from mice CC15- 1, 
GG 1 5M- I and GG 1 5M-3, from the results of non-competitive 
ELISA, were used for competitive ELISA. The concentration of 
DNA added was 5g/ml, see table 11. 
Table 11, Competitive ELISA using Mice Sera 
Test Serum Serum Dilution Inhibitor % Inhibition 
CC15-1 1:50 CCI5 42 
GG15M-1 1:200 GG15 30 
GG15M-3 1:50 GGI5 10 
The results from competitive ELISA confirm that antibody was 
being produced that bound to both immobilised DNA duplexes and 
that this binding was inhibited in the presence of competing DNA. 
Although duplexes were chosen that contained the relevant 
mismatches, it should be noted, as previously discussed (section 3.4), 
the detection of antibody binding to a DNA duplex containing a 
mismatched base pair does not provide absolute identification of anti-
mismatched base pair antibodies. This situation does not present 
itself for classical haptens, where inhibition in competitive assay does 
provide antibody binding identification. 
Where competitive studies with DNA duplexes containing a 
mismatched base pair show no inhibition there is clearly no 
recognition of the mismatch. Where positive inhibition with a 
mismatch containing duplex occurs a further competitive ELISA 
using duplex DNA without a mismatched base pair could be carried 
out. If competitive assays gave no inhibition for duplexes without a 
mismatch, but inhibition occurred for a mismatch containing duplex, 
this would indicate the presence of anti-mismatched base pair 
antibodies. However, when immunogenic material is administered to 
animals a wide range of antibodies are released into the serum. 
There will be variations in both specificity as well as affinity of 
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antibodies in the sera. Thus, where an anti-DNA antibody response 
occurs, competitive assay of serum indicating inhibition with both 
mismatch containing and non-mismatch containing duplexes is highly 
probable. Therefore, until monoclonal antibodies are produced an 
absolutely conclusive screen for anti-mismatched base pair 
antibodies will not be possible. This problem is fundamental to this 
project and would occur whatever screening strategy was employed. 
These assays indicate that the 1 5mer oligonucleotide duplex 
sequences being used as immunogen were evoking an immune 
response. Fusion experiments were conducted using the spleens of 
mice where competitive ELISA of sera showed inhibition. 
3.5.3 Fusion Experiments 
After fusion experiments the cells were observed under a 
microscope for the first two weeks post fusion. The first fusion 
carried out (mouse spleen GG 1 SM- 1) failed to produce any actively 
growing hybrid cells. They were discarded after 10 days. At this 
time fusions were routinely working when carried out by more 
experienced staff on other projects. Therefore, there was no concern 
regarding any reagents being used. Due to the failure of the first 
fusion it was decided prudent to practice the fusion procedure. 
Spleens from non-immunised mouse could be used, but if 
successful would produce no useful material. Several of the sera 
obtained from mice immunised  with 1 Smer duplex were only 
screened using the non-competitive ELISA, see section 3.5.2.1. All 
sera (CC 15-1, GG15M-1 and GG15M-3) tested in competitive 
ELISA gave inhibition. It was thought reasonable to assume some of 
the other supernatants would have shown inhibition. Five fusion 
experiments were carried out prior to fusions on CC 15-1 and 
GG1 SM-i. All five test fusions and subsequent fusion experiments 
produced live hybrid cells immediately post-fusion. In addition, 
plasmacytoma and splenocytes were observed to die over the first 
five days. 
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When hybrid colonies were sufficiently large, just visible 
without the aid of a microscope (- 0.5-1.0mm diameter), samples of 
the growth medium were removed so that antibody secreted into it 
could be measured. The growth medium of actively growing cells 
were first screened for the presence of mouse immunoglobulin G 
(IgG), IgG ELISA. Positive IgG producers were then screened for 
the presence of anti-DNA antibodies. 
The IgG screen in the format used serves to establish the wells 
producing  IgG so that supernatant from these wells could be selected 
for further investigation. Typically, this assay reduced the number of 
test wells for anti-DNA assays by about 20-40% of the total number 
of wells produced by fusion experiments. The levels of antibody in 
established hybridoma culture supernatants are typically 10-75 
tg/nil. Fusion wells may contain less than this, but the assay was 
able to detect 0.1 tg/ml of mouse IgG, see Graph 6, and thus all IgG 
producers should be detected. 
GRAPH 6. STANDARD CURVE FOR MOUSE IqG 
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Usually greater than 50% of the wells contained colonies that 
were sufficiently large to be screened at about the same time. Using 
the ELISA format it was more convenient to screen all fusion wells at 
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the same time. Where supernatants from fusion wells gave no 
binding in the IgG ELISA were kept if the well contained very small 
colonies. This would be re-screened when the colonies increased in 
size. 
3.5.3.1 iSmer Oligonucleotide Duplexes 
Fusion experiments produced hybrid cell lines that were: 
actively growing in cell culture medium, 
secreting mouse IgG 
secreting IgG that recognises some structural component of 
DNA. 
Table 12. 15mer Fusion Assay Results 
MOUSEIIMMIJNOGEN IgG ASSAY DNA ASSAY 
AC15-1 Positive Positive 
AC 1 5M- I Positive Positive 
AC 1 5M-2 Positive Positive 
AA1 5-1 Positive Positive 
CC15-1 Positive Positive 
GG15M-2 Positive Positive 
GG1 5M-3 Positive Positive 
The DNA assay was a non-competitive ELISA using the 
appropriate mismatch containing duplex as coating material. 
Competitive ELISA failed to identify any colonies producing anti-
mismatch base pair specific antibodies. For the five test fusions no 
competitive assays were carried out using the sera. It was unknown 
if inhibition was likely to occur. For GG1SM-3 the inhibition seen 
when screening the sera was small, only 10%. This low inhibition 
may not be significant. Alternatively it may reflect a limited immune 
response. This means relatively few spleen cells would be producing 
the relevant antibodies. Fusion experiments rely on immunisation 
boosting the numbers of relevant splenocytes. 
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Significantly, when spleens were obtained from mice 
immunised with DNA/MeBSA complexes (e.g. GG15M-3) all the 
spleens were approximately double the size of the spleens after 
immunisations with non-complexed DNA. The MeBSA may be 
forming the immunodominant regions of the immunogen. The use of 
MeBSA to complex DNA may be useful to produce a polyclonal 
antisera containing anti-DNA antibodies, but may be less useful for 
producing monoclonal antibodies. 
As competitive assays using the supernatants from hybridomas 
obtained by fusion experiments were being conducted for mice 
immunised with 1 5mer duplexes it became apparent that 
modifications in the ELISA and fusion procedure needed to be 
addressed. The UV-irradiation procedure coats the DNA in a 
random orientation onto the surface of the test wells. This may 
obscure or alter a mismatch base pair recognition site. Alternative 
assay procedures need to investigated. 
Secondly, the cells growth medium contains a high 
concentration (10%) of foetal calf serum (FCS). When supernatants 
were removed from growing cells the FCS will be a potential source 
of nuclease enzymes. No positive competitive inhibition studies 
were obtained  from supernatants where fusions were carried out 
using spleens from mice immunised with 1 5mer duplexes. The 
presence of FCS may have significantly influenced competitive 
ELISA results. 
3.5.4 75mer Oligonucleotide Duplexes and C100P 
At the same time as alternative coating methods 2(A-C) 
involving the use of biotin/streptavidin binding were being 
investigated, alternative immunogens were produced. These were 
AC75, GC75 and C lOOP, see chapter 2. Immunisations were carried 
out using these immunogens without the formation of MeBSA 
complexes. 
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3.5.5 Assay Development using Coating Methods 2(A-C 
Alternative coating procedures included the use of streptavidin 
and biotmylated oligonucleotide, coating methods 2(A-C). The 
streptavidin/biotin binding system was chosen due to the strong and 
selective affinity of the complex KD = 1O-'. The complex is stable 
at extremes of pH, and various buffer conditions, making the reaction 
essentially irreversible. Although avidin could have been used, 
streptavidin was preferred. Streptavidin lacks the carbohydrate 
residues associated with avidin. Although these residues would aid 
binding of avidin to microtitre plates, they may also increase non-
specific binding of other assay components during the assay. The 
isoelectric point of streptavidin is in the neutral range. This is the pH 
at which most ELISAs are carried out so this will reduce non-specific 
interactions during the assay. 
3.5.5.1 Confirmation of Duplex Formation by Coating Method 
2(A). 
Coating method 2(A) allows a specifically 5'- biotinylated 
single strand oligonucleotide to bind to plates precoated with 
streptavidin (see figure 24). A second strand, either fully 
complementary or containing a single base pair mismatch, was 
introduced. 
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FIGURE 24. BIOTIN/STREPTAVIDIN EUSA 




4. Add Groh Medium 	5. Detect with Anti-Mouse 
Enzyme Linked IgG 
To ensure the binding of the second strand was occurring an 
additional series of 5'- specifically labelled second strand were 
produced. These second strands would also form either fully 
complementary duplexes or would contain a central base pair 
mismatch. The label used was Dinitrophenyl (DNP), and detection 
of DNP was via an enzyme labelled anti-DNP antibody, and colour 
development. The use of DNP labelled oligonucleotides would 
provide information on first strand binding to streptavidin coated 
plates and second strand forming a duplex, (see figure 25). 
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FIGURE 25. BIOTIN/STREPTAVIDIN ELISA 
CONFORMATION USING DNP LAPT 
1. Coat with Streptavidin 	2. Add ssDNA - Biotin 	3. Add DNP-Second Strand 
Substrate 	Product 
4. Add Anti-DNP Fn2yn 5. Detect Colour Production 
Linked IgG 
For fully complementary strands a dose response curve was 
obtained, see Graph 7. As the concentration of DNP labelled 
oligonucleotide (T2 1 -DNP) was increased, the amount of DNP 
detected also increased. In the absence of Biotin-A21 no binding of 
T21-DNP was observed. This indicates that duplex formation was 
responsible for the availability of DNP detection. The binding of 
T21-DNP appears to reach saturation at greater than 50ngIml T21-
DNP. 
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These experiments were repeated using DNP labelled 
oligonucleotides similar to T21-DNP but the central base was 
replaced with A or C (TAT-DNP and TCT-DNP respectively). 
When incubated  on Biotin-A21 coated plates they would create an 
AA or AC base pair mismatch. Unfortunately, weaker dose response 
curves were obtained where duplexes were formed using these 
sequences. This means that the amount of duplex oligonucleotide 
formed was less where a mismatch was formed on introducing the 
second strand. Although there will still be duplex oligonucleotide 
present, in this format there will also be a proportion of biotinylated 
single stranded oligonucleotide in the assay. 
The Tin of two non-covalently attached single stranded 
oligonucleotides forming a duplex is also dependent upon the 
concentration of the duplex. The concentration of oligonucleotide 
used to coat wells in ELISA experiments is very low and the amount 
of oligonucleotide that actually binds is even less. The Tm  of two 
non-covalently attached single stranded oligonucleotides forming a 
duplex with a mismatched base pair is considerably lower than that 
for a fully matched sequence. The anti-DNA assay also has an extra 
incubation and wash step compared with the anti-DNP detection 
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assay. Once the oligonucleotide duplex is formed in coating the 
plates and excess unbound oligonucleotide is washed away, the 
concentration of oligonucleotide will be so small that any dissociated 
strands will never re-associate. 
Additionally, it cannot be assumed that biotin-A2 1, or any 
other biotin labelled oligonucleotide immobilised, via the biotin., at 
one end to a solid phase, presents all bases for hybridisation to 
another complementary oligonucleotide. The first, or even second, 
base might be sterically hindered by its proximity to the streptavidin. 
This will cause the incoming  second strand to slightly overhang the 
biotin inimobilised strand. Thus a mixture of fully matched DNA 
duplex, a mismatch base pair site and single stranded DNA may be 
presented for antibody recognition even where duplex formation has 
occurred. The uncertainty surrounding the completeness of duplex 
oligonucleotide and the presence of single stranded oligonucleotide 
means that this assay format would not be suitable for our 
requirements. 
The use of streptavidinlbiotin labelled oligonucleotides was 
modified to produce a more effective coating procedure. A DNA 
duplex was synthesised to be of a similar nature to the 1 5mer 
duplexes used as immunogen in previous experiments, stabilised by 
an inter strand linker, but with an additional 5'-terminal biotin 
attached. The Tin of the biotin-AC 1 5mer duplex (AC 1 5B) was 50°C 
in UV melting studies. This was the same as the unbiotinylated 
AC 15 duplex. Duplex melting is a unimolecular process and, 
therefore, independent of oligonucleotide concentration, as 
previously described. Hence, when AC 1 5B binds to streptavidin 
coated plates it will remain as a duplex. This coating method was 
used for anti-DNA experiments with subsequent fusions. 
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3.5.5.2 Detection of Nuclease Enzymes by DNA Digestion Assay 
3.5.5.2.1 Nuclease Degradation 
In an assay system in which oligonucleotides are coated with 
random orientation 'effectively flat' (methods 1 (A-D)) onto the 
surface of microtitre plates, the oligonucleotides are probably not 
available for interaction with nuclease enzymes. However, in 
competitive assays and where the oligonucleotides are coated by the 
biotinlstreptavidin method, oligonucleotides will probably be more 
accessible to nuclease enzymes. A DNA digestion assay was carried 
out to investigate the extent of oligonucleotide degradation. Plates 
coated with single stranded DNA (cytosine 20mers end labelled with 
biotin, (C20B) were incubated with cell culture medium, autoclaved 
cell culture medium, and cell culture medium containing EDTA (a 
nuclease inhibitor). DNA remaining undigested was subsequently 
detected using a commercially available anti-DNA antibody, see 
Graph 8. 
GRAPH 8. DNA DIGESTION ASSAY 
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The results of the DNA digestion assay clearly shows that 
DNA digestion occurs with concentrated medium, but that the 
amount of digestion is reduced by: 
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decreasing the concentration of the medium, i.e. diluting  the 
enzyme concentration 
heat inactivation  by autoclaving; 
addition of EDTA as a nuclease inhibitor. 
The effect of nuclease enzymes could be reduced by any of the 
above measures. However, supernatants from cell lines may only 
contain small amounts of antibody. Dilution of the supernatants may 
reduce the concentration of antibody such binding during ELISA was 
no longer detected. Anti-DNA antibody producing cell lines may 
then be missed, especially if low affinity antibodies are being 
produced. B-DNA is known to be poorly immunogenic. The 
enhancement of immunogenicity by the presence of a mismatch is 
unknown. The amount of dilution before loss of signal occurs will 
vary greatly between cell lines/antibody  produced. 
Heat inactivation of supernatants by autoclaving would mean 
loss of antibody function, so this is unsuitable. We have shown, see 
Graph 9, that a commercially available murine IgG can be heated to 
56°C, for 30 minutes, and still be recognised as a murine 
monoclonal, using an anti-murine IgG assay. 
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EDTA is used as a nuclease inhibitor in most molecular 
biological work and was adopted for use. Unfortunately the first set 
of fusion assay results using EDTA in all wash and buffer solutions 
gave low end point colour production. The use of EDTA was further 
investigated to establish its suitability in anti-DNA ELISAs. 
3.5.5.2.2 The Effect of EDTA using an Anti-DNA Antibody. 
Biotin end labelled single strand (C2013) was attached to 
streptavidin coated plates. Anti-DNA antibodies at various 
concentrations were then allowed to bind with the immobilised 
oligonucleotide. All of the antibody incubation steps and wash steps 
were earned out using a buffer containing 0, 10 and 100mM EDTA. 
Graph 10 shows the results of including EDTA in an anti-DNA 
antibody ELISA, the immobilised DNA being detected was the single 
stranded oligonucleotide (C2013). The antibody used was 
commercially available, not an in house product of previous work. It 
is clear that 100mM EDTA completely abolishes detection of 
antibody binding. In the absence of EDTA antibody binding was 
detected at anti-DNA antibody concentrations between 1.0 and 
5.0g/ml. In the presence of 10mM EDTA the amount of binding 
was reduced by about 50%. 
GRAPH 10 EFFECT OF EDTA ON ANTI-DNA ANTIBODY/DNA 
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3.5.5.2.3 Effect of EDTA on Anti-DNP Antibody/DNP Binding 
The ELISA was investigated to establish where EDTA was 
affecting the assay, the anti-DNA antibody/DNA interaction or some 
other component of the assay. The assay was carried out using a 
duplex oligonucleotide (AT IOBL) labelled at one end with biotin and 
the other with DNP. Graph 11, shows the result of EDTA added to 
the buffers and wash solutions using an oligonucleotide duplex, 
labelled at one end with biotin to allow binding to streptavidin coated 
plates, and at the other end with DNP to allow detection via an anti-
DNP antibody. 
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In the absence of EDTA a dose response was observed as 
anti-DNP antibody was diluted. As the amount of EDTA added was 
increased there was a corresponding decrease in signal at all anti-
DNP antibody dilutions investigated. It can clearly be seen that the 
presence of as little as 25 x 1 OmM EDTA causes a deleterious 
effect in the assay. It was uncertain as to the nature of the effect. 
Although a similar effect was reported for other anti-DNA ELISAs 
(Brosalina et al., 1988; Pyun et al., 1993), it was not reported for 
anti-DNP assays. It was decided to look at the effect of EDTA on 
peroxidase function specifically. 
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3.5.5.2.4 Effect of EDTA on the Enzyme Activity of Antibody-
Peroxidase Conjugate with ABTS 
The peroxidase conjugated second antibody used to detect anti 
mouse IgG was incubated with various concentrations of ABTS (the 
peroxidase enzymes substrate used in our ELISAs) with and without 
the addition of 1mM EDTA. Graph 12 and 13, shows the effect of 
EDTA on peroxidase function after 5 minutes and 35 minutes. 
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After 5 minutes there was an increase in colour development 
with increasing ABTS substrate with or without EDTA. Although 
EDTA does appear to have a slight inhibitory effect on peroxidase 
function at all ABTS concentrations. In the absence of EDTA the 
ABTS continued to be converted to a colour product at all ABTS 
concentrations, graph 13. However, in the presence of EDTA the 
green product did not increase over the time course of the assay (35 
minutes). The amount of coloured product did not simply remain low 
(similar to amounts seen at 5 minutes), rather it actually decreased to 
virtually zero at all concentrations of ABTS used. EDTA must alter 
the enzymic activity of horseradish peroxidase, or it interacts with 
and alters the coloured product of the reaction. 
As colour production does occur initially the enzyme must be 
at least partially functional. EDTA may form a colourless complex 
with the coloured product of the reaction? Alternatively it may allow 
the enzyme to further interact with the ABTS product fonmng a 
secondary, colourless product? Whatever the cause, EDTA clearly 
cannot be used at this stage of the assay. It was decided that the 
buffers and wash steps used after supernatant incubation would have 
to be carried out in the absence of EDTA. It is believed the 
supernatant will be most likely source of nuclease related problems. 
Additionally, once anti-DNA antibody binding to DNA has occurred 
the antibody will probably afford sufficient protection to the DNA of 
any further nuclease interaction with DNA. 
3.5.5.3 Immobilisation of AC15B 
When using the commercially available anti-DNA antibody to 
test the effects of EDTA, we obtained weaker signals if AC 1 SB was 
used, and stronger signals if the single strand C20B was used to coat 
plates. It was uncertain if this reflected the fact that the duplex was 
weakly antigenic for the anti-DNA antibody, compared to C2013, or 
if the duplex was not binding to streptavidin coated plates efficiently. 
Biotin is internalised by streptavidin, positioned 9.0 angstroms below 
the surface of the protein. Single stranded DNA may be sufficiently 
flexible to allow binding of end labelled biotin to streptavidin. By 
comparison duplex DNA is far more rigid and binding between biotin 
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and streptavidin may be sterically hindered givrng reduced interaction 
at the binding site, and hence reduced coating of duplex DNA. 
Although the commercially available biotin phosphoramidite 
monomer contained a linker arm, it was decided that extension of this 
linker may enhance DNA duplex coating. 
3.5.5.3.1 75mer DNA Duplex and CHOPS 
Before synthesis of this modified biotin labelled 
oligonucleotide could be carried out, two fusion experiments had 
been carried out using the spleens from AC75 immunised mice and 
one fusion from a C lOOP immunised mouse. The growth medium of 
hybridomas formed were awaiting screening. Cytosine 1 OOmer 
(Cl OOPS) was synthesised as a single strand to raise antibodies that 
may interact with cytosine containing mismatches. Therefore, it may 
be possible to inimobilise antibodies to cytosine containing 
mismatches, such as AC or CC, by coating with single stranded 
cytosine (C20B). Fusion wells from AC75 and C lOOPS 
immunisations were subsequently tested for anti-DNA activity using 
plates coated with AC 1 5B duplex and C20B single stranded DNA. 
After visual analysis the IgG ELISA and non-competitive anti-
DNA ELISA all three fusions produced hybrids that were actively 
growing in cell culture medium, were secreting mouse IgG, and were 
secreting IgG that recognised some structural component of DNA. 
3.5.5.3.1.1 AC75mer Duplexes 
Antibody production was screened for using C20B and 
AC 1 SB as coating material. Increased amounts of antibody binding 
were observed when C20B was used compared to AC 1513 duplex as 
coating material. For several supernatants tested antibody binding 
was detected using C20B, but was negligible using AC 1 5B. The 
supernatant from only one well gave inhibition in competitive studies. 
The results of a series of competitive assays obtained using the 
growth medium of fusion well 2C 11 (well location coded 
AC75/2C11) using C20B as coating material are shown in Graphs 14 
and 15. 
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Graph 14 shows the result of a competitive assay for 
supernatant AC75/2C1 1 at a range of supernatant dilutions. In the 
absence of competing  DNA (AC75) a decrease in antibody binding 
was observed as the supernatant was diluted. In addition in the 
absence of C20B as coating material no non-specific binding was 
detected. Antibodies are thus recognising and binding to some 
component of the DNA coat (single stranded cytosine). However, no 
inhibition of antibody binding  was detected when incubation of 
supernatant with AC75 (lOp.gIml) was earned out. 
Graph 15 shows the result of a competitive assay at a fixed, 
and limiting, supernatant dilution for AC75/2C1 1 using several 
concentrations of AC75, CC 15 and c lOOPS as inhibitor. As 
expected antibody binding was not inhibited when AC75 was used as 
competitor at 0. 1-1Og/m1. Inhibition of antibody binding was 
detected when using either Cl OOP single strand and CC 1 Smer duplex 
as competitor. The inhibition with Cl OOPS was greater than that for 
CC1 5. This may reflect the greater number of cytosine  bases in 
C lOOPS. CC15 and C20B contain no phosphorothioate bases, 
therefore, the response appears to be directed towards normal DNA. 
The antibodies do not appear to be recognising AT matched pairs or 
AC mismatched pairs. Therefore, it appears that the antibodies are 
recognising the CC mismatched base pair. 
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GRAPH 15. AC75/2C11 COMPETITIVE ASS"I 
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Cloning experiments were carried out in attempts to produce a 
monoclonal cell line from this fusion well. Cloning experiments 
produced many wells in which single colonies were observed. 
However, none of them produced antibodies that showed inhibition 
to any test antigens AC75, CC15 or C lOOPS, at 10pgIm1. Problems 
associated with cloning experiments will be discussed later in this 
chapter and chapter 4. 
3.5.5.3.1.2 C100PS Single Strand 
One of the fusion wells (3C6) from mice immunised with 
C lOOPS single stranded oligonucleotide produced antibodies that 
bound to the coating material (single  stranded C20B) and gave 
positive inhibition with AC75 in competitive ELISA. Cells from well 
3C6 were used for cloning experiments in an attempt to produce a 
monoclonal cell line. Cloning experiments produced 27 wells 
containing single colonies, 10 of these produced antibody that bound 
to the coating material and, therefore, competitive assays were 
carried out, see Table 13. 
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Table 13, C100P/3C6 First Clone Test Results 
WELL IgG ASSAY DNA ASSAY % INHIBITION 
Dl0 Positive Positive 0 
El Positive Positive 46.7 
G7 Positive Positive 60.0 
G9 Positive Positive 60.3 
Gil Positive Positive 49.7 
G12 Positive Positive 47.4 
Hi Positive Positive 57.1 
H2 Positive Positive 34.4 
H3 Positive Positive 61.8 
H6 Positive Positive 49.3 
Inhibitor was AC75 10jg/m1 
Nine of the wells produced antibody that gave positive 
inhibition with AC75 in competitive ELISA. Although there was 
variation in the amount of inhibition produced by the supernatant of 
each well, this does not necessarily mean that different monoclonal 
cell lines have been produced. The variation in percentage inhibition 
may reflect differences in cell numbers and/or antibody titres when 
the cell growth medium was sampled. 
These results clearly demonstrate that an antibody produced 
recognises structural features of single stranded DNA, and a duplex 
composed of AT base pairs and AC mismatched base pairs. 
Inhibition studies were then conducted using GC75 as inhibitor. 
GC75 was an identical duplex to AC75 except that the four AC 
mismatched base pair sites in AC75 were replaced with GC matched 
base pairs. Similar inhibition results were obtained using this non-
mismatched duplex in competitive ELISA as for those using 
mismatch containing duplexes. Therefore, these monoclonal 
antibodies do not specifically recognise mismatched base pairs in 
dsDNA. 
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3.5.6 Enhanced Biotin - Duplex Immobilisation 
The previous results were obtained  using ssDNA as coating 
material, while testing for mismatches in DNA duplexes. Although 
anti-DNA antibody production was detected, the use of ssDNA as 
coating material was not desirable and some cell lines producing anti-
DNA mismatched base pairs antibodies may be missed. 
Oligonucleotide sequences similar to the biotinylated 1 5mer 
duplex, but containing an extra interstrand linker between the biotin 
and the oligonucleotide were synthesised. The inclusion of the extra 
interstrand linker should reduce possible steric hindrance and allow 
DNA duplexes to be bound to plates efficiently. Sequences of this 
nature were synthesised containing AC and GT mismatches. All 
subsequent fusions were screened using this assay. Sequences 
containing a dinitrophenyl group were also synthesised to allow 
optimisation of conditions for the binding of this modified 
oligonucleotide to streptavidin coated plates. 
3.5.6.1 Optimisation of Assay Conditions 
To investigate the possibility that steric hindrance of the 
binding of the biotinylated oligonucleotides to streptavidin coated 
onto microtitre plates was occurring, a series of modified 
oligonucleotides were synthesised, see Table 14. Oligonucleotides 
were synthesised such that single strands and duplexes would present 
DNP at one end, and biotin directly linked (as previously carried out) 
or biotin linked to the oligonucleotide via an extended spacer arm (to 
reduce steric hindrance) at the other. 
Table 14, Oligonucleotides for Assay 3 Optimisation 
NAME SEQUENCE 
C1OB DNP-C1p-Biotin 
Cl OBL DNP-C 1  p-X-Biotin 
Cl lB DNP-C1 i  -Biotin 
AT 1 OB A1 p-DNP-X-T 1  p-Biotin 
ATI OBL A1 p-DNP-X-T1 p-X-Biotin 
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Oligonucleotides ClUB and C1OBL were synthesised to 
investigate whether the incorporation of a linker between biotin and 
the oligonucleotide increased the amount of oligonucleotide binding 
to streptavidin coated plates. Graph 16 shows a comparison of the 
binding of these two strands, at a variety of oligonucleotide 
concentrations (100-0.39 x10-10M). Binding  of oligonucleotides to 
the solid phase was detected using a peroxidase conjugated anti-DNP 
antibody, described previously (sections 3.5.5.2.3). As the amount 
of biotin-ssDNA-DNP added to coated wells was increased the 
amount detected increased. Binding reached a maximum at above 
300pM of DNA. This probably reflects saturation of streptavidin 
binding sites. 
GRAPH 16. EFFECT OF LINKER ON BIOTIN-ssDNA BINDING TO 
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The binding of the oligonucleotide with an extended linker 
resulted in almost identical binding. The attachment of biotin via a 
linker to single strands was clearly unnecessary, as biotin directly 
attached to the oligonucleotide did not appear to cause steric 
hindrance. In the absence of streptavidin coating neither type of 
ssDNA was found to bind, at all concentrations of ssDNA. 
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The presence of the linker in Cl OBL displaces the DNP group 
from the solid phase to a greater extent compared to the DNP in 
C lOB. To confirm that these observations reflected the effect of 
biotin linker on streptavidin binding  and not proximity of the DNP 
group to a solid phase, these experiments were repeated using Cl lB. 
The binding of Cl 1 B, C lOB and Cl OBL to streptavidin coated plates 
at all oligonucleotide concentrations tested were equivalent, results 
not shown. 
The above experiment was repeated using oligonucleotide 
duplexes, AT lOB and AT 1 OBL, instead of ssDNA. Graph 17 shows 
the result of the dilution of these duplexes on streptavidin coated 
plates. There was clearly a difference in the amount of binding 
between the two duplexes. The duplex with biotin attached via a 
linker (AT I OBL) binds to a greater extent at all concentrations under 
the assay conditions. It should be noted that the duplex with biotin 
directly attached does bind to streptavidin coated plates. 
GRAPH 17. EFFECT OF LINKER ON BIOTIN-dsDNA BINDING TO 
STREPTAVIDIN COATED PLATES 
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For both duplexes the amount of bound material becomes 
saturated. The maximum binding of AT1OBL was at a concentration 
of 5 x  0 9M. This represents an approximate 10 fold reduction in 
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concentration of oligonucleotide compared to that used in previous 
experiments. The use of DNP labelled oligonucleotides allowed us 
to confirm that the duplexes were bound to the solid phase. Control 
experiments using AT1OBL showed that in the absence of 
streptavidin no binding of duplex was detected, see graph 17. 
The peroxidase conjugated anti-DNP labelled antibody was 
also shown to give no binding to either streptavidin coated plates or 
non-DNP labelled oligonucleotides attached (via biotin) to 
streptavidin coated plates. In addition, incubations with non-
biotinylated oligonucleotides labelled with DNP using the previous 
assay conditions produced no colour end point. This indicates that 
the assay specifically involves biotin labelled oligonucleotides 
binding to streptavidin coated plates. As DNP labelled 
oligonucleotides could be used to monitor the binding of 
oligonucleotide duplexes it was decided to use these to optimise 
assay conditions. 
3.5.6.1.1 Effect of Streptavidin Concentration on Duplex 
Binding. 
Streptavidin was used to coat microtitre plates at a variety of 
concentrations (50-0.2jig/ml). Each streptavidin coated plate was 
then incubated with AT1OBL (0.5, 5.0, and 50 x10-9M). Binding 
was detected in the usual way via the presence of DNP groups. 
Graph 18 shows the effect of various coating concentrations for 
streptavidin at three oligonucleotide concentrations. There appears 
to be no difference in oligonucleotide binding for AT1OBL between 5 
and 50 x1 0-9M, for all of the streptavidin concentrations. Maximum 
binding occurs for streptavidin coated at 1 Vg/m1 and AT 1 OBL at 5 
x10-9M. At the lower AT1OBL concentration (0.5 x10-9M) there 
was a clear dose response dependant upon the concentration of 
streptavidin used. However, the maximum binding  at 0.5 x10 9M 
AT1OBL was less than that for 5 x10 9M AT1OBL. 
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GRAPH 18. EFFECT OF STREPTAVIDIN CONCENTRATION ON 
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3.5.6.1.2 Effect of Streptavidin Coating Time. 
Streptavidm (1 ig/m1) was used to coat microtitre plates for 0, 
0.5, 1.0, 2.5, 5.0, 7.5, 15, and 24 hours. Duplex oligonucleotide 
AT1OBL at various concentrations (5.0-0.02 x1 0 9M) was allowed 
to bind.  Graph 19 shows the result of duplex binding at various 
streptavidin concentrations. In the absence of streptavidin, no 
binding for any AT1OBL concentrations tested was observed. 
Maximum binding occurred at 2.5 hours with ATIOBL at a 
concentration of 5.0 x10 9M. Incubation of streptavidin for 7.5, 15 
or 24 hours gave no increase in duplex binding. 
135 
GRAPH 19. EFFECT OF STREPTAVIDIN COATING TIME ON 
BIOTIN-L-dsDNA BINDING 
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3.5.6.1.3 Effect of Incubation Time on AT10BL Binding. 
Plates were coated with streptavidin (lj..tg/ml) for 2.5 hours, 
and then incubated  with AT1OBL (5.0 x10-9M) for a time scale of 0-
420 minutes. Graph 20 shows the effect of AT1OBL binding versus 
incubation time. Binding of AT10BL was very rapid (about 80% 
bound in the first 15 minutes). The binding  eventually reached a 
maximum after 120 minutes. 
GRAPH 20. BIOTIN-L-dsDNA INCUBATION TIME ON 
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The coating of the biotin-linker-oligonucleotide duplex to 
streptavidin coated plates was now optimised as outlined below. 
Plates were coated with streptavidin (I j.tg/ml) for 2.5 hours, and then 
incubated with appropriate oligonucleotides (5.0 x10 9M) for 2 
hours. For screenmg the antibodies produced by AC75 
immunisations AC30BL was used to coat microtitre plates, for 
GT75 immunisations GT3OBL was used, and for C lOOP 
immunisations AC30BL and C20BL were used. C20BL was used as 
antibodies that may bind to this may also bind to CC75 duplexes 
(containing CC mismatched base pairs). The duplex CC30BL was 
not available at this time. 
3.5.7 Use of Serum Free Medium 
As previously discussed there was concern as to the possible 
inhibition of anti-DNA antibody/oligonucleotide binding in the 
presence of EDTA. Dr. P Aston and E. Ackerman (SRC) were 
testing various serum free media for the production and growth of 
hybndoma cell lines. Serum free medium would not only reduce the 
cost, they also simplify subsequent antibody purification. For our 
purposes the use of serum free medium may greatly decrease 
nuclease contamination in test supernatants. 
Fusions from inimunised mice were subsequently carried out 
using a 3:1 mix of serum free:complete medium. Thus fusions 
experiments were conducted in a medium containing 2.5% (instead 
of 10%) foetal calf serum (FCS). The medium was changed as 
normal except, after 5 days the FCS was reduced to 1%, and then 
0.5% after 10 days, screening usually being carried out after 14 days. 
For all of the fusion experiments carried out using reduced FCS there 
was no significant change in the number wells produced containing 
actively growing hybridomas (typically >90%) compared to fusions 
using normal serum levels. When using low FCS concentrations the 
degree of attachment of cells to the culture plates was slightly 
reduced, but not sufficiently to cause cell loss when changing or 
testing supernatants. Therefore, it was acceptable to use reduced 
serum levels when carrying out fusion experiments. 
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3.5.8 Studies with Anti-Bromodeoxyuridine Antibodies 
The structure of 5-bromodeoxyuridine (BdU) is similar to that 
of thymine. Antibodies raised against BdU are commercially 
available. It was thought that if these antibodies bound to single 
stranded oligonucleotides containing thymine then they may also bind 
to thymine containing mismatches, in a manner analogous to the 
proposed binding of anti-C lOOPS antibodies to cytosine containing 
mismatches. 
Oligonucleotides T20B, C20B, and A20B were attached to 
streptavidin coated plates. Graph 21 shows the results of the binding 
of various concentrations of anti-BdU antibodies to coated plates. 
There was clearly a dose response, although weak, for the binding of 
these antibodies to single stranded oligonucleotides containing 
thymine (T2013). No binding of anti-BdU antibodies occurred using 
immobilised A20B or C2013, or in the absence of oligonucleotides. 




0.1 --------------- ------------------ A~ ----------------------------- ---------------- 
0.05 
20 	 40 	 80 	 160 	 320 	 640 
Oiotin-T20 -n---- Biotin-G20 	• 	iofln-A20 	No Coot 
The binding of anti-BdU antibodies to plates coated with 
duplexes containing a GT mismatch (GT30BL) or AC mismatch 
(AC30BL) was investigated. These antibodies showed no binding to 
either duplex at all antibody concentrations tested. Further studies 
using these antibodies were not carried out. 
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3.5.9 Screening Using Improved DNA Immobilisation 
Procedures for coating duplex oligonucleotides containing a 
mismatched base pair were optimised. Reduction of potential 
nuclease enzyme interference was addressed. There was greater 
confidence that the screening assay was presenting a mismatched 
base pair such that it was available for recognition by any anti-
mismatch specific antibodies that may be produced by immunisation 
and fusion experiments. 
3.5.9.1 GT75 Fusions 
Two fusion experiments were carried out using splenocytes 
from GT75 immunised mice. Supernatants were tested by non-
competitive ELISA, 27 wells were positive. Of these 15 gave 
positive inhibition studies when GT75 (lOp.g/ml) was used as a 
competitive inhibitor, see Table 15. 




















Inhibition studies were then carried out comparing GC75 
inhibition with the GT75 inhibition, shown above. All of the test 
wells indicated no difference in inhibition with the exception of test 
supernatants taken from 5C9 and 5D7, see Table 16. 







5C9 26.3 0.0 
5D7 54.3 41.7 
5C9 showed some inhibition (26.3%) in the presence of a 
duplex containing a mismatch, GT75, and no inhibition with a similar 
sequence without a mismatch, GC75, suggesting specific recognition 
of the mismatch had occurred. The absorbance measured in the 
ELISA was low, indicating low affinity antibodies or a low 
concentration of antibody was present in the test supernatant. The 
colonies were relatively slow growing compared to other hybridoma 
colonies. This may reduce the amount of antibody released into the 
growth medium. The inhibition for 5D7 was greater, but the 
difference in inhibition was slight. It was decided to carry out 
cloning experiments for both of these cell lines. 
For cells from fusion well 5C9 no colonies were obtained from 
fusion experiments, despite the addition of hybridoma growth 
medium supplement to the cells. For 5D7 cloning experiments 
produced 21 wells containing single colonies. However, none of 
these monoclonals gave inhibition in competitive studies. One mixed 
clone well, containing several colonies, did show inhibition in 
competitive studies, but the inhibition was equivalent for both GT75 
and GC75 as inhibitor. No other wells were found to give positive 
inhibition. 
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3.5.9.2 AC75 Fusion 
A non-competitive ELISA was carried out using dilutions of 
the serum from the pre-fusion bleed of an AC75 immunised mouse, 
graph 22. 
GRAPH 22. ANTISERUM DILUTION FOR MOUSE AC751 
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Antibody was found to be present that bound to the coating material. 
A fusion was carried out producing 43 wells indicating binding in 
non-competitive assays. Seven of these gave positive inhibition in a 
competitive assay, see Table 17. 











Inhibitor was AC75, lOp.g/ml. 
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Similar percentage inhibitions were found when using GC75 
(lOtg/ml) as inhibitor. It was possible that some of the wells 
contained a mixed population of hybndoma cell types e.g. one colony 
producing anti-mismatch antibodies and another colony producing 
anti-DNA antibodies. Competitive studies may then not reflect the 
true inhibition of one colony but rather inhibition of a mixed antibody 
population. 
It was decided to carry out cloning experiments on wells 
whose test supernatants gave high inhibitions. Cloning  experiments 
were carried out on ILC8, 1C10, 1G3 and 4D6. Many wells were 
produced containing single colonies, however, they all gave 
inhibition to duplexes with or without mismatched base pairs in 
competitive assays. One of the 4D6 single colony wells was further 
cloned to produce the monoclonal cell line AC75/4D6/4.12. This cell 
line was subsequently used to compare oligonucleotide binding in 
different assay buffers (phosphate buffer versus tris buffer), see 
below. 
3.5.9.3 Effect of Buffer Conditions 
It was reported (Pisetsky and Semper, 1984) that buffer 
conditions can influence the binding of anti-DNA antibodies to DNA 
in ELISA experiments. We had produced a monoclonal antibody 
that bound to all of the duplex oligonucleotides tested. Non-
competitive and competitive assays were carried out using PBS/Tw 
or TBS/Tw in the anti-DNA antibody binding step only. Graph 23 
shows the result of a non-competitive ELISA for AC7514D6/4.12. 
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GRAPH 23. EFFECT OF BUFFER CONDITIONS IN NON- 
COMPETITIVE ELISA USING AC75/1 4D6 SUPERNATANT 
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Although both produce dose dependent dilution curves, the 
shapes of the curves were clearly very different. The binding  of the 
antibody to coated plates in PBS/Tw was greater at all dilutions of 
antibody. Competitive studies were then carried out, see Table 18, at 
three antibody dilutions. Antibody dilutions were selected from the 
result of non-competitive studies. 
Table 18. Competitive Assay on AC75/4D6/4.12 in Two Buffers 
BUFFER PBSITw pH 7.2 TBSITw pH 7.2 
% Inhibition AC75 45 <5 
%JnhibitionAC75 39 <5 
% Inhibition AC75 1 	44 1 	<5 
Inhibitor AC75 10pg/ml 
The buffer used was greatly influencing the amount of 
inhibition in competitive studies. There was virtually no inhibition of 
binding in the presence of TBS compared to PBS. Pisetsky and 
Semper (1984) found that the binding of antibodies to DNA can vary 
greatly depending on the buffer. Some antibodies were found to have 
relatively increased binding to DNA in TBS, others in PBS. 
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Pisetsky and Semper (1984) gave no explanation to this 
variability in binding of anti-DNA antibodies. It is worth noting that 
in non-competitive ELISA anti-DNA antibody binding  to DNA 
coated plates was reduced for TBS/Tw compared to PBS/Tw. 
Subsequently high inhibitions were observed in competitive ELISAs 
using PBS/Tw as buffer, and virtually no inhibition when using 
TBS/Tw as buffer. 
Tris may alter conformation adopted by the antibody binding 
site and/or the DNA. Conformational changes in the antibody 
binding site could give rise to reduced antibody binding to DNA, 
indicated in graph 23. However, as a limiting amount of antibody 
was used in the competitive ELISA some inhibition (albeit different 
to that seen for PBS/Tw) would be expected to occur. 
Alternatively, the conformation of the DNA duplex may be 
altered in the presence of TBS/Tw. It could be argued that the effect 
of TBS/Tw on altering the conformation of the immobilised DNA 
and inhibitor DNA may be different. The immobilised  DNA was a 
relatively short duplex. It was a single strand modified with a central 
tetraethylene glycol linker allowing it to form a stable self 
complimentary duplex. In addition it was immobilised (via biotin 
streptavidin interactions) at one end to a solid phase. By comparison 
the DNA used as inhibitor was a relatively long duplex. It had none 
of the potential restrictions suggested for the immobilised strand for 
conformational alteration. In addition it contains twice as many 
mismatched base pairs, and these may aid conformational change. 
Anti-DNA antibodies in TBS/Tw may thus be able to 
recognise relatively unaltered immobilised DNA (non-competitive 
ELISA). However, they may be unable to recognise 
conformationally altered inhibitor DNA (competitive ELISA), 
producing no inhibition. There are of course other buffers that may 
be used in antibody screening experiments. Clearly it would be 
impossible to test all of them while screening  fusion and cloning 
experiments for anti-mismatch antibodies. However, it should be 
noted that useful antibodies may be lost by not examining a variety of 
buffer conditions. 
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3.5.9.4 C100PS Fusions 
Non-competitive ELISAs were earned out using sera from 
pre-fusion bleeds for two C lOOPS immunised mice, see graph 24. 
GRAPH 24. ANTISERA DILUTION FOR MICE C100PS-1 AND 21 
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The serum of both mice contained antibodies that bound to the 
coating material, the titre for mouse 2 was slightly higher. Fusions 
were then carried out. 26 fusion wells indicated antibody binding  in 
non-competitive ELISA. Five of these gave positive inhibition 
against C100PS, three of these (wells 1-5C7 and 2-3G7, 2-3Gb) 
gave positive inhibition in competitive assay against duplexes, see 
Table 19. 










1-5C7 >80 40.2 39.5 19.8 
2-3G7 >80 10.0 79.4 <5 
2-3G10 >80 <5 11.2 <5 
Inhibitor at 1 Op.g/ml 
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As expected, positive wells show very high inhibition when 
incubated with C lOOPS. Fusion well 1-5C7 appears to contain 
antibodies that recognise duplexes containing AC and CC 
mismatches, to a slightly greater extent than duplexes containing GC 
base pairs in place of the mismatches. This may represent antibodies 
that recognise mismatched base pairs in a duplex, but also cross react 
with non-mismatched sequence. It should also be noted that a fusion 
well may contain a mixed cell population and thus inhibition with 
GC75 may represent binding by antibodies other than those 
recognising the mismatch containing duplexes. 
The binding of antibody from 2-3G7 appear to be directed 
towards duplexes containing a CC mismatch, compared with AC 
mismatched or GC non-mismatched duplexes. 2-3G10 showed only 
slight inhibition with CC75, but virtually no inhibition with either GC 
matched or AC mismatch containing duplexes. Cells from these 
wells were used for cloning experiments. 
Using our protocol perfect cloning experiments should 
produce approximately 36 wells that contain single colonies. For 
single colony cell lines producing the desired antibody further 
cloning experiment will be carried out to ensure monoclonality. 
However, in practice single colony wells from the first cloning 
experiment probably are monoclonal. Cloning experiments over the 
course of this study have generally been reasonably efficient, 
producing greater than 25 single colony wells in most cases. 
However, when screening cloned cell lines many of them have not 
given results similar to those seen for fusion wells from which the 
cloned cells were obtained. Where this occurs, predominantly anti-
DNA binding activity seems to be lost. 
This could suggest that some of the fusion results generated 
false positives, and there could be a fundamental problem with the 
screening strategy. However, the fusions discussed in sections (3.5) 
did produce clone wells producing antibodies with similar properties 
to the fusion wells from which they were obtained. 
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It is known that genetic instability of hybridomas occurs 
immediately post fusion. This can lead to a loss in antibody 
production and/or secretion. In addition, the loss of desired antibody 
secreting cells may occur because the cells secreting antibody of 
interest represent the minority cell type in the fusion wells, if the 
anti-DNA antibody secreting cells were in the minority then cloning 
experiments would rarely isolate single colony cell lines with the 
desired antibody production. Increasing the number of cloning 
experiments from one fusion well should increase the probability of 
isolating the desired clone. To this end two cloning experiments 
were conducted in subsequent cloning experiments, to improve the 
chances of obtaining the desired monoclonals. 
Ideally the entire fusion well may be cloned to ensure the 
desired clone was isolated. This approach would generally be 
disregarded as unpractical, due to the huge numbers of cells present 
(thousands) when fusions are screened. Keeping thousands of 
monoclonal cell lines in cell culture would be expensive and time 
consuming. More importantly, depending on the relative colony 
growth rate, the ability to accurately screen these numbers of cell 
lines becomes a problem. This will be discussed further in section 4. 
More than 50 single colony wells were obtained for each 
fusion well in cloning experiments. Despite this no anti-mismatched 
base pair antibodies were identified, by competitive ELISA, for 2-
3G7, 2-3G10. Three wells containing single colonies were obtained 
for 2-3G10 that produced anti C lOOPS antibodies, these were used to 
further investigate the effect of EDTA on antibody/DNA binding, see 
later. Anti-dsDNA duplex antibodies were obtained for the 
monoclonal cell lines derived from C100PS/1-5C7. 
3.5.9.4.1 Monoclonals from C100PS/1-5C7 
As previously discussed for antibodies from AC75/4D6/4 .12 
cell line the type of buffer used in the anti-DNA antibody binding 
reaction influenced the results obtained. Non-competitive assays on 
monoclonals from C100PS/1-5C7 were carried out using both 
PBS/Tw and TBS/Tw. For all C100PS/1-5C7 monoclonals tested 
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higher antibody titres were observed if the anti-DNA antibody 
incubation was carried out in PBS/Tw, than in TBS/Tw. In many 
cases the amount of binding detected using TBS/Tw as buffer were 
so low that the hybridomas producing the test supernatants would 
have been discarded. It was also found that using PBS/Tw at half 
strength increased the amount of antibody detected in non-
competitive assays. Antibody/antigen interaction are usually directly 
proportional to salt concentration, so this was not unexpected. 
Cloning experiments from C100PS/1-5C7 produced 51 wells 
containing single colonies, 40 of these produced antibodies giving 
positive inhibition of greater than 70% with C lOOPS (10tg/ml). 
Inhibition studies with duplex oligonucleotides were then carried out. 
Table 20 shows the results from competitive studies carried out on 
appropriate dilutions of antibody containing supernatants in 
0.5xPBS/Tw. 












1.1 67 89 65 
1.2 65 89 54 
1.4 49 75 30 
1.6 58 82 38 
5.1 62 89 7 
5.2 65 91 28 
5.4 59 88 <5 
5.9 50 86 <5 
5.10 38 75 <5 
5.11 38 72 <5 
5.12 57 87 <5 
5.19 62 75 <5 
5.23 52 81 <5 
Inhibitor at 1 Ojtg/ml 
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These results represent inhibition studies at fixed antibody 
dilution at one relatively high concentration of inhibitor. It can be 
seen that CC75 gives the best inhibition and thus was recognised in 
preference to non-mismatched sequences, and some of those 
containing AC mismatched base pairs. The stability of the duplexes 
was in part dependent upon the salt concentration of the buffer, 
therefore, the use of a reduced salt buffer may increase the exposure 
of cytosine containing mismatches, at AC and CC mismatch base 
pair sites, to antibodies in our experiments. 
This was the first set of experiments demonstrating the 
presence of monoclonal antibodies with some reactivity to a 
mismatched base pair in a DNA duplex. Further experiments should 
be carried out to test the specificity of these antibodies, and on the 
sensitivity of assays that can be produced using these antibodies. It 
should be noted that these were not mismatch specific antibodies, 
and were not analogous to mismatch repair proteins. Instead they 
represent antibodies that recognise single stranded oligonucleotides 
containing cytosine,  with sufficient cross reactivity to detect lOpg/m1 
of duplexes containing CC and to a lesser extent AC mismatches. A 
great deal of work would be required to establish all of the cross 
reactivities of these antibodies. Details of this will be discussed later. 
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3.6 EXPERIMENTAL 
Production of monoclonal antibodies 
All of the procedures leading to the production of monoclonal 
antibodies, including immunisations, splenocyte preparation., general 
cell culture, fusion and cloning experiments were based on 
procedures routinely used by the immunochemistry group at Shell 
Research Centre (SRC). They were adapted from the techniques of 
Kohler and Milstein (1975 and 1976). 
Immunisations 
Immunisations were carried out by Dr J.P.Aston (SRC), on 
female BALB/c mice. Three mice were used for each mimunogen. 
Primary injections and secondary boost injections were subcutaneous 
into the nape of the neck. Pre-fusion boosts were given by 
intraperitoneal and intravenous injection on days 3 and 2 prior to 
fusion experiments. 
15mer Duplexes 
Primary injections were carried out with a mismatched DNA 
duplex (1OOtg) in isolation from a carrier protein or complexed with 
the methyl ester of BSA (MeBSA). The immunogen was injected as 
an emulsion in Freunds Complete Adjuvant (Sigma Chemical 
Company). 
Secondary injections were carried out after three weeks. The 
same procedure as above was used except Freunds Incomplete 
Adjuvant (Sigma Chemical Company) was used to form the 
emulsion. Pre-fusion boosts were carried out at least 1 month after 
secondary injections. Pre-fusion boosts contained DNA (1OOig) in 
aq. NaCl (0. 15M). 
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75mer Duplexes and C100PS Single Strand 
Primary injections were carried out with duplex or single 
stranded DNA (1 00tg)in isolation from a carrier protein. The 
immunogen was injected as an emulsion in Hunters Titermax 
Adjuvant. Secondary injections were carried out as above using 
Freunds Incomplete Adjuvant. Pre-fusion boosts were injected with 
DNA (1 OOpg) in aq. NaCl (0.1 5M). 
Bleeds were taken from immuriised mice one week after 
secondary injections. Serum from bleeds was obtained by 
centrifugation. Serum was tested for the presence of anti-DNA 
immunoglobulins by Enzyme Linked Immunosorbent Assay 
(ELISA), described later. 
Hybridoma production 
Cell culture reagents 
Roxwell Park Memorial Institute cell culture medium - 1640 
(RPMII-1640 or RPM1I) was supplied by Gibco Europe Ltd. 
Complete medium is RPM1I containing L-glutamine (4mM), sodium 
pyruvate (1mM), penicillin (1 OOU/ml), streptomycin (1 OOU/ml), 
Myoclone plus foetal calf serum (10%) supplied by Gibco Europe 
Ltd. HT medium is complete medium containing hypoxanthine 
(100mM), and thymidine (16mM) supplied by BDH Ltd. HAT 
medium is complete medium containing hypoxanthine (100mM), 
thymidine (16mM), aminopterin (0.4mM) supplied by BDH Ltd. 
Serum free/protein free medium was supplied by Gibco Europe Ltd. 
Complete serum free medium is made as complete RPMII, omitting 
the FCS. Polyethylene glycol (PEG) and dimethylsulphoxide 
(DMSO) both hybridoma grade were obtained from Sigma 




Splenocytes, for fusion experiments, were obtained from 
spleens of mice, two days after the second pre-fusion boost 
injections. Spleens were removed from terminally anaesthetised 
mice and placed in RPMI (20m1), at 40C. All subsequent operations 
were carried out in a cell culture laboratory in laminar flow hoods 
using aseptic techniques. All cell culture fluids were pre-warmed to 
370C before being used. 
Spleens were trimmed of connective tissue, then transferred to 
a sterile Petri dish. A superficial longitudinal cut was made along the 
length of the spleen with a scalpel. Splenocytes were gently 
dispersed from the organ using two 1 OmI syringes fitted with 26-
gauge needles, each containing RPMI (lOmi). One syringe was used 
to anchor the spleen, the other to puncture it and expel fluid in 
successive small areas, using the fluid from first one and then the 
other syringe. The cell suspension, typically 0.6-1.2 x 108  cells, was 
then pelleted by centrifugation at 1000 rpm for five minutes. 
Fusion of Splenocytes with Plasmacytoma Cell Line 
Sp2/1-Ag14 (Sp2) a non-immunoglobulin producing 
plasmacytoma cell line was used as the fusion partner in fusion 
experiments. For each fusion three 200m1 culture flasks were grown 
to near confluency with the Sp2 cell line. The Sp2 cells adhere to the 
plastic surface of culture flasks. They were carefully removed by 
gentle scraping, with a rubber tipped rod, from the flasks and pelleted 
by centrifugation at 1000 rpm for five minutes. 
Sp2 cells and splenocytes were resuspended separately in 
RPMJ (lOmi) and were measured for cell viability by trypan blue 
exclusion. Tiypan blue cannot pass through the membranes of live 
cells, but readily passes into dead cells. The total cell yield per 
spleen was usually 0.6-1.2 x 108  with greater than 90% of the cells 
able to exclude trypan blue. Sp2 and splenocyte cell suspensions 
were combined to give  107 Sp2 cells and 108  splenocytes. The 
152 
mixed cell suspension was then divided into six equal volumes and 
each pelleted at 1000 rpm for five minutes,  each pellet serving as a 
separate fusion experiment. 
For each fusion the supernatant was removed from the mixed 
pellet and PEG (300j.i!) added dropwise over 30 seconds with 
continuous agitation of the pellet. RPMII (6m1) was then added 
dropwise over 60 seconds with gentle shaking to resuspend the cell 
mixture. The cell suspension was then pelleted by centrifugation at 
1000 rpm for 5 minutes. The supernatant was removed and the pellet 
resuspended in complete medium (6m1). The cell suspension was 
then dispensedin aliquots (60 x 1 OOj.tl) to each of the central wells of 
a 96 well cell culture plate. HAT medium (lOOp.l) was added to each 
of the wells. The cell culture plates were then placed in a humid 
incubator at 370C with a filtered gas supply of 5% CO2 in air. 
Post-fusion cell culture 
Cell culture supernatant (1 00p1) was removed from each 
fusion well and replaced with HAT medium (100..tl) on day 1, 3, 5 
and 7 post fusion. This was continued on day 9, 11 and 13 using HT 
medium, after which complete medium was used. Usually by day 10 
post fusion post fusion the cells were of sufficient density to initiate 
screening for anti-DNA antibodies. Positive anti-DNA antibody 
producing cell lines then underwent cloning experiments in an 
attempt to produce monoclonal cell line by limiting dilution. 
Occasionally Hybri-plus media supplement (10%v/v) was added if 
poor growth was observed. All 96 well culture plates were 
monitored for up to four weeks post fusion to allow slow growing 
hybridomas to reach sufficient density to initiate screening. 
Cloning by Limiting Dilution 
Cloning  by limiting dilution aims to produce monoclonal 
hybridoma cells from actively growing hybridomas from fusion 
experiments. This was achieved by diluting cell suspensions into 96 
well cell culture plates such that several rows should contain a single 
cell per well. A feeder layer of cells, providing cell-cell contact and 
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growth factors was required to help maintain cell viability, this is 
important for extremely low density cell dispersions. Thymocyte cell 
suspensions were used, and obtained as follows. 
A 4-6 week old female BALB/c mouse was killed by overdose 
anaesthesia. Using sterile dissecting instruments  an incision was 
made along the mid line of the thorax to the neck. The thoracic 
cavity was opened and two thymus lobes, lying anterior to the heart, 
were removed and transferred to a sterile container containing RPMI 
(lOmis). 
All subsequent operations were carried out in a cell culture 
laboratory in laminar flow hoods using aseptic techniques. Thymus 
lobes were placed in a sterile petn dish containing RPMI (lOmls), at 
370C. Thymocytes were dispersed by gently teasing the thymus with 
forceps. The cell suspension was then pelleted by centrifugation at 
1000 rpm for five minutes and the pellet was resuspended in 
complete medium (20mls). 
Thymocyte suspension (4mls) was added to approximately 
200 hybridomas. Thymocyte/hybridoma cell suspension (2 .4mls) 
was added to the first 2 rows of a 96 well cell culture plate (100 j.il 
per well), leaving 1 .6mls unused. Thymocyte suspension (2.4mls) 
was then added to the remaining thymocyte/hybridoma cell 
suspension (1 .6mls), gently mixed, then dispensed as above into 
rows 3 and 4, again leaving  1.6mls unused. Thymocyte suspension 
(1 .6mls) was then added to the remaining thymocyte/hybndoma cell 
suspension (1 .6mls), gently mixed, then dispensed as above into 
rows 5 and 6, leaving 0.8mls unused. Finally the remaining 
thymocyte/hybridoma suspension (0.8mls) was added to the 
thymocyte suspension (1 .6nils), and dispensed into rows 7 and 8. 
Complete medium (100il) was added to each of the 96 wells, 
and the cell culture plates were then placed in a humid incubator at 
370C with a filtered gas supply of 5% CO2 in air. Theoretically each 
set of two rows will contain on average 5, 2, 1, and 0.5 hybridoma 
cells per well, respectively. 
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After 10-14 days the plates were examined microscopically for 
colony formation and those producing actively growing colonies 
were screened for the presence of anti-DNA antibodies. To ensure 
monoclonality, cloning by limiting dilution was repeated twice for 
any positive wells from the first round of cloning. 
Freezing Cells 
Approximately 106  cells were pelleted by centrifugation at 
1000 rpm for 5 minutes. The pellet was resuspended in foetal calf 
serum containing 10% DMSO (0.5mls) at 40C. The cell suspension 
was transferred to a cryotube, placed into a freezing container 
containing propan-2-ol, and stored overnight at -700C. Cryotubes 
were then transferred to liquid nitrogen for long term storage. 
Thawing Cells 
Cells were rapidly thawed from cryotubes, in a 550C water 
bath, with gently shaking to resuspend the cells. The cell suspension 
was diluted with RPMI (I Orals), prewarmed to 370C, then pelleted 
by centrifugation at 1000 rpm for 5 minutes. The pellet was 
resuspended in complete medium (2mls), prewarmed to 370C, and 
dispensed (imi) into two 2m1 wells of a cell culture plate. These 
were then placed into a humid incubator at 370C, with a filtered gas 
supply of 5% CO2 in air. 
Enzyme Linked Immunosorbent Assay (ELISA) 
Reagents 
2,2-Azinobis (3 -ethylbenzthiazoline) sulfonic acid (ABTS), 
hydrogen peroxide (30%), polyoxyethylene sorbitan monolaurate 
(Tween 20 or Tw), sodium carbonate, and streptavidin were obtained 
from Sigma Chemical Company. Citric acid, disodium hydrogen 
orthophosphate, sodium chloride and sodium hydrogen carbonate 
were obtained from BDH Chemical Company. Phosphate buffered 
saline (PBS) tablets were obtained from Oxoid Ltd. Reduced Mg2 
and Ca 2+  PBS was obtained from ICN Flow. 
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Coating  buffer (pH 9.6) contains sodium bicarbonate (1.6g), 
sodium hydrogen carbonate (2.9g) in 1 litre of distilled water. PBS 
(pH 7.2) contains 10 PBS tablets in 1 litre of distilled water. 
PBS/Tw contains 10 PBS tablets, and Tween 20 (0.5g) in 1 litre of 
distilled water. Reduced strength PBS/Tw (0.5x PBS/Tw) contains 5 
PBS tablets, and Tween 20 (0.5g) in 1 litre of distilled water. 
TBS/Tw contained 0.01M Tris, 137mM NaCl and 0.05% (w!v) 
Tween 20, pH 7.2. Peroxidase buffer contains disodium hydrogen 
orthophosphate (4.41g), citric acid (4.58g), 30% hydrogen peroxide 
(1 80j.il) in 500m1 distilled water. ABTS concentrate contains ABTS 
(0.75g) in 50m1 distilled water. Peroxidase buffer and ABTS 
concentrate are filtered (0.2.i filter) and stored at 40C. ABTS 
(0.6mgniti) in peroxidase buffer was prepared on the day of use for 
all ELISA experiments. Colour was allowed to develop for 30 
minutes prior to measuring. 
Mouse IgG standards were obtained from Sigma. Rabbit anti-
DNA antibodies were obtained from Boerhringer Mannheim. 
Peroxidase conjugated swine anti-rabbit antibodies, peroxidase 
conjugated rabbit anti-mouse antibodies, rabbit anti-mouse antibodies 
and mouse anti-bromodeoxyuridine antibody (anti-BrdUrd, Bu 20a) 
were obtained from Dako Ltd. All assays were carried out using 96 
well microtitre plates (Nunc Maxisorb). End point colour 
development was measured using a 96 well microplate reader 
(Molecular Device VMax), the data was analysed and stored using a 
NEC Powermate SXI20/VI computer. 
ELISA Plate Coating Conditions 
1. Non-specific adsorption of DNA to microtitre wells. 
(A) Untreated plates : 96 well microtitre plates were coated 
(100tlIweIl) with 15mer DNA duplexes (AA 15, AC 15, GG15 or 
CC15; 1jxg/ml) in Tris buffered saline (TBS, Tris 10mM, sodium 
chloride 150mM, pH 7.2). The DNA was allowed to passively bind 
overnight at room temperature. Unbound material was then removed 
by washing with PBS (4 x 200l). Non-bound sites on the plates 
were then blocked (200.tl1we1l) with gelatin (0.1%), in distilled water 
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for one hour. Plates were then washed as above using PBS/Tw and 
then sealed and stored at 40C until required. 
Poly-L-Lysine treated plates (adapted from Fisher and Ziff, 
1981): Plates were precoated (lOOi.ilIwell) with poly-L-lysine 
(50j.xg/ml) in distilled water for two hours then washed with TBS/Tw 
(4 x 200 j.xl). 1 5mer DNA duplexes as described above were then 
allowed to bind as L(A) for two hours. Unbound material was 
removed by washing with PBS (4 x 200p1). Non-bound sites on the 
plates were blocked (200 j.tl/well) with gelatin (0.1%), in distilled 
water, or (200 jtllwell) with poly-L-glutamate (50j.iglml), in distilled 
water, for one hour. Plates were then washed and sealed as above. 
MeBSA treated plates (adapted from Rubin et al., 1983): 
Plates were precoated (l00.tl1well) with MeBSA (0.1%), in distilled 
water, for two hours then washed with TBSITw (4 x 200l). 1 5mer 
DNA duplexes as described above were then allowed to bind as 
L(A) for two hours. Plates were then washed, blocked and stored as 
described in 1 (A). 
UV-Irradiated plates (adapted from Zouali and Stollar, 1986): 
Plates were UV-irradiated  at 254nm for 18 hours. DNA binding, 
blocking and storage was carried out as 1(C). 
2. Specific attachment of DNA to microtitre plates (adapted from 
Enilen et al., 1990). 
(A) Duplex coat formation via complementary single strands: 
Plates were coated (100l/well) with streptavidin (lp.g/ml) in coating 
buffer (pH 9.6). Unbound material was removed by washing with 
PBS (4 x 200j.xl). Non-bound sites on the plates were blocked 
(200tlIwel1) with gelatin (0.1 % (w/v)), in distilled water for one 
hour. Plates were washed as above using PBSITw prior to coating 
(100 j.il/well) with biotin end labelled single  stranded DNA sequence 
AAAB (200ng/nil), in PBSITw containing 0.2mM EDTA (PTE). 
Plates were washed with PTE (4 x 200m1). A duplex was formed by 
adding a single stranded DNA sequence (100..d/well), in PTE, either 
fully complementary TTT (400ng/ml), or such that a single base pair 
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mismatch would form TCT or TAT (400ng/ml), for two hours. 
Plates were washed with PTE (4 x 200 j.tl), and stored as previously 
described (see also detection of duplex formation). 
Coating with thermally stabilised I Smer duplex: 
Plates were coated in the same way as 2 (A) except a biotinylated 
duplex AC 1 5B (400ng/ml) was used instead of biotin labelled single 
stranded oligonucleotides. AC15B was a 15mer duplex containing a 
central AC mismatch, stabilised at one end with a tetraethylene 
glycol linker, and biotinylated at the opposite end (cf. AC 15 used as 
immunogen or coating material above). Plates were blocked and 
stored as described in 2 (A). 
Coating with single stranded DNA: 
Plates were coated as 2(A) with a biotin labelled cytosine 20mer 
C20B (400ngIml), blocked and stored as described in 2(A). 
Detection of Duplex Formation in 2 (A). 
Detection of duplex formation was evaluated by using DNP 
end labelled single stranded DNA sequences. These would be either 
fully complementary TTTDNP (400ngIml), or such that a single base 
pair mismatch would form TCTDNP or TATDNP (400ngIml), when 
incubated on plates precoated with AAAB (as in 2 (A)). Plates were 
then washed with PTE (4 x 200p.l). Formation of the duplex was 
measured by detection of the DNP group. A peroxidase enzyme 
conjugated anti-DNP antibody (lOOp.l!well) was added (1:15,000 
dilution), in PBS/Tw. Plates were washed with PBSITw (4 x 200tl), 
then a colourless peroxidase substrate (100tl1well) of ABTS 
(0.6mg/nil) in peroxidase buffer was added. In the presence of 
peroxidase enzymes this produces a coloured product which can be 
measured spectrophotometrically at 405nm. 
Anti-DNA antibody screens of mice sera 
Serum from mice were screened for the presence of anti-DNA 
antibody using non-competitive and competitive ELISA techniques 
using the coating procedures described in 1(A-D). Initially non 
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competitive ELISAs were carried out. The serum was diluted in 
PBS/Tw (1:50), then double diluted to give 9 or 10 dilutions. These 
were incubated (1 OOp.lIwell) on microtitre plates for two hours. 
Plates were washed as above using PBS/Tw. A peroxidase 
conjugated rabbit anti-mouse antibody (lOOpJIwell) diluted in 
PBS/Tw (1:1000), was added for one hour. Plates were washed as 
above using PBS/Tw. Colour development was produced and 
monitored as previously described. 
Non-competitive ELISAs of serum produce dilution-response 
curves. Where good dilution-response curves were obtained for mice 
serum, competitive ELISAs were carried out. A limiting dilution of 
serum was incubated with a range of concentrations of DNA (100-
0.1jg/m1) in PBS/Tw. These were then incubated on coated plates 
(100 pd/well), and developed as in the non-competitive ELISA 
described above. 
3.6.1 Screening of fusions for anti-DNA antibody production 
Mouse IgG ELISA 
Plates were coated (1 OOp.1/well) with a rabbit anti-mouse 
antibody (1:1000) in coating buffer, for two hours. Plates were 
washed with PBS/Tw as previously described. Supernatants from 
fusion wells (100tl/we1l) were transferred to these plates, and 
incubated for one hour. Plates were washed as above. Peroxidase 
conjugated rabbit anti-mouse antibody (lOOpiIwell) diluted in 
PBS/Tw (1:1000), was added for one hour. Plates were washed and 
ABTS was added. Colour development was monitored as previously 
described. 
Assays using coating procedures 1(A-D). 
Non-competitive ELISA. 
Supernatants from fusion wells (lOOpd/well) were transferred 
to coated plates, and incubated for two hours. Plates were washed as 
above, and then a peroxidase conjugated rabbit anti-mouse antibody 
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(lOOp.IIwell) diluted in PBS/Tw (1:1000), was added for one hour. 
Plates were then washed as above using PBS/Tw. Colour 
development was monitored as previously described. 
Competitive ELISA. 
Supernatants from fusion wells (1 OOj..il) were incubated with a 
range of concentrations of DNA (100-0.1tg/ni1 in lOOpi) in PBS/Tw 
and with PBS/Tw (lOOpi) only as a control. These assay solutions 
were transferred to coated plates (1 00tl/we1l), and incubated for two 
hours. Plates were washed as above. Assay procedure and colour 
development was carried out as previously described. 
Assays using coating procedures 2(A-C) 
Non-competitive ELISA. 
Supernatants from fusion wells (50i11wel1) were transferred to 
coated plates containing PBS/Tw with EDTA (1.0 or 0.2mM), and 
incubated for two hours. Plates were washed with PBS/Tw with 
EDTA (1 .OmIvl) as above. Assay procedure and colour development 
was carried out as previously described. 
Competitive ELISA. 
Supernatants from fusion wells (50jil) were incubated with a 
range of concentrations of DNA (100-0.1p.g/ml in lOOpi) in PBS/Tw 
with EDTA (1.0 or 0.2mM). These assay solutions were transferred 
to coated plates (100 j.ilIwell), and incubated for two hours. Plates 
were washed with PBS/Tw with EDTA (1.0mM) as above. Assay 
procedure and colour development was carried out as previously 
described. 
DNA Digestion assay 
Tissue culture medium, autoclaved tissue culture medium, and 
tissue culture medium with EDTA (50mM) were diluted in PBS/Tw. 
The medium was incubated (l00pilwell) on plates coated with single 
160 
stranded cytosine 20mer end labelled with biotin (C20B) by 
procedure 2(C). After one hour wells were washed with PBS/Tw as 
above, and incubated (100.t1/well) with a commercially available 
rabbit anti-DNA antibody (0. 1mg/mi) in PBS/Tw for two hours. 
Plates were washed in PBS/Tw and a peroxidase conjugated swine 
anti-rabbit antibody was added (100 jtl/well) in PBS/Tw (1:500) for 
one hour. Plates were washed and colour development was carried 
out as previously described. 
Investigating Anti-Bromodeoxyuridine Antibodies 
Plates were coated (100 jtIJwell) with streptavidin (lj.ig/ml) in 
coating buffer (pH 9.6), for 2.5 hours. Unbound material was 
removed by washing with PBS (4 x 200pJ). Non-bound sites on the 
plates were blocked with gelatin as previously described. Plates 
were then coated (1 OOj.ilIwell) with either biotin-linker  end labelled 
single stranded DNA sequence T20B, C20B, and A20B or biotin-
linker end labelled duplexes AC30B, and GT30B (5x10 9M), in 
PBS/Tw, for 2 hours. 30 wells were coated for each sequence. A 
further 30 streptavidin coated wells were incubated with PBS/Tw 
only to serve as a series of controls. Plates were washed with 
PBS/Tw (4 x 200 j.xl). 
Anti-BrdUrd was diluted 1:20 in PBS/Tw and then double 
diluted to give 9 dilutions (1:20 - 1:5120), in PBS/Tw. PBS/Tw was 
also used as a control blank for the antibody. Anti-BrdUrd dilutions 
(100 jtl/well) were then incubated in oligonucleotide coated or blank 
wells, in triplicate, for 1 hour. Plates were washed and developed 
with a peroxidase conjugated rabbit anti-mouse antibody as 
previously described. 
Testing Biotin-Linker Coating Procedure 
Standard procedure 
Streptavidin and oligonucleotide concentration and incubation 
times were varied to establish coating conditions. All streptavidin 
coated plates were blocked with gelatin as previously described. 
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Detection of DNP labelled oligonucleotides was carried out using 
peroxidase enzyme conjugated anti-DNP antibody (lOOpi/well) 
diluted 1:15,000 in PBS/Tw. Colour development was previously 
described. 
Single Stranded Oligonucleotides 
Plates were coated with streptavidin (1 j..tg/ml), or with coating 
buffer only as a control. Single stranded oligonucleotides C 1 OB, 
C1OBL, and Cl I  (100 x10M) were double diluted in PBS/Tw to 
give 9 dilutions (100-0.39 xl0 9M), PBS/Tw only serving as a blank. 
These oligonucleotides were 5-biotin and 3'-DNP labelled. 
Oligonucleotide dilutions (1 OOp.IIweIl) were incubated on 
streptavidin coated or blank wells, for 2 hours. Further assay 
development was carried out as previously described. 
Double Stranded Oligonucleofides 
The above assay was repeated except duplex forming 
oligonucleotides AT 1 OB and AT 1 OBL were used in place of single 
stranded oligonucleotides. All coating and assay conditions were 
identical. N.B. These duplexes were 5-biotin labelled, with a central 
DNP group as part of the tetraethylene glycol linker such that on 
duplex formation the biotin and DNP groups are at opposing ends of 
the duplex. The Biotin binding at the solid phase (streptavidin). 
Optimisation of Biotin-Linker-Oligonucleotide Immobilisation 
Streptavidin Concentration 
Streptavidin (50pgIm1) in coating buffer was diluted with 
coating buffer to give 9 dilutions (50-0.20jg/ml). Plates were coated 
with various streptavidin concentrations (1 OOpilwell), coating buffer 
only serving as a blank, for 2 hours. AT1OBL (50, 5 and 0.5 x10 -M) 
in PB S/Tw were added (1 OOj..tLfwell) for each coating concentration, 
in triplicate, for 2 hours. Further assay development was carried out 
as previously described. 
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Streptavidin Coating Time 
Plates were coated (lOOpJlwell) with streptavidin (1tg/ml) in 
coating buffer for 24, 15, 7.5, 5, 2.5, 1.0 and 0.5 hours, coating 
buffer only was used as 0 hour blank. AT1OBL (5.0 x10M) in 
PBS/Tw was double diluted, to give 9 dilutions (5.0-0.02 xl0 9M), in 
PBS/Tw. AT1OBL concentrations (100il!well) were then added to 
each of the above coated wells, in triplicate, for 2 hours. Plates were 
washed and developed as previous described. 
Oligonucleotide Coating Time 
Plates were coated (lOOp.lIwell) with streptavidin (lp.glml) in 
Coating buffer for 2.5 hours. AT1OBL (5xl0 9M) in PBS/Tw was 
added (lOOpJlwell) to coated plates for 420, 300, 220, 120, 60, 30, 
and 15 minutes, PBS/Tw only serving as 0 minute blank. Plates were 
washed and then developed as previously described. 
Optimised Coating Conditions 
Subsequently all anti-DNA antibody production was screened 
using the optimised oligonucleotide immobilisation procedure. N.B. 
The oligonucleotides used for screening were not DNP labelled. The 
assay procedure was as outlined below:- 
Plates were coated (100 j.tllwell) with streptavidin (lp.g/ml) in 
coating buffer, for 2.5 hours. Plates were washed and blocked with 
gelatin (0.1% (w/v)) and were ready for immediate use, or could be 
stored sealed, at 40C, for several months. Oligonucleotides A20BL, 
C20BL, T20BL, AC30BL, and GT30BL (5x10-9M) in PBS/Tw were 
added to streptavidin coated plates (lOOpJJwell), for 2 hours. Plates 
were washed and used for screening anti-DNA antibodies in serum 
or cell culture supernatants. 
Antibody containing supernatants from fusion and cloning 
experiments were always screened using plates freshly coated with 
oligonucleotide. Supernatants were always diluted 1:1 with PBS! Tw 
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for non-competitive assays. Any positives underwent competitive 
assays as previously described. 
Effect of ETDA on Assay using C20B-Oligonucleotide 
Buffers and wash solutions were adjusted with EDTA such 
that they contained 0, 10 and 100mM EDTA. Oligonucleotide C20B 
(400ngInil) in PBS/Tw with or without EDTA were added 
(lOOpi/well) to streptavidin coated plates and allowed to bind for 2 
hours. Plates were washed and a commercially available anti-DNA 
antibody, (5j.ig/ml) was double diluted in PBS/Tw with or without 
EDTA to give 7 dilutions (5-0.6jiglml). These were added 
(1 00tlIwe1l) for 1 hour. Plates were then washed and developed as 
previously described. 
Effect of ETDA on Assay using DNP-Oligonucleotide 
PBS/Tw containing EDTA (10, 1.0, 0. 1, 0.025, 0.0025mM) or 
PBS/Tw only was used in all buffer and wash solutions. AT1OBL 
(5x10M) in PBS/Tw +1- EDTA was added (100 ji/wel1) to 
streptavidin coated plates for 2 hours. Plates were washed and then 
developed using PBS/Tw +1- EDTA at all stages except in the 
peroxidase substrate buffer. 
Effect of EDTA on Peroxidase Function 
Peroxidase conjugated rabbit anti-mouse antibody (1:1000) 
was added (lOitl) to peroxidase buffer (imi) with or without EDTA 
(1mM) containing either 300, 200, 100, 50 or 25pJ ABTS (0.6mg/ml) 
in peroxidase buffer. Colour development was measured in duplicate 
after 5 and 30 minutes, using 1 00tlIwe1l in a microtitre plate. 
Immobilised Oligonucleotide Serum Incubation 
Oligonucleotide C20B (400ngIml) in PBS/Tw was added 
(100p/well) to streptavidin coated plates for 2 hours. Myoclone plus 
FCS untreated, or heat inactivated in an autoclave, was double 
diluted in PBS/Tw to give (Neat, 1:2, 1:4, 1:8, 1:16, 1:32). Serum 
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dilutions were added to coated wells (lOOiilIwell) and allowed to 
incubate for 1 hour. Plates were washed and a commercially 
available anti-DNA antibody (1jg/mI) in PBSITw was added 
(1 00t1/well) for 1 hour. Plates were then washed and developed as 
previously described. Control wells were set up containing no serum 
with or without anti-DNA antibody, and no oligonucleotide with 
normal or treated serum. 
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CHAPTER 4. GENERAL DISCUSSION AND 
CONCLUSIONS 
The analysis of the interaction of DNA with genotoxic agents 
is fundamental to monitoring human carcinogen exposure and 
assessment of the associated risk. Much work has been carried out 
on the methodology to detect DNA adducts. However, many 
genotoxic agents will interact with DNA which then may undergo 
repair or replication. These processes will remove the adducted base 
but may lead to a point mutation at the site of interaction. The use of 
the PCR coupled to DNA sequencing has provided the most general 
method to detect abnormal DNA sequences. Although PCR is 
relatively simple the overall process is still labour intensive. 
Alternative methods of detection have focused on converting 
the point mutation into a base pair mismatch, by denaturation and 
annealing of the mutated strand in an excess of non-mutated 
complementary DNA. Detection of mismatched sites are then 
carried by techniques such as single stranded conformation 
polymorphism, oligonucleotide hybridisation, denaturing gradient gel 
electrophoresis, RNase A cleavage of RNA:DNA duplexes and 
others discussed in chapter one. 
More recently mismatch repair enzymes (such as Mut Y and 
thymidine DNA glycosylase) have been used to detect point 
mutations in the form of base pair mismatches in duplexes (Hsu et 
al., 1994). The enzymes being used in a similar way to RNase A. 
However, these methods are limited in the sensitivity of the assay 
systems. At best they only detect mutations if there are mutations in 
greater than 2% of the DNA being tested. Where the mutation is 
occurring at very low frequency enrichment methods are required. 
Mismatch repair proteins may serve as a potential means to 
enrich mismatch base pair containing duplexes. The assay conditions 
would need to be modified such that recognition occurred with no 
cleavage. The major draw back at the moment is these enzymes are 
not readily available in a highly purified form. 
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Monoclonal antibodies raised against mismatched base pairs 
may serve as a highly specific method for immuno-enrichment of 
DNA sequences containing point mutations. This type of analysis 
would provide a means of determining mutation at any locus at the 
molecular level with the sensitivity and precision required to assess 
low level cancer risk. The study has focused on the production of 
monoclonal antibodies to specific base pair mismatches in synthetic 
DNA duplexes. Two distinct areas of research were produced. 
Firstly, the production of DNA duplexes containing mismatched base 
pairs for immunisation experiments and antibody screening was 
described in chapter 2. Secondly, inimunisation and fusion 
experiments to produce antibody, and subsequent identification of 
antibody binding properties was described in chapter 3. 
A considerable amount of data is available concerning the 
structure of mismatched base pairs in DNA duplexes. Mismatched 
base pairs have been shown to be structurally and thermodynamically 
different from normal Watson-Crick base pairs. These differences 
have been detected by physical, chemical and biological techniques. 
Of particular interest is the fmding that mismatched base pair 
recognition enzymes exist in both prokaryotes and eukaryotes. This 
means protein recognition of mismatched base pairs in DNA 
duplexes occurs. 
Although the immune system can be stimulated to produce 
antibodies to certain types of nucleic acid, e.g. Z-DNA, RNA-DNA 
hybrids, mammalian B-DNA has not been shown to be immunogenic 
in test animals. The immunogenic nucleic acids all possess non-B-
DNA structures/conformations. A mismatched base pair provides an 
altered structure to B-DNA and thus provides a possible recognition 
site for immune recognition. However, for most occurrences of anti-
nucleic acid antibodies a large proportion, or the entire immunogen., 
is in the altered conformation, not just one base pair. 
The current study has aimed to develop a novel method to 
detect rarely occurring point mutations in DNA, with high sensitivity. 
The point mutation will be detected by the artificial production of a 
mismatched base pair at the site of mutation, and subsequent 
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detection of the mismatched base pair. A variety of DNA duplexes 
were constructed containing mismatched base pairs, for immune 
recognition. 
The use of automated DNA synthesisers allowed us to produce 
large amounts of specific DNA sequences, rapidly and such that 
purification was easily achieved. A major concern was the thermal 
stability of relatively short duplexes, especially as the presence of a 
mismatch will destabilise the duplex. In order to ensure thermal 
stability, single stranded sequences were chemically linked at one 
terminus via a tetraethylene glycol linker to a complementary strand 
such that the duplex contained a central base pair mismatch. The 
chemical linkage was carried out as part of the automated synthesis. 
Duplexes of this nature were found to be thermally stable, and 
additionally the thermal stability was independent of concentration, 
thus they would not dissociate even at high dilution. 
Attempts to increase the duplexes stability to nuclease 
degradation was carried out. Duplexes were prepared as described 
above except the phosphate groups were all converted into 
phosphorothioate groups, which affords stability to nuclease 
enzymes. However, these duplexes were found to be thermally 
unstable and, therefore, unsuitable for immunisation experiments. It 
may be worth investigating the use of mixed phosphate and 
phosphorothioate containing duplexes for immunisation. The 
thermally stable duplexes were used to immunise mice alone or as 
complexes with methylated BSA. Methylated BSA may also reduce 
nuclease degradation by sterically hindering the approach of the 
enzyme to the DNA. 
A considerable amount of time was then devoted to developing 
a screening method capable of detecting the production of anti-
mismatched antibodies. There is a great deal of uncertainty as to the 
possible immunogenic nature of mismatched base pairs, and devising 
a suitable assay was a considerable task. When using the initial 
screening methods we were uncertain if the assay was capable of 
detecting mismatched based pairs in DNA duplexes. Where anti-
DNA antibodies and specifically anti-mismatched base pair 
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antibodies were not detected we were uncertain if the assay had 
failed or that we were simply not achieving the desired immune 
response. It is possible that antibody screening methods used during 
the first 6-12 months of the immunochemical portion of the study 
may have not detected potentially useful antibodies. The difficulty 
and uncertainty in developing a screening assay was fuelled by the 
varied and contradictory requirements for anti-DNA antibody assays 
presented in the literature. 
In initial screening procedures oligonucleotides were 
immobilised in a random orientation to the surface of microtitre 
plates. This random orientation may not have allowed the antibody 
to interact with the base pair mismatch. Limited information was 
obtained from these experiments and no anti-mismatched base pair 
antibodies were detected. 
As improved assay procedures were being developed 
alternative sources of immunogen were investigated. Larger duplex, 
75mers, were constructed such that they contained four evenly 
spaced single base pair mismatches. Additionally these duplexes had 
five phosphorothioate containing base pairs at the 3' terminus to 
improve stability against possible nuclease degradation. In addition, 
a complete C 1 OOmer single stranded phosphorothioate (Cl OOPS) was 
constructed. Antibodies that recognise cytosine bases should be 
produced and these may cross react with cytosine  containing 
mismatches (A:C; C:C; T:C). 
Subsequent methods to screen for antibody production 
concentrated on improved immobilisation techniques. Methods to 
specifically immobilise duplexes by end labelling with biotin 
followed by incubation with streptavidin coated plates were 
investigated. It was found that biotin labelled duplexes stabilised by 
a tetraethylene glycol linker, as previously discussed, were required. 
In addition the biotin had to be attached to the duplex via a second 
linker or steric hindrance, caused by the proximity of the fairly rigid 
duplex to the biotin, reduced the subsequent binding of biotin to 
streptavidin coated plates. 
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Using this coating procedure we investigated antibody 
production in a variety of assay conditions. Variations in buffers e.g. 
PBS/Tw vs TBS/Tw, produced considerable differences in antibody 
binding during both non-competitive and competitive assays. For the 
monoclonal antibody tested (AC75114D614.12) TBS/Tw gave less 
antibody binding in non-competitive assays (compared to PBS/Tw) 
and no inhibition in competitive assays. Pisetsky and Semper (1984) 
noted some monoclonal anti-DNA antibodies had altered antigen 
binding, dependant upon buffer used. 
Alterations in binding may reflect slight structural changes in 
duplex conformation caused by the buffer. Alterations in binding 
were only investigated using mismatch containing duplexes. The 
presence of a mismatched pair may facilitate duplex conformational 
change. However, the duplexes investigated by Pisetsky and Semper 
(1984) were fully matched, thus a mismatch site is not prerequisite 
for this phenomena. This finding  was of great concern as the variety 
of possible buffers is huge. Clearly it would be impossible to screen 
the hundreds of test wells produced in fusion and cloning 
experiments to determine the ideal or effective assay conditions for 
different anti-DNA antibody populations. 
To reduce possible nuclease enzyme degradation of DNA, 
EDTA in wash solutions and buffers was investigated. EDTA was 
found to greatly interfere with the peroxidase/ABTS reaction and to 
reduce anti-DNA antibody/DNA interactions. Thus the use of this 
compound to preserve the DNA in the test system was then 
detrimental to the detection of the DNA in the test system. Serum 
free/protein free cell culture medium was used for fusion and cloning 
to reduce nuclease contamination. The use of reduced FCS in these 
experiments did not effect the numbers of hybridomas produced or 
the ability to produce wells containing single colonies in cloning 
experiments. 
For several of the supernatants obtained from fusion wells 
(containing mixed cell populations) inhibition studies indicated 
antibodies were present that had some specificity to mismatched base 
pairs in duplexes. However, we were unable to generate monoclonal 
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cell lines with similar specificity. The cloning  procedure used 
routinely obtained greater than 25 single colony wells per cloning 
experiment. The hybridomas produced may be genetically unstable, 
losing the ability to secrete antibody and/or produce antibody. 
In addition, hybridoma formation is rare event. The 
production of monoclonal antibodies would not be possible if it were 
not for the ability to increase the relative amount of the desired 
splenocytes, for fusion, by immuriisation. If this were not possible it 
would be extremely unlikely that the desired clones could be 
isolated. Where the mismatched based pair provides only a weak 
immunogenic stimulus to the immune system, splenocytes producing 
the desired antibody will be in the minority, compared to good 
immunogens. Where this occurs the desired hybridoma production 
will be an extremely rare event. Hybndomas secreting the desired-
antibody 
esired
have a greater probability of being over grown at the post 
fusion stage, and thus less likely to be isolated in cloning 
experiments. 
The cell growth medium for clone and fusion wells are not 
identical, and this may also explain some of the differences observed. 
Clone wells contain a large amount of dead material from the feeder 
cells and unlike fusion wells this material will not be removed. The 
growth medium is not changed between carrying out the cloning 
procedure and the screening for antibody production. The degraded 
and partially degraded DNA within the supernatants may interact 
with antibody released into the supernatant prior to screening, as 
suggested by Ehrenstein et al., (1993). 
Where Cl OOPS was used as an immunogen we obtained 
hybridomas secreting antibody into the growth medium that showed 
high titres against single stranded cytosine  containing 
oligonucleotides. Monoclonal antibody producing cell lines were 
produced that recognised duplexes containing C:C and A:C 
mismatches but not to fully matched duplexes. It should be noted 
that these are not mismatch specific antibodies as they bound to 
single stranded oligonucleotide. However, they did not bind to the 
duplex containing fully matched base pairs. 
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Alternative antibody production technology 
There are potentially two other methods to generate 
antibodies, both of which may overcome drawbacks of the traditional 
immunisation and hybridoma technology methods. Firstly, 
splenocytes can be isolated from non-inimunised mice and antigenic 
material can then be introduced in vitro. At the moment this method 
is not used routinely, although it has certain advantages over the 
classical in vivo approaches. The main advantage is that the 
environment in which immunisation occurs is under greater control. 
Problems associated with in vivo metabolism (including nuclease 
enzyme degradation) are greatly reduced. Also weaker immunogens 
have been shown to produce immune responses with this technique, 
important when using DNA. In addition it requires less antigen and 
the antigen does not need to be coupled to a carrier protein. 
Secondly, over the last few years there has been an increasing 
amount of work focusing on recombinant phage display antibody 
production first described at the start of the decade (McCafferty et 
al., 1990; Clarkson et al., 1991). This technology serves to by-pass 
the hybridoma techniques by genetically engineering monoclonal 
antibodies (reviewed by Winter and Milstein, 1991). Briefly, the 
technology allows the mRNA coding for the antibody to be isolated 
and then converted to cDNA. This eDNA sequence can then be 
incorporated into a phage, such that antibodies may be produced in 
unlimited quantities. More importantly it is possible to manipulate 
the binding site of the antibodies produced, by the introduction of 
mutations at the antigen binding regions in the eDNA. This could 
allow the manipulation of anti-DNA antibodies such that anti-
mismatched base pair antibodies are produced. 
Both of these techniques potentially provide alternative 
methods to produce anti-mismatched base pair antibodies. The later 
probably requiring some initial work with traditional hybridoma 
techniques in order to have mRNA, from anti-DNA antibody 
secreting hybridomas, to manipulate. 
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Conclusions 
In conclusion, a great deal of work has led to the development 
of improved assay methods aimed at detecting the production of anti-
mismatched base pair antibodies after immunisation experiments. 
This study did not produce any monoclonal cell lines producing 
specific anti-mismatched base pair antibodies. However, cell growth 
medium after fusions contained antibodies that showed inhibition to 
mismatch containing duplexes in competitive assays. Cloning 
experiments failed to isolate these monoclonal cell lines producing 
antibodies. Further work may need to focus on the cloning 
procedure. However, part of the difficulty could be sheer numbers of 
experiments that need to be carried out. It was reported, see main 
text, that 20,000 fusion wells were screened in the development of a 
monoclonal to the immunogen Z-DNA, this work produced one 
useful monoclonal cell line. 
It was discussedin the introduction to chapter 3 that ELISA 
was not the only screening method available. However, for the 
number of samples we were handling it was the preferred method. 
Throughout the course of the screening experiments improvements in 
assay methodology were developed. Each step appearing to give us 
an improved assay. When screening for antibodies produced by a 
poorly immunogenic  material it would be expected that isolating a 
desired monoclonal would be an extremely rare event, similar to the 
production of anti-Z-DNA antibodies. The coating methods 
developed could be used for non-competitive and competitive 
ELISA, and thus should be used to screen a large number of fusion 
experiments. 
I feel that much has been learned regarding the types of 
immunogen that should be used to produce anti-mismatched 
antibodies. The larger duplexes containing multiple mismatched base 
pairs and end labelled with phosphorothioate bases have proved 
useful. These may be rendered more stable to nuclease attack during 
inimunisations by the inclusion of phosphorothioate groups within the 
duplex. The use of poly-cytosme 1 00mer as a complete 
phosphorothioate produced antibodies that were able to recognise 
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duplexes containing CC and AC mismatches. These antibodies could 
be used to detect or enrich DNA duplexes containing mismatched 
base pairs single stranded DNA was not present. To date poly-
cytosine 1 OOmer is the only sequence used that produce anti-
mismatched base pair antibodies, poly T, A and G have yet to be 
studied. A number of suggestions for continued work on this project 
are presented. 
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4.1 FUTURE WORK 
The production of monoclonal cell lines that produce 
antibodies with specific recognition of a base pair mismatch in DNA 
compared to native DNA has proved elusive. However, pre-clonal 
stages of the work provided implications that the production of 
antibodies to a mismatched base pair was possible. Outlines of 
possible future work aimed at producing anti-mismatched base pair 
antibodies are discussed below. 
The use of hybridoma cell lines already produced. 
Continued use of the established ELISA methodology to screen 
the production of hybndoma cell lines of current interest. 
Extensive screening of the large numbers of cell lines produced by 
fusion experiments prior to the improved ELISA. 
Production of a solution phase immunoassay, possibly utilising 
radiolabelled DNA. 
The synthesis of a more immunogenic source of DNA. 
The original 1 5mer duplexes were synthesised as normal 
phosphate oligonucleotides. One major concern is the 
degradation of these duplexes during the immunisation  regime 
(see also 4.1.4). By replacing an oxygen atom in DNAs 
phosphate group with a sulphur atom (producing a 
phosphorothioate) the serum half life will be increased. Creating 
complete phosphorothioate sequences proved unsuccessful due to 
thermal instability. However, this could be overcome by the 
selective addition of phosphorothioate groups at some but not all 
positions within the duplex. 
The use of DNA-RNA hybrids as a source of immunogenic 
material. The native B-DNA conformation is poorly immunogenic 
whereas RNA-DNA hybrids are more immunogenic. Mismatched 
base pairs could be incorporated into this hybrid in a manner 
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similar to the synthetic DNA duplexes. The enhancement in the 
mimunogenicity of the entire duplex may increase the 
inimunogenicity of a mismatched base pair within the duplex. 
This approach could be coupled to selective phosphorothioate 
inclusion. 
Experiments to specifically conjugate oligonucleotides to proteins 
proved unsuccessful. The use of streptavidin/biotin 
inimobilisation of oligonucleotides could be adapted such that 
streptavidin/biotin oligonucleotides could be used as an 
immunogen. This would greatly increase the molecular weight of 
the immunogen and possible provide some hindrance to nuclease 
enzymes. 
The use of poly-thyniine, poly-guanine, and poly-adenine 
lOOmers as complete phosphorothioates as immunogens. 
Cloning procedures 
Investigation of the DNA content of clone wells may be important. 
If DNA levels produced by dying feeder cells was high cloning 
procedures in the absence of feeder cells may need to be 
investigated. Cloning could be carried out using cell culture 
medium enhanced with growth factors. 
Alternatives antibody production methodologies 
Use of phage display technology to modify anti-DNA antibody 
binding such that anti-mismatched base pair antibodies are 
produced. 
Use of in vitro antibody production to reduce the effect of 
nuclease degradation of antibody. 
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